Coronavirus vaccine preparations
Non-naturally occurring coronavirus spike polypeptides, modified for stability and epitope presentation, address the challenge of vaccine stabilization and immune response induction against SARS-CoV-2, ensuring effective virus neutralization across diverse environments.
Patent Information
- Application Number
- JP2024532444
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-05
- Filing Date
- 2022-11-30
- Publication Date
- 2024-12-06
AI Technical Summary
The development of vaccines against highly sophisticated pathogens like SARS-CoV-2 is challenging due to their evasion mechanisms and the difficulty in stabilizing vaccines, especially in environments without refrigeration.
The use of non-naturally occurring coronavirus spike (CoV) polypeptides, specifically modified S1 and S2 subunits, to create nanoparticles with enhanced stability and epitope presentation, optionally associated with a surfactant core, for inducing immune responses.
The modified CoV polypeptides and nanoparticles demonstrate improved stability and immune response induction, effectively neutralizing the virus under various environmental conditions, including those without refrigeration.
Smart Images

Figure 2024545420000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to the following applications: U.S. Patent Application No. 63 / 284,497, filed November 30, 2021; U.S. Patent Application No. 63 / 292,120, filed December 21, 2021; U.S. Patent Application No. 63 / 293,519, filed December 23, 2021; U.S. Patent Application No. 63 / 332,530, filed April 19, 2022; and U.S. Patent Application No. 63 / 367,678, filed July 5, 2022, the contents of which are incorporated by reference herein in their entirety for all purposes.
[0002] Description of electronically filed text files The contents of the electronic sequence listing (NOVV_096_01WO_SeqList_ST26.xml; size: 623,736 bytes; created on: November 30, 2022) are incorporated herein by reference in their entirety.
[0003] Field The present disclosure generally relates to non-naturally occurring coronavirus (CoV) spike (S) polypeptides, as well as nanoparticles and vaccines containing same, useful for stimulating an immune response. The nanoparticles provide antigens, e.g., glycoprotein antigens, typically produced using recombinant approaches, optionally associated with a surfactant core. The nanoparticles have improved stability and enhanced epitope presentation. The disclosure also provides compositions containing the nanoparticles, methods for producing them, and methods for stimulating an immune response. [Background technology]
[0004] Background of the Invention Infectious diseases remain a problem worldwide. While progress has been made in developing vaccines against some pathogens, many still remain a threat to human health. The sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has caused 6.5 million deaths worldwide. SARS-CoV-2 coronavirus belongs to the same family of viruses as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which have killed hundreds of people over the past 17 years. SARS-CoV-2 causes the disease COVID-19. Summary of the Invention [Problem to be solved by the invention]
[0005] The development of vaccines to prevent or reduce the severity of life-threatening infectious diseases such as SARS-CoV-2 coronavirus is desirable. However, human vaccine development remains challenging due to the highly sophisticated evasion mechanisms of pathogens and the difficulty of stabilizing vaccines. Optimally, a vaccine should induce antibodies that block or neutralize infectious agents and remain stable in a variety of environments, including those where refrigeration is not possible. [Means for solving the problem]
[0006] Summary of the Invention The present disclosure provides non-naturally occurring CoV S polypeptides suitable for inducing an immune response against SARS-CoV-2. The present disclosure also provides nanoparticles containing the glycoprotein as well as methods for stimulating an immune response.
[0007] The present disclosure also provides CoV S polypeptides suitable for inducing an immune response against multiple coronaviruses, including SARS-CoV-2, Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS).
[0008] A CoV S polypeptide, (i) an S1 subunit having an inactivated furin cleavage site, wherein the S1 subunit comprises an N-terminal domain (NTD), a receptor binding domain (RBD), subdomains 1 and 2 (SD1 / 2), and the inactivated furin cleavage site has the amino acid sequence of QQAQ (SEQ ID NO: 7); The NTD optionally comprises one or more modifications selected from the group consisting of: (a) a deletion of one or more amino acids selected from the group consisting of amino acids 11 to 14, 56, 57, 130, 131, 132, 144, 145, 198, 199, 228, 229, 230, 231, 234, 235, 236, 237, 238, 239, 240, and combinations thereof; and (b) a mutation of one or more amino acids selected from the group consisting of amino acids 5, 6, 7, 11, 12, 13, 14, 51, 53, 54, 56, 57, 62, 63, 67, 70, 82, 125, 129, 131, 132, 133, 134, 139, 143, 144, 145, 170, 177, 197, 198, 199, 200, 201, 202, 209, 229, 233, 239, 240, 244, 245, and combinations thereof; and (c) Insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215 Includes; the RBD optionally comprises one or more amino acid mutations selected from the group consisting of amino acids 326, 333, 355, 358, 360, 362, 363, 392, 395, 404, 419, 426, 427, 431, 432, 433, 439, 440, 447, 464, 465, 471, 473, 477, 480, 481, 483, 485, 488, 492, and combinations thereof; and The SD1 / 2 domain optionally comprises one or more amino acid mutations selected from the group consisting of 534, 557, 591, 600, 601, 626, 642, 645, 664, 666, 668, and combinations thereof. S1 subunit; and (ii) the S2 subunit, wherein amino acids 973 and 974 are proline; The S2 subunit optionally has one or more modifications selected from the group consisting of: (a) deletion of one or more amino acids from 676 to 685, 676 to 702, 702 to 711, 775 to 793, 806 to 815, and combinations thereof; and (b) one or more amino acid mutations selected from the group consisting of 688, 691, 703, 751, 783, 843, 846, 875, 937, 941, 956, 968, 969, 1014, 1058, 1105, 1163, 1186, and combinations thereof; and (c) deletion of one or more amino acids from the TMCT containing, S2 subunit; and (i) any one combination of the modifications in (a) to (c) and (ii) (a) to (c). Includes; Provided herein are CoV S polypeptides in which the amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2.
[0009] In embodiments, the one or more modifications are (i) 6, 14, 54, 70, 82, 129, 133, 134, 139, 143, 144, 170, 197, 199, 200, 239, 244, 326, 333, 355, 358, 360, 362, 363, 392, 395, 404, 427, 431, 432, 433, 439, 447, 464, 465, 471, 473, 477, 480, 483, 485, 488, 492, 534, 591, 601, 626, 642, 645, 666, 66 (ii) a mutation of one or more amino acids selected from the group consisting of 8, 691, 751, 783, 843, 941, 956, 968, and 1186; (ii) a deletion of one or more amino acids selected from the group consisting of 11, 12, 13, 56, 57, 130, 131, 132, 144, 145, and 198; (iii) an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; and combinations of modifications in (i) to (iii), wherein the amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2.In embodiments, the one or more modifications are T6I, T6R, A14S, A54V, V70A, T82I, G129D, H133Q, K134E, W139R, E143G, F144L, Q170E, I197V, L199I, V200E, V200G, G239V, G244S, G326D, G326H, R333T, L ... 55I, S358F, S358L, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, V432P, G43 3S, L439R, L439Q, N447K, S464N, T465K, E471A, F473V, F473S, F477S, Q480R, G483S, Q485 R, N488Y, Y492H, T534K, T591I, D601G, G626V, H642Y, N645S, N666K, P668H, S691L, N751K, D783Y, N843K, Q941H, N956K, L968F, D1186N, a deletion of amino acid 11, a deletion of amino acid 12, a deletion of amino acid 13, a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 130, a deletion of amino acid 131, a deletion of amino acid 132, a deletion of amino acid 144, a deletion of amino acid 145, a deletion of amino acid 198, and an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215, and combinations thereof; the amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2.
[0010] In embodiments, provided herein is a CoV S glycoprotein comprising a combination of modifications selected from the group consisting of:
[0011] (i)A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N , T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H , N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215;
[0012] (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;
[0013] (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215;
[0014] (iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;
[0015] (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;
[0016] (vi) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0017] (vii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0018] (viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0019] (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0020] (x) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;
[0021] (xi)T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S 464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;
[0022] (xii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0023] (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0024] (xiv)T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S 358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S46 4N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131;
[0025] (xv)T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S36 2F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F 473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131;
[0026] (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;
[0027] (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; and (xviii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; the amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2. In embodiments, the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, the NTD of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the NTD of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, the RBD of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the RBD of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.In embodiments, the S1 subunit of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the S1 subunit of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, the S2 subunit of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the S2 subunit of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, SD1 / 2 of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SD1 / 2 of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, each of the NTD, RBD, S1 subunit, S2 subunit, and SD1 / 2 of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the respective NTD, RBD, S1 subunit, S2 subunit, and SD1 / 2 of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, the CoV S glycoprotein comprises a protein tag. In embodiments, the protein tag is at the N-terminus of the glycoprotein. In embodiments, the protein tag is at the C-terminus of the glycoprotein.In embodiments, the protein tag is selected from a polyglutamic acid tag, a FLAG tag, an HA tag, a polyHis tag (having about 5-10 histidines) (SEQ ID NO: 101), a hexahistidine tag (SEQ ID NO: 100), an 8x-His tag (having 8 histidines) (SEQ ID NO: 102), a Myc tag, a glutathione-S-transferase tag, a green fluorescent protein tag, a maltose binding protein tag, a thioredoxin tag, an Fc tag, or a combination thereof. In embodiments, the CoV S glycoprotein comprises an N-terminal signal peptide. In embodiments, the N-terminal signal peptide is selected from any one of SEQ ID NOs: 5, 117, 154, and 193.
[0028] In embodiments, provided herein is a nucleic acid comprising a CoV S glycoprotein described herein. In embodiments, the nucleic acid is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleic acid of any one of SEQ ID NOs: 196, 197, 198, 199, 201, 202, 204, 206, 208, 210, 212, 214, or 216. In embodiments, provided herein is a vector comprising the nucleic acid of claim 18 or 19.
[0029] In embodiments, provided herein are nanoparticles comprising a CoV S glycoprotein described herein and a non-ionic surfactant core. In embodiments, the nanoparticles have a melting temperature of at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, at least 65°C, or about 55°C to about 65°C, as determined by differential scanning calorimetry, after about one month of storage at 4°C. In embodiments, the nanoparticles have a melting temperature of at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, at least 65°C, or about 55°C to about 65°C, as determined by differential scanning calorimetry, after about one month of storage at 25°C. In embodiments, the nanoparticles have a melting temperature of at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, or about 55°C to about 65°C after about one month of storage at 37°C, as determined by differential scanning calorimetry. In embodiments, the nanoparticles have a Zavg diameter of about 30 nm to about 65 nm or about 30 nm to about 50 nm after about one month of storage at 4°C, as determined by dynamic light scattering. In embodiments, the nanoparticles have a Zavg diameter of about 30 nm to about 65 nm or about 30 nm to about 50 nm after about one month of storage at 25°C, as determined by dynamic light scattering. In embodiments, the nanoparticles have a Zavg diameter, as determined by dynamic light scattering, of about 30 nm to about 120 nm, about 30 nm to about 80 nm, or about 30 nm to about 60 nm after about one month of storage at 37° C. In embodiments, the nanoparticles have a polydispersity index, as determined by dynamic light scattering, of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 4° C.In embodiments, the nanoparticles have a polydispersity index of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 25° C., as determined by dynamic light scattering. In embodiments, the nanoparticles have a polydispersity index of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 37° C., as determined by dynamic light scattering. In embodiments, the nonionic surfactant is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65), and polysorbate-80 (PS80). In embodiments, the nonionic surfactant is PS80.
[0030] In embodiments, provided herein is a cell that expresses a CoV glycoprotein described herein. In embodiments, the cell is an insect cell.
[0031] In embodiments, provided herein are immunogenic compositions comprising at least one CoV S glycoprotein described herein or a nanoparticle described herein and a pharmaceutically acceptable buffer. In embodiments, the composition comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 different CoV S glycoproteins. In embodiments, at least one CoV The S glycoproteins were (i) A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F; (ii) deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N , T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S , S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215;(iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (vi) T6I, A14 S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (vii) V3G, T6I, A14S, G129D, V200G, G326D , S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;(viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (x) T6I, A14S, G129D, K134 E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xi) T6I, A14S, G129D, K134E, W1 39R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13;(xii)T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S 464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K , deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H , D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiv) T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131;(xv)T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S362F, T363A, D392N, R395S, K404N , N427K, V432P, G433S, N447K, S464N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H , N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362 F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57;and (xviii) a combination of modifications selected from the group consisting of T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131. In embodiments, the immunogenic composition comprises at least one CoV S glycoprotein that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243. In embodiments, the immunogenic composition comprises a CoV S glycoprotein that has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the CoV S glycoprotein of SEQ ID NO: 87. In embodiments, the immunogenic composition comprises a CoV S glycoprotein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the CoV S glycoprotein of SEQ ID NOs: 85-89, 105, 106, and 112-115. In embodiments, the immunogenic composition comprises an mRNA encoding the SARS-Cov-2 spike glycoprotein; The immunogenic composition comprises a plasmid DNA encoding the SARS-CoV-2 spike glycoprotein, a viral vector encoding the SARS-CoV-2 spike glycoprotein, or an inactivated SARS-CoV-2 virus. In embodiments, the immunogenic composition comprises at least one, at least two, at least three, or at least four hemagglutinin (HA) glycoproteins, each HA glycoprotein being from a different influenza strain. In embodiments, the immunogenic composition comprises a respiratory syncytial virus (RSV) fusion (F) glycoprotein. In embodiments, the immunogenic composition comprises (i) a first CoV S glycoprotein having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polypeptide of SEQ ID NO: 87, and (ii) a second CoV S glycoprotein having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the polypeptide of SEQ ID NO: 175. In embodiments, the immunogenic composition comprises from about 1 μg to about 50 μg; from about 3 μg to about 25 μg, from about 5 μg to about 25 μg, or from about 5 μg to about 100 μg of CoV S glycoprotein. In embodiments, the immunogenic composition comprises about 1 μg to about 50 μg; about 3 μg to about 25 μg, about 5 μg to about 25 μg, or about 5 μg to about 100 μg of each CoV S glycoprotein. In embodiments, the immunogenic composition comprises about 5 μg of CoV S glycoprotein. In embodiments, the immunogenic composition comprises about 5 μg of each CoV S glycoprotein. In embodiments, the immunogenic composition comprises an adjuvant. In embodiments, the adjuvant is a saponin adjuvant.In an embodiment, the saponin adjuvant comprises at least two types of iscom particles, a first iscom particle comprising Quillaja Saponaria Molina Fraction A and no Quillaja Saponaria Molina Fraction C; and a second iscom particle comprising Quillaja Saponaria Molina Fraction C and no Quillaja Saponaria Molina Fraction A. In an embodiment, Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C comprise about 85% and about 15% by weight, respectively, of the combined weight of Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C in the adjuvant. In embodiments, Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C comprise about 92% by weight and about 8% by weight, respectively, of the combined weight of Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C in the adjuvant. In embodiments, Quillaja Saponaria Molina Fraction A comprises at least about 85% by weight, with Quillaja Saponaria Molina Fraction C comprising the remainder, of the combined weight of Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C in the adjuvant. In embodiments, Quillaja Saponaria Molina Fraction A comprises 50-96% by weight, with Quillaja Saponaria Molina Fraction C comprising the remainder, of the combined weight of Quillaja Saponaria Molina Fraction A and Quillaja Saponaria Molina Fraction C in the adjuvant.In embodiments, the immunogenic composition comprises about 25 μg to about 100 μg of adjuvant. In embodiments, the immunogenic composition comprises about 50 μg of adjuvant.
[0032] Provided herein are pre-filled syringes containing the immunogenic compositions described herein. In embodiments, provided herein are methods for stimulating an immune response against SARS-CoV-2 or a heterologous SARS-CoV-2 strain, comprising administering to a subject an immunogenic composition described herein. In embodiments, the method comprises administering 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of the immunogenic composition. In embodiments, the method comprises administering a first dose of the immunogenic composition and a second dose of the immunogenic composition about 3 weeks after the first dose. In embodiments, the method comprises administering a first dose of the immunogenic composition and a second dose of the immunogenic composition about 21 days after the first dose. In embodiments, the method comprises administering a first dose of the immunogenic composition and a second dose of the immunogenic composition about 28 days after the first dose. In embodiments, the method includes administering at least three doses of the immunogenic composition, wherein the third dose of the immunogenic composition is administered at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, or at least 24 months after the first or second dose. In embodiments, the method includes administering a second immunogenic composition that is different from the first immunogenic composition. In embodiments, the second immunogenic composition comprises mRNA encoding the SARS-CoV-2 spike glycoprotein, plasmid DNA encoding the SARS-CoV-2 spike glycoprotein, a viral vector encoding the SARS-CoV-2 spike glycoprotein, or an inactivated SARS-CoV-2 virus. In embodiments, the second immunogenic composition comprises at least one, at least two, at least three, or at least four hemagglutinin (HA) glycoproteins, each HA glycoprotein being from a different influenza strain.In embodiments, the second immunogenic composition comprises a different CoV S glycoprotein than the first immunogenic composition. In embodiments, the second immunogenic composition comprises a respiratory syncytial virus (RSV) fusion (F) protein. In embodiments, the immunogenic composition is administered intramuscularly. In embodiments, the method comprises administering the immunogenic composition in a pre-filled syringe. In embodiments, the methods include administering the immunogenic composition to a subject for at least about 2 months, at least about 2.5 months, at least about 3 months, at least about 3.5 months, at least about 4 months, at least about 4.5 months, at least about 5 months, at least about 5.5 months, at least about 6 months, at least about 6.5 months, at least about 7 months, at least about 7.5 months, at least about 8 months, at least about 8.5 months, at least about 9 months, at least about 9.5 months, at least about 10 months, at least about 10.5 months, at least about 11 months, at least about 11.5 months, at least about 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least about 18 months, at least about 19 months, at least about 20 months, at least about 21 months, at least about 22 months, at least about 23 months, at least about 24 months, at least about 25 months, at least about 26 months, at least about 27 months, at least about 28 months, at least about 29 months, at least about 30 months, at least about 31 months, at least about 32 months, at least about 33 months, at least about 34 months, at least about 35 months, at least about 36 months, at least about 37 months, at least about 38 months, at least about 39 months, at least about 40 months, at least about 41 months, at least about 42 months, at least about 43 months, at least about 44 months, at least about 45 months, at least about 46 months, at least about 47 months, at least about 48 months, at least about 49 months, at least about 50 months, at least about 51 months, at least about 52 months, at least about 53 months, about 50% to about 99%, about 50% to about 95%, about 50% to about 90%, about 50% to about 85%, about 50% to about 80%, about 60% to about 99%, about 65% to about 95%, about 65% to about 90%, about 65% to about 85%, or about 65% to about 85% over a period of at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, or at least 24 months. Prevents COVID-19 with about 69% to about 81%, about 60% to about 95%, about 60% to about 90%, about 60% to about 85%, about 60% to about 80%, about 40% to about 99%, about 40% to about 95%, about 40% to about 90%, about 40% to about 85%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to about 65%, about 40% to about 55%, or about 40% to about 50% effectiveness.In embodiments, the methods include administering the immunogenic composition for up to about 2 months, up to about 2.5 months, up to about 3 months, up to about 3.5 months, up to about 4 months, up to about 4.5 months, up to about 5 months, up to about 5.5 months, up to about 6 months, up to about 6.5 months, up to about 7 months, up to about 7.5 months, up to about 8 months, up to about 8.5 months, up to about 9 months, up to about 9.5 months, up to about 10 months, up to about 10.5 months, up to about 11 months, up to about 11.5 months, up to about 12 months, up to 13 months, up to 14 months, up to 15 months, up to 16 months, up to 17 months, up to 18 months, up to 19 months, up to 20 months, up to about 21 months, up to about 22 months, up to about 23 months, up to about 24 months, up to about 25 months, up to about 26 months, up to about 27 months, up to about 28 months, up to about 29 months, up to about 30 months, up to about 31 months, up to about 32 months, up to about 33 months, up to about 34 months, up to about 35 months, up to about 36 months, up to about 37 months, up to about 38 months, up to about 39 months, up to about 40 months, up to about 41 months, up to about 42 months, up to about 43 months, up to about 44 months, up to about 45 months, up to about 46 months, up to about 47 months, up to about 48 months, up to about 49 months, up to about 50 months, up to about 51 months, up to about 52 months, up to about 53 months, up to about 54 Approximately 50% to approximately 99%, approximately 50% to approximately 95%, approximately 50% to approximately 90%, approximately 50% to approximately 85%, approximately 50% to approximately 80%, approximately 60% to approximately 99%, approximately 65% to approximately 95%, approximately 65% to approximately 90%, approximately 65% to approximately 85%, approximately 69% to approximately 81%, approximately 60% to approximately Prevents COVID-19 with an effectiveness of 95%, about 60% to about 90%, about 60% to about 85%, about 60% to about 80%, about 40% to about 99%, about 40% to about 95%, about 40% to about 90%, about 40% to about 85%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to about 65%, about 40% to about 55%, or about 40% to about 50%. In embodiments, the heterologous SARS-CoV-2 strain has a PANGO lineage selected from the group consisting of B.1.1.529; BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.1.1.7, B.1.351, P.1, B.1.617.2, AY, B.1.427, B.1.429, B.1.525, B.1.526, B.1.617.1, B.1.617.3, P.2, B.1.621, or B.1.621.1. In embodiments, the heterologous SARS-CoV-2 strain has a World Health Organization label of alpha, beta, gamma, delta, epsilon, iota, kappa, zeta, mu, or omicron.Provided herein are methods of stimulating an immune response in a subject against SARS-CoV-2, a heterologous SARS-CoV-2 strain, influenza virus, or a combination thereof, comprising administering an immunogenic composition described herein.Provided herein are methods of stimulating an immune response in a subject against SARS-CoV-2, a heterologous SARS-CoV-2 strain, influenza virus, respiratory syncytial virus (RSV), or a combination thereof, comprising administering an immunogenic composition described herein.
[0033] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief explanation of the drawings]
[0034] [Figure 1] Figure 1 shows a schematic of the wild-type amino acid sequence of the SARS-CoV-2 spike (S) protein (SEQ ID NO: 1). The furin cleavage site RRAR (SEQ ID NO: 6) is highlighted in bold and the signal peptide is underlined.
[0035] [Figure 2] Figure 2 shows the primary structure of the SARS-CoV-2 S polypeptide with an inactive furin cleavage site, a fusion peptide deletion, and K986P and V987P mutations. Domain positions are numbered relative to the amino acid sequence of the wild-type CoV S polypeptide from SARS-CoV-2 containing the signal peptide (SEQ ID NO: 1).
[0036] [Figure 3]Figure 3 shows the primary structure of the BV2378 CoV S polypeptide with an inactive furin cleavage site, a fusion peptide deletion of amino acids 819-828, and K986P and V987P mutations. Domain positions are numbered relative to the amino acid sequence of the wild-type CoV S polypeptide from SARS-CoV-2 containing the signal peptide (SEQ ID NO: 1).
[0037] [Figure 4] Figure 4 shows the purification of CoV S polypeptides BV2364, BV2365, BV2366, BV2367, BV2368, BV2369, BV2373, BV2374, and BV2375. The data reveal that BV2365 (SEQ ID NO: 4) and BV2373 (SEQ ID NO: 87), which contain an inactive furin cleavage site with the amino acid sequence QQAQ (SEQ ID NO: 7), are expressed as a single chain (S0). In contrast, CoV S polypeptides containing an intact furin cleavage site (e.g., BV2364, BV2366, and BV2374) are cleaved, as evidenced by the presence of the cleavage product S2.
[0038] [Figure 5] FIG. 5 shows by biolayer interferometry that CoV S polypeptides BV2361, BV2365, BV2369, BV2365, BV2373 and BV2374 bind to human angiotensin-converting enzyme 2 precursor (hACE2).
[0039] [Figure 6] Figure 6 shows that biolayer interferometry shows that BV2361 derived from SARS-CoV-2 does not bind to the MERS-CoV receptor dipeptidyl peptidase IV (DPP4), and that the MERS S protein does not bind to human angiotensin-converting enzyme 2 precursor (hACE2).
[0040] [Figure 7] FIG. 7 shows that BV2361 binds to hACE2 by enzyme-linked immunosorbent assay (ELISA).
[0041] [Figure 8] FIG. 8 shows the primary structure of the BV2373 CoV S polypeptide and the modifications K986P and V987P to the furin cleavage site.
[0042] [Figure 9] FIG. 9 shows the purification of wild-type CoV S polypeptide and CoV S polypeptides BV2365 and BV2373.
[0043] [Figure 10] Figure 10 shows the cryo-electron microscopy (cryoEM) structure of the BV2373 CoV S polypeptide overlaid on the cryoEM structure of the SARS-CoV-2 spike protein (EMB ID: 21374).
[0044] [Figures 11A-F] Figures 11A-11F show that CoV S spike polypeptides BV2365 and BV2373 bind to hACE2. Biolayer interferometry reveals that BV2365 (Figure 11B) and BV2373 (Figure 11C) bind to hACE2 with dissociation kinetics similar to that of the wild-type CoV S polypeptide (Figure 11A). ELISA shows that the wild-type CoV S polypeptide (Figure 11D) and BV2365 (Figure 11E) bind to hACE2 with similar affinity, but BV2373 binds to hACE2 with higher affinity (Figure 11F).
[0045] [Figure 12A] Figures 12A-12B show the effect of stress conditions, such as temperature, two freeze / thaw cycles, oxidation, agitation, and extreme pH, on the binding of CoV S polypeptides BV2373 (Figure 12A) and BV2365 (Figure 12B) to hACE2. [Figure 12B]Figures 12A-12B show the effect of stress conditions, such as temperature, two freeze / thaw cycles, oxidation, agitation, and extreme pH, on the binding of CoV S polypeptides BV2373 (Figure 12A) and BV2365 (Figure 12B) to hACE2.
[0046] [Figure 13A] Figures 13A-13B show anti-CoV S polypeptide IgG titers 13, 21, and 28 days after immunization of mice with two doses (Figure 13A) and one dose (Figure 13B) of 0.1 μg to 10 μg of BV2373, with or without Fraction A and Fraction C iscom matrices (e.g., MATRIX-M™). [Figure 13B] Figures 13A-13B show anti-CoV S polypeptide IgG titers 13, 21, and 28 days after immunization of mice with two doses (Figure 13A) and one dose (Figure 13B) of 0.1 μg to 10 μg of BV2373, with or without Fraction A and Fraction C iscom matrices (e.g., MATRIX-M™).
[0047] [Figure 14] FIG. 14 shows the induction of antibodies that block hACE2 interactions in mice immunized with one or two doses of 0.1 μg to 10 μg of BV2373 with or without MATRIX-M™.
[0048] [Figure 15] FIG. 15 shows virus-neutralizing antibodies detected in mice immunized with one or two doses of 0.1 μg to 10 μg of BV2373, with or without MATRIX-M™.
[0049] [Figure 16] Figure 16 shows viral load (SARS-CoV-2) in the lungs of Ad / CMV / hACE2 mice immunized with either a single dose of BV2373 or two doses of BV2373 spaced 14 days apart, with or without MATRIX-M™.
[0050] [Figure 17A] Figures 17A-17C show the weight loss exhibited by mice after immunization with BV2373. Figure 17A shows the effect of immunization with a single 0.01 μg, 0.1 μg, 1 μg, or 10 μg dose of BV2373 plus MATRIX-M™ on weight loss. Figure 17B shows the effect of immunization with two doses of BV2373 (0.01 μg, 0.1 μg, 1 μg) plus MATRIX-M™ on weight loss. Figure 17C shows the effect of immunization with two doses of BV2373 (10 μg) in the presence or absence of MATRIX-M™ on weight loss. [Figure 17B] Figures 17A-17C show the weight loss exhibited by mice after immunization with BV2373. Figure 17A shows the effect of immunization with a single 0.01 μg, 0.1 μg, 1 μg, or 10 μg dose of BV2373 plus MATRIX-M™ on weight loss. Figure 17B shows the effect of immunization with two doses of BV2373 (0.01 μg, 0.1 μg, 1 μg) plus MATRIX-M™ on weight loss. Figure 17C shows the effect of immunization with two doses of BV2373 (10 μg) in the presence or absence of MATRIX-M™ on weight loss. [Figure 17C] Figures 17A-17C show the weight loss exhibited by mice after immunization with BV2373. Figure 17A shows the effect of immunization with a single 0.01 μg, 0.1 μg, 1 μg, or 10 μg dose of BV2373 plus MATRIX-M™ on weight loss. Figure 17B shows the effect of immunization with two doses of BV2373 (0.01 μg, 0.1 μg, 1 μg) plus MATRIX-M™ on weight loss. Figure 17C shows the effect of immunization with two doses of BV2373 (10 μg) in the presence or absence of MATRIX-M™ on weight loss.
[0051] [Figure 18A]Figures 18A-18B show the effect of BV2373 on lung histopathology in mice 4 days (Figure 18A) or 7 days (Figure 18B) after infection with SARS-CoV-2. [Figure 18B] Figures 18A-18B show the effect of BV2373 on lung histopathology in mice 4 days (Figure 18A) or 7 days (Figure 18B) after infection with SARS-CoV-2.
[0052] [Figure 19] FIG. 19 shows the number of IFN-γ-secreting cells after ex vivo stimulation in the spleens of mice immunized with BV2373 in the absence of adjuvant compared to mice immunized with BV2373 in the presence of MATRIX-M™.
[0053] [Figure 20A] Figures 20A-20E show the frequency of cytokine-secreting CD4+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 20A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 20B shows the frequency of TNF-α-secreting CD4+ T cells. Figure 20C shows the frequency of IL-2-secreting CD4+ T cells. Figure 20D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 20E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 20B] Figures 20A-20E show the frequency of cytokine-secreting CD4+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 20A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 20B shows the frequency of TNF-α-secreting CD4+ T cells. Figure 20C shows the frequency of IL-2-secreting CD4+ T cells. Figure 20D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 20E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 20C]Figures 20A-20E show the frequency of cytokine-secreting CD4+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 20A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 20B shows the frequency of TNF-α-secreting CD4+ T cells. Figure 20C shows the frequency of IL-2-secreting CD4+ T cells. Figure 20D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 20E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 20D] Figures 20A-20E show the frequency of cytokine-secreting CD4+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 20A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 20B shows the frequency of TNF-α-secreting CD4+ T cells. Figure 20C shows the frequency of IL-2-secreting CD4+ T cells. Figure 20D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 20E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 20E] Figures 20A-20E show the frequency of cytokine-secreting CD4+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 20A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 20B shows the frequency of TNF-α-secreting CD4+ T cells. Figure 20C shows the frequency of IL-2-secreting CD4+ T cells. Figure 20D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 20E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2.
[0054] [Figure 21A]Figures 21A-21E show the frequency of cytokine-secreting CD8+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 21A shows the frequency of IFN-γ-secreting CD8+ T cells. Figure 21B shows the frequency of TNF-α-secreting CD8+ T cells. Figure 21C shows the frequency of IL-2-secreting CD8+ T cells. Figure 20D shows the frequency of CD8+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 21E shows the frequency of CD8+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 21B] Figures 21A-21E show the frequency of cytokine-secreting CD8+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 21A shows the frequency of IFN-γ-secreting CD8+ T cells. Figure 21B shows the frequency of TNF-α-secreting CD8+ T cells. Figure 21C shows the frequency of IL-2-secreting CD8+ T cells. Figure 20D shows the frequency of CD8+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 21E shows the frequency of CD8+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 21C] Figures 21A-21E show the frequency of cytokine-secreting CD8+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 21A shows the frequency of IFN-γ-secreting CD8+ T cells. Figure 21B shows the frequency of TNF-α-secreting CD8+ T cells. Figure 21C shows the frequency of IL-2-secreting CD8+ T cells. Figure 20D shows the frequency of CD8+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 21E shows the frequency of CD8+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 21D]Figures 21A-21E show the frequency of cytokine-secreting CD8+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 21A shows the frequency of IFN-γ-secreting CD8+ T cells. Figure 21B shows the frequency of TNF-α-secreting CD8+ T cells. Figure 21C shows the frequency of IL-2-secreting CD8+ T cells. Figure 20D shows the frequency of CD8+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 21E shows the frequency of CD8+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 21E] Figures 21A-21E show the frequency of cytokine-secreting CD8+ T cells in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 21A shows the frequency of IFN-γ-secreting CD8+ T cells. Figure 21B shows the frequency of TNF-α-secreting CD8+ T cells. Figure 21C shows the frequency of IL-2-secreting CD8+ T cells. Figure 20D shows the frequency of CD8+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 21E shows the frequency of CD8+ T cells expressing IFN-γ, TNF-α, and IL-2.
[0055] [Figure 22] Figure 22 shows the frequency of CD4+ or CD8+ cells expressing one (single), two (double), or three (triple) cytokines selected from IFN-γ, TNF-α, and IL-2 in the spleens of mice immunized with BV2373 in the presence or absence of MATRIX-M™.
[0056] [Figure 23A] Figures 23A-23C show the effect of immunization with BV2373 in the presence or absence of MATRIX-M™ on type 2 cytokine secretion from CD4+ T cells. Figure 23A shows the frequency of IL-4-secreting cells. Figure 23B shows the frequency of IL-5 CD4+ secreting cells. Figure 23C shows the ratio of IFN-γ-secreting CD4+ T cells to IL-4-secreting CD4+ T cells. [Figure 23B]Figures 23A-23C show the effect of immunization with BV2373 in the presence or absence of MATRIX-M™ on type 2 cytokine secretion from CD4+ T cells. Figure 23A shows the frequency of IL-4-secreting cells. Figure 23B shows the frequency of IL-5 CD4+ secreting cells. Figure 23C shows the ratio of IFN-γ-secreting CD4+ T cells to IL-4-secreting CD4+ T cells. [Figure 23C] Figures 23A-23C show the effect of immunization with BV2373 in the presence or absence of MATRIX-M™ on type 2 cytokine secretion from CD4+ T cells. Figure 23A shows the frequency of IL-4-secreting cells. Figure 23B shows the frequency of IL-5 CD4+ secreting cells. Figure 23C shows the ratio of IFN-γ-secreting CD4+ T cells to IL-4-secreting CD4+ T cells.
[0057] [Figure 24A] Figures 24A-24B show the effect of immunizing mice with BV2373 in the presence or absence of MATRIX-M™ on germinal center formation by assessing the presence of CD4+ T follicular helper cells (TFH). Figure 24A shows the frequency of CD4+ T follicular helper cells in the spleen, and Figure 24B shows the phenotype of CD4+ T follicular helper cells (e.g., CD4+CXCR5+PD-1+). [Figure 24B] Figures 24A-24B show the effect of immunizing mice with BV2373 in the presence or absence of MATRIX-M™ on germinal center formation by assessing the presence of CD4+ T follicular helper cells (TFH). Figure 24A shows the frequency of CD4+ T follicular helper cells in the spleen, and Figure 24B shows the phenotype of CD4+ T follicular helper cells (e.g., CD4+CXCR5+PD-1+).
[0058] [Figure 25A]Figures 25A-25B show the effect of immunizing mice with BV2373 in the presence or absence of MATRIX-M™ on germinal center (GC) B cell formation by assessing the presence of GC B cells. Figure 25A shows the frequency of GC B cells in the spleen, and Figure 25B reveals the CD4+ T follicular helper cell phenotype (e.g., CD19+GL7+CD-95+). [Figure 25B] Figures 25A-25B show the effect of immunizing mice with BV2373 in the presence or absence of MATRIX-M™ on germinal center (GC) B cell formation by assessing the presence of GC B cells. Figure 25A shows the frequency of GC B cells in the spleen, and Figure 25B reveals the CD4+ T follicular helper cell phenotype (e.g., CD19+GL7+CD-95+).
[0059] [Figure 26A] Figures 26A-26C show the effect of immunization with BV2373, with or without MATRIX-M™, on antibody responses in Anubis baboons. Figure 26A shows anti-SARS-CoV-2 S polypeptide IgG titers in baboons after immunization with BV2373. Figure 26B shows the presence of hACE2 receptor-blocking antibodies in baboons after a single immunization with 5 μg or 25 μg of BV2373 in the presence of MATRIX-M™. Figure 26C shows virus-neutralizing antibody titers after a single immunization with BV2373 and MATRIX-M™. [Figure 26B] Figures 26A-26C show the effect of immunization with BV2373, with or without MATRIX-M™, on antibody responses in Anubis baboons. Figure 26A shows anti-SARS-CoV-2 S polypeptide IgG titers in baboons after immunization with BV2373. Figure 26B shows the presence of hACE2 receptor-blocking antibodies in baboons after a single immunization with 5 μg or 25 μg of BV2373 in the presence of MATRIX-M™. Figure 26C shows virus-neutralizing antibody titers after a single immunization with BV2373 and MATRIX-M™. [Figure 26C]Figures 26A-26C show the effect of immunization with BV2373, with or without MATRIX-M™, on antibody responses in Anubis baboons. Figure 26A shows anti-SARS-CoV-2 S polypeptide IgG titers in baboons after immunization with BV2373. Figure 26B shows the presence of hACE2 receptor-blocking antibodies in baboons after a single immunization with 5 μg or 25 μg of BV2373 in the presence of MATRIX-M™. Figure 26C shows virus-neutralizing antibody titers after a single immunization with BV2373 and MATRIX-M™.
[0060] [Figure 27] Figure 27 shows a significant correlation between anti-SARS-CoV-2 S polypeptide IgG titers and neutralizing antibody titers in baboons after immunization with BV2373.
[0061] [Figure 28] FIG. 28 shows the frequency of IFN-γ secreting cells in peripheral blood mononuclear cells (PBMCs) of baboons immunized with BV2373 in the presence or absence of MATRIX-M™.
[0062] [Figure 29A] Figures 29A-29E show the frequency of cytokine-secreting CD4+ T cells in PBMCs of baboons immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 29A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 29B shows the frequency of IL-2-secreting CD4+ T cells. Figure 29C shows the frequency of TNF-α-secreting CD4+ T cells. Figure 29D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 29E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 29B]Figures 29A-29E show the frequency of cytokine-secreting CD4+ T cells in PBMCs of baboons immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 29A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 29B shows the frequency of IL-2-secreting CD4+ T cells. Figure 29C shows the frequency of TNF-α-secreting CD4+ T cells. Figure 29D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 29E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 29C] Figures 29A-29E show the frequency of cytokine-secreting CD4+ T cells in PBMCs of baboons immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 29A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 29B shows the frequency of IL-2-secreting CD4+ T cells. Figure 29C shows the frequency of TNF-α-secreting CD4+ T cells. Figure 29D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 29E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 29D] Figures 29A-29E show the frequency of cytokine-secreting CD4+ T cells in PBMCs of baboons immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 29A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 29B shows the frequency of IL-2-secreting CD4+ T cells. Figure 29C shows the frequency of TNF-α-secreting CD4+ T cells. Figure 29D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 29E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2. [Figure 29E]Figures 29A-29E show the frequency of cytokine-secreting CD4+ T cells in PBMCs of baboons immunized with BV2373 in the presence or absence of MATRIX-M™. Figure 29A shows the frequency of IFN-γ-secreting CD4+ T cells. Figure 29B shows the frequency of IL-2-secreting CD4+ T cells. Figure 29C shows the frequency of TNF-α-secreting CD4+ T cells. Figure 29D shows the frequency of CD4+ T cells secreting two cytokines selected from IFN-γ, TNF-α, and IL-2. Figure 29E shows the frequency of CD4+ T cells expressing IFN-γ, TNF-α, and IL-2.
[0063] [Figure 30] Figure 30 shows a schematic of the coronavirus spike (S) protein (SEQ ID NO: 109) (BV2384). The furin cleavage site GSAS (SEQ ID NO: 97) is single underlined, and the K986P and V987P mutations are double underlined.
[0064] [Figure 31] Figure 31 shows a schematic of the coronavirus spike (S) protein (SEQ ID NO: 86) (BV2373). The furin cleavage site QQAQ (SEQ ID NO: 7) is single underlined, and the K986P and V987P mutations are double underlined.
[0065] [Figure 32] Figure 32 shows the purification of CoV S polypeptides BV2373 (SEQ ID NO: 87) and BV2384 (SEQ ID NO: 109).
[0066] [Figure 33] Figure 33 shows a scanning densitometry plot of BV2384 (SEQ ID NO: 109) purity after purification.
[0067] [Figure 34] Figure 34 shows a scanning densitometry plot of BV2373 (SEQ ID NO: 87) purity after purification.
[0068] [Figure 35A] Figures 35A-35B show the induction of anti-S antibodies (Figure 35A) and neutralizing antibodies (Figure 35B) in response to administration of BV2373 and MATRIX-M™. Cynomolgus macaques were administered one or two doses (days 0 and 21) of 2.5 μg, 5 μg, or 25 μg of BV2373 with 25 μg or 50 μg of MATRIX-M™ adjuvant. Controls received neither BV2373 nor MATRIX-M™. Antibodies were measured on days 21 and 33. [Figure 35B] Figures 35A-35B show the induction of anti-S antibodies (Figure 35A) and neutralizing antibodies (Figure 35B) in response to administration of BV2373 and MATRIX-M™. Cynomolgus macaques were administered one or two doses (days 0 and 21) of 2.5 μg, 5 μg, or 25 μg of BV2373 with 25 μg or 50 μg of MATRIX-M™ adjuvant. Controls received neither BV2373 nor MATRIX-M™. Antibodies were measured on days 21 and 33.
[0069] [Figure 36A]Figures 36A-36B show reduction of SARS-CoV-2 viral replication by vaccine formulations disclosed herein, as assessed in bronchoalveolar lavage (BAL) in Cynomolgus macaques. Cynomolgus macaques were administered BV2373 and MATRIX-M™ as indicated. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. Subjects were challenged with 1 x 10 pfu of SARS-CoV-2 virus on day 37. Viral RNA (Figure 36A, corresponding to total RNA present) and viral subgenomic RNA (Figure 36B, corresponding to replicating virus) levels were assessed in bronchiolar lavage (BAL) 2 or 4 days (d2pi and d4pi) after challenge with infectious virus. Most subjects showed no viral RNA. Small amounts of RNA were measured in some subjects on day 2. By day 4, no RNA was measured except in two subjects at the lowest dose of 2.5 μg. Subgenomic RNA was not detected on days 2 or 4, again except in one subject at the lowest dose. [Figure 36B]Figures 36A-36B show reduction of SARS-CoV-2 viral replication by vaccine formulations disclosed herein, as assessed in bronchoalveolar lavage (BAL) in Cynomolgus macaques. Cynomolgus macaques were administered BV2373 and MATRIX-M™ as indicated. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. Subjects were challenged with 1 x 10 pfu of SARS-CoV-2 virus on day 37. Viral RNA (Figure 36A, corresponding to total RNA present) and viral subgenomic RNA (Figure 36B, corresponding to replicating virus) levels were assessed in bronchiolar lavage (BAL) 2 or 4 days (d2pi and d4pi) after challenge with infectious virus. Most subjects showed no viral RNA. Small amounts of RNA were measured in some subjects on day 2. By day 4, no RNA was measured except in two subjects at the lowest dose of 2.5 μg. Subgenomic RNA was not detected on days 2 or 4, again except in one subject at the lowest dose.
[0070] [Figure 37A]Figures 37A-37B show reduction of SARS-CoV-2 viral replication by vaccine formulations disclosed herein, as assessed in nasal swabs, in Cynomolgus macaques. Cynomolgus macaques were administered BV2373 with MATRIX-M™, as indicated. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. Subjects were challenged with 1 x 10 SARS-CoV-2 virus on day 37. Viral RNA (Figure 37A) and viral subgenomic (sg) RNA (Figure 37B) were assessed by nasal swabs 2 and 4 days post-infection (d2pi and d4pi). Most subjects showed no viral RNA. Small amounts of RNA were measured in some subjects on days 2 and 4. Subgenomic RNA was not detected on either day 2 or day 4. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. These data demonstrate that the vaccine reduces nasal total viral RNA by 100-1000-fold and sgRNA to undetectable levels, confirming that the immune response to the vaccine blocks viral replication and prevents viral spread. [Figure 37B]Figures 37A-37B show reduction of SARS-CoV-2 viral replication by vaccine formulations disclosed herein, as assessed in nasal swabs, in Cynomolgus macaques. Cynomolgus macaques were administered BV2373 with MATRIX-M™, as indicated. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. Subjects were challenged with 1 x 10 SARS-CoV-2 virus on day 37. Viral RNA (Figure 37A) and viral subgenomic (sg) RNA (Figure 37B) were assessed by nasal swabs 2 and 4 days post-infection (d2pi and d4pi). Most subjects showed no viral RNA. Small amounts of RNA were measured in some subjects on days 2 and 4. Subgenomic RNA was not detected on either day 2 or day 4. Subjects were immunized on day 0, and in the two-dose group, on days 0 and 21. These data demonstrate that the vaccine reduces nasal total viral RNA by 100-1000-fold and sgRNA to undetectable levels, confirming that the immune response to the vaccine blocks viral replication and prevents viral spread.
[0071] [Figure 38A] Figures 38A-38B show anti-CoV S polypeptide IgG titers 21 and 35 days after immunization of Cynomolgus macaques with one dose (Figure 38A) or two doses (Figure 38B) of BV2373 and 25 μg or 50 μg of MATRIX-M™. [Figure 38B] Figures 38A-38B show anti-CoV S polypeptide IgG titers 21 and 35 days after immunization of Cynomolgus macaques with one dose (Figure 38A) or two doses (Figure 38B) of BV2373 and 25 μg or 50 μg of MATRIX-M™.
[0072] [Figure 38C]Figures 38C-38D show hACE2 inhibitory titers in Cynomolgus macaques 21 and 35 days after immunization with one (Figure 38C) or two (Figure 38D) doses of BV2373 (5 μg) and MATRIX-M™ (25 μg or 50 μg). [Figure 38D] Figures 38C-38D show hACE2 inhibitory titers in Cynomolgus macaques 21 and 35 days after immunization with one (Figure 38C) or two (Figure 38D) doses of BV2373 (5 μg) and MATRIX-M™ (25 μg or 50 μg).
[0073] [Figure 38E] Figure 38E shows a significant correlation between anti-CoV S polypeptide IgG titers and hACE2 inhibitory titers in Cynomolgus macaques after administration of BV2373 and MATRIX-M™. Data for groups 2-6 from Table 4 are shown.
[0074] [Figure 39] Figure 39 shows anti-CoV S polypeptide titers and hACE2 inhibitory titers in Cynomolgus macaques 35 days after immunization with two doses of BV2373 and MATRIX-M™ or with convalescent human serum (Groups 2, 4, and 6) from Table 4. These data demonstrate that the anti-CoV S polypeptide titers and hACE2 inhibitory titers of Cynomolgus macaques immunized with BV2373 and MATRIX-M™ are superior to those immunized with convalescent serum.
[0075] [Figure 40A]Figures 40A-40B show the SARS-CoV-2 neutralization titers of Cynomolgus macaques immunized with BV2373 and MATRIX-M™, as determined by cytopathic effect (CPE) (Figure 40A) and plaque reduction neutralization test (PRNT) (Figure 40B). [Figure 40B] Figures 40A-40B show the SARS-CoV-2 neutralization titers of Cynomolgus macaques immunized with BV2373 and MATRIX-M™, as determined by cytopathic effect (CPE) (Figure 40A) and plaque reduction neutralization test (PRNT) (Figure 40B).
[0076] [Figure 41] Figure 41 shows the timing of administration in a clinical trial evaluating the safety and efficacy of a vaccine containing BV2373 and, where appropriate, MATRIX-M™. AESI indicates adverse events of special interest. MAEE indicates adverse events requiring medical attention, and SAE indicates serious adverse events.
[0077] [Figure 42A] Figures 42A-42B show local (Figure 42A) and systemic (Figure 42B) adverse events experienced by patients in a clinical trial evaluating a vaccine containing BV2373 and MATRIX-M™. Groups A-E are identified in Table 5. The data indicate that the vaccine was well tolerated and safe. [Figure 42B] Figures 42A-42B show local (Figure 42A) and systemic (Figure 42B) adverse events experienced by patients in a clinical trial evaluating a vaccine containing BV2373 and MATRIX-M™. Groups A-E are identified in Table 5. The data indicate that the vaccine was well tolerated and safe.
[0078] [Figure 43A]Figures 43A-43B show anti-CoV S polypeptide IgG titers (Figure 43A) and neutralization titers (Figure 43B) 21 and 35 days after immunization in participants in a clinical trial evaluating a vaccine containing BV2373 and MATRIX-M™. Horizontal bars indicate the interquartile range (IRQ) and median area under the curve, respectively. Whisker endpoints equal the maximum and minimum values below or above the median ± 1.5 × IQR. The convalescent serum panel includes specimens from PCR-confirmed COVID-19 participants from Baylor College of Medicine (29 specimens for ELISA and 32 specimens for microneutralization (MN IC>99)). COVID-19 severity is indicated as a red mark for hospitalized patients (including intensive care settings), a blue mark for patients treated as outpatients (samples collected in the emergency department), and a green mark for asymptomatic (exposed) patients (samples collected from contact / exposure assessments). [Figure 43B] Figures 43A-43B show anti-CoV S polypeptide IgG titers (Figure 43A) and neutralization titers (Figure 43B) 21 and 35 days after immunization in participants in a clinical trial evaluating a vaccine containing BV2373 and MATRIX-M™. Horizontal bars indicate the interquartile range (IRQ) and median area under the curve, respectively. Whisker endpoints equal the maximum and minimum values below or above the median ± 1.5 × IQR. The convalescent serum panel includes specimens from PCR-confirmed COVID-19 participants from Baylor College of Medicine (29 specimens for ELISA and 32 specimens for microneutralization (MN IC>99)). COVID-19 severity is indicated as a red mark for hospitalized patients (including intensive care settings), a blue mark for patients treated as outpatients (samples collected in the emergency department), and a green mark for asymptomatic (exposed) patients (samples collected from contact / exposure assessments).
[0079] [Figure 44A]Figures 44A-44C show the correlation between anti-CoV S polypeptide IgG titers and neutralizing antibody titers in patients administered convalescent serum (Figure 44A), two 25 μg doses of BV2373 (Figure 44B), and two doses (5 μg and 25 μg) of BV2373 with MATRIX-M™ (Figure 44C). A strong correlation was observed between neutralizing antibody titers and anti-CoV-S IgG titers in patients treated with convalescent serum or adjuvanted BV2373, but not in patients treated with BV2373 in the absence of adjuvant. [Figure 44B] Figures 44A-44C show the correlation between anti-CoV S polypeptide IgG titers and neutralizing antibody titers in patients administered convalescent serum (Figure 44A), two 25 μg doses of BV2373 (Figure 44B), and two doses (5 μg and 25 μg) of BV2373 with MATRIX-M™ (Figure 44C). A strong correlation was observed between neutralizing antibody titers and anti-CoV-S IgG titers in patients treated with convalescent serum or adjuvanted BV2373, but not in patients treated with BV2373 in the absence of adjuvant. [Figure 44C] Figures 44A-44C show the correlation between anti-CoV S polypeptide IgG titers and neutralizing antibody titers in patients administered convalescent serum (Figure 44A), two 25 μg doses of BV2373 (Figure 44B), and two doses (5 μg and 25 μg) of BV2373 with MATRIX-M™ (Figure 44C). A strong correlation was observed between neutralizing antibody titers and anti-CoV-S IgG titers in patients treated with convalescent serum or adjuvanted BV2373, but not in patients treated with BV2373 in the absence of adjuvant.
[0080] [Figure 45A]Figures 45A-45D show the frequency of antigen-specific CD4+ T cells producing the T helper 1 (Th1) cytokines interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2, and the T helper 2 (Th2) cytokines IL-5 and IL-13, shown in cytokines from participants in Groups A (placebo, Figure 45A), B (25 μg BV2373, Figure 45B), C (5 μg BV2373 and 50 μg MATRIX-M™, Figure 45C), and D (25 μg BV2373 and 50 μg MATRIX-M™, Figure 45D) after stimulation with BV2373. "Any two" in the Th1 cytokine panel refers to CD4+ T cells capable of producing two types of Th1 cytokines at the same time point. "All three" refers to CD4+ T cells that simultaneously produce IFN-γ, TNF-α, and IL-2. "Both" in the Th2 panel refers to CD4+ T cells that can produce the Th2 cytokines IL-5 and IL-13 at the same time. [Figure 45B] Figures 45A-45D show the frequency of antigen-specific CD4+ T cells producing the T helper 1 (Th1) cytokines interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2, and the T helper 2 (Th2) cytokines IL-5 and IL-13, shown in cytokines from participants in Groups A (placebo, Figure 45A), B (25 μg BV2373, Figure 45B), C (5 μg BV2373 and 50 μg MATRIX-M™, Figure 45C), and D (25 μg BV2373 and 50 μg MATRIX-M™, Figure 45D) after stimulation with BV2373. "Any two" in the Th1 cytokine panel refers to CD4+ T cells capable of producing two types of Th1 cytokines at the same time point. "All three" refers to CD4+ T cells that simultaneously produce IFN-γ, TNF-α, and IL-2. "Both" in the Th2 panel refers to CD4+ T cells that can produce the Th2 cytokines IL-5 and IL-13 at the same time. [Figure 45C]Figures 45A-45D show the frequency of antigen-specific CD4+ T cells producing the T helper 1 (Th1) cytokines interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2, and the T helper 2 (Th2) cytokines IL-5 and IL-13, shown in cytokines from participants in Groups A (placebo, Figure 45A), B (25 μg BV2373, Figure 45B), C (5 μg BV2373 and 50 μg MATRIX-M™, Figure 45C), and D (25 μg BV2373 and 50 μg MATRIX-M™, Figure 45D) after stimulation with BV2373. "Any two" in the Th1 cytokine panel refers to CD4+ T cells capable of producing two types of Th1 cytokines at the same time point. "All three" refers to CD4+ T cells that simultaneously produce IFN-γ, TNF-α, and IL-2. "Both" in the Th2 panel refers to CD4+ T cells that can produce the Th2 cytokines IL-5 and IL-13 at the same time. [Figure 45D] Figures 45A-45D show the frequency of antigen-specific CD4+ T cells producing the T helper 1 (Th1) cytokines interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2, and the T helper 2 (Th2) cytokines IL-5 and IL-13, shown in cytokines from participants in Groups A (placebo, Figure 45A), B (25 μg BV2373, Figure 45B), C (5 μg BV2373 and 50 μg MATRIX-M™, Figure 45C), and D (25 μg BV2373 and 50 μg MATRIX-M™, Figure 45D) after stimulation with BV2373. "Any two" in the Th1 cytokine panel refers to CD4+ T cells capable of producing two types of Th1 cytokines at the same time point. "All three" refers to CD4+ T cells that simultaneously produce IFN-γ, TNF-α, and IL-2. "Both" in the Th2 panel refers to CD4+ T cells that can produce the Th2 cytokines IL-5 and IL-13 at the same time.
[0081] [Figure 46A-B] Figure 46A shows the primary structure of the wild-type SARS-CoV-2 S polypeptide containing the signal peptide, numbered relative to SEQ ID NO: 1. Figure 46B shows the primary structure of the wild-type SARS-CoV-2 S polypeptide without the signal peptide, numbered relative to SEQ ID NO: 2.
[0082] [Figure 47] Figure 47 shows the randomization of subjects in a Phase 3 clinical trial evaluating the efficacy, immunogenicity and safety of BV2373 in combination with Fraction A and Fraction C Iscom Matrix (MATRIX-M™) adjuvants.
[0083] [Figure 48] Figure 48 is a Kaplan-Meyer plot showing the incidence of symptomatic COVID-19 (cumulative event rate (%) experienced by subjects after vaccination with BV2373 in combination with Iscom Matrix (MATRIX-M™) or placebo in Fraction A and Fraction C).
[0084] [Figure 49] Figure 49 shows the vaccine efficacy of BV2373 in combination with Fraction A and Fraction C iscom matrix (MATRIX-M™) against SARS-CoV-2 containing a CoV S polypeptide having the amino acid sequence of SEQ ID NO:1, or a heterologous B.1.1.7 SARS-CoV-2 strain containing a CoV S polypeptide with a deletion of amino acids 69, 70, and 144 and the following mutations: N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H.
[0085] [Figure 50]Figure 50 is a graph showing adverse events experienced by subjects after the first vaccination dose (labeled "Vaccination 1") and second vaccination dose (labeled "Vaccination 2") with BV2373 (labeled "A") or placebo (labeled "B") in combination with Fraction A and Fraction C Iscom Matrix (MATRIX-M™).
[0086] [Figure 51] Figure 51 shows a diagram of the BV2438 CoV S polypeptide. Structural elements include a cleavable signal peptide (SP), N-terminal domain (NTD), receptor binding domain (RBD), subdomains 1 and 2 (SD1 and SD2), the S2 cleavage site (S2'), the fusion peptide (FP), heptad repeat 1 (HR1), the central helix (CH), heptad repeat 2 (HR2), the transmembrane domain (TM), and the cytoplasmic tail (CT). Amino acid changes from the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 1 are indicated in black text below the line drawing.
[0087] [Figure 52A] Figure 52A shows a Coomassie blue-stained reducing SDS-PAGE gel of purified full-length BV2438, showing the major protein product at the expected molecular weight of approximately 170 kD. Figure 52B shows a scanning densitometry graph. Figure 52C shows a negative-stain transmission electron micrograph of BV2438. BV2438 forms well-defined, bulb-shaped particles with a length of 15 nm and a width of 11 nm (left panel). Trimers exhibited an 8 nm flexible linker connected to PS-80 micelles (left panel). Class average images showed good agreement between the rS-B.1.351 trimer and the cryo-EM-solved structure of the prefusion SARS-CoV-2 trimeric spike protein ectodomain (PDB ID 6VXX) overlaid on the 2D image (center panel). The right panel shows two BV2438 trimers anchored to PS-80 micelles. [Figure 52B] Figure 52A shows a Coomassie blue-stained reducing SDS-PAGE gel of purified full-length BV2438, showing the major protein product at the expected molecular weight of approximately 170 kD. Figure 52B shows a scanning densitometry graph. Figure 52C shows a negative-stain transmission electron micrograph of BV2438. BV2438 forms well-defined, bulb-shaped particles with a length of 15 nm and a width of 11 nm (left panel). Trimers exhibited an 8 nm flexible linker connected to PS-80 micelles (left panel). Class average images showed good agreement between the rS-B.1.351 trimer and the cryo-EM-solved structure of the prefusion SARS-CoV-2 trimeric spike protein ectodomain (PDB ID 6VXX) overlaid on the 2D image (center panel). The right panel shows two BV2438 trimers anchored to PS-80 micelles. [Figure 52C] Figure 52A shows a Coomassie blue-stained reducing SDS-PAGE gel of purified full-length BV2438, showing the major protein product at the expected molecular weight of approximately 170 kD. Figure 52B shows a scanning densitometry graph. Figure 52C shows a negative-stain transmission electron micrograph of BV2438. BV2438 forms well-defined, bulb-shaped particles with a length of 15 nm and a width of 11 nm (left panel). Trimers exhibited an 8 nm flexible linker connected to PS-80 micelles (left panel). Class average images showed good agreement between the rS-B.1.351 trimer and the cryo-EM-solved structure of the prefusion SARS-CoV-2 trimeric spike protein ectodomain (PDB ID 6VXX) overlaid on the 2D image (center panel). The right panel shows two BV2438 trimers anchored to PS-80 micelles.
[0088] [Figure 53]Figure 53 shows the mouse study design for Example 10. Groups of mice (n=20 / group) were immunized with various combinations of recombinant S (rS) BV2438 (SA) or BV2373 (WU) proteins in a prime / boost regimen on study days 0 and 14. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 + BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo). Serum and tissues were collected at the time points listed in the figure.
[0089] [Figure 54A-B]Figures 54A-54B show anti-SARS-CoV-2 S IgG serum titers in serum collected on day 21 of the mouse study in Example 10. ELISA was used to measure antibody titers against the Wuhan-Hu-1 spike protein (Figure 54A) or B.1.351 spike protein (Figure 54B). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figures 54C-D show functional antibody titers (measured by ELISA) in serum collected on day 21 that were capable of disrupting binding between the SARS-CoV-2 receptor hACE2 and the Wuhan-Hu-1 spike protein (Figure 54C) or B.1.351 spike protein (Figure 54D). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figure 54E shows SARS-CoV-2 neutralizing antibody titers in serum collected on day 32 from n=5 animals / group were determined using a PRNT assay. Sera were evaluated for their ability to neutralize SARS-CoV-2 USA-WA1, B.1.351 variant, or B.1.1.7 variant. For each group, bars indicate geometric mean titers (GMTs), and error bars indicate 95% confidence intervals (CIs). Individual animal titers are indicated by symbols. Statistical significance was calculated by performing one-way ANOVA with Tukey's post-hoc test on log10 transformed data. [Fig. 54C-D]Figures 54A-54B show anti-SARS-CoV-2 S IgG serum titers in serum collected on day 21 of the mouse study in Example 10. ELISA was used to measure antibody titers against the Wuhan-Hu-1 spike protein (Figure 54A) or B.1.351 spike protein (Figure 54B). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figures 54C-D show functional antibody titers (measured by ELISA) in serum collected on day 21 that were capable of disrupting binding between the SARS-CoV-2 receptor hACE2 and the Wuhan-Hu-1 spike protein (Figure 54C) or B.1.351 spike protein (Figure 54D). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figure 54E shows SARS-CoV-2 neutralizing antibody titers in serum collected on day 32 from n=5 animals / group were determined using a PRNT assay. Sera were evaluated for their ability to neutralize SARS-CoV-2 USA-WA1, B.1.351 variant, or B.1.1.7 variant. For each group, bars indicate geometric mean titers (GMTs), and error bars indicate 95% confidence intervals (CIs). Individual animal titers are indicated by symbols. Statistical significance was calculated by performing one-way ANOVA with Tukey's post-hoc test on log10 transformed data. [Figure 54E]Figures 54A-54B show anti-SARS-CoV-2 S IgG serum titers in serum collected on day 21 of the mouse study in Example 10. ELISA was used to measure antibody titers against the Wuhan-Hu-1 spike protein (Figure 54A) or B.1.351 spike protein (Figure 54B). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figures 54C-D show functional antibody titers (measured by ELISA) in serum collected on day 21 that were capable of disrupting binding between the SARS-CoV-2 receptor hACE2 and the Wuhan-Hu-1 spike protein (Figure 54C) or B.1.351 spike protein (Figure 54D). For each group, the bars indicate the geometric mean titer (GMT), and the error bars indicate the 95% confidence interval (CI). Individual animal titers are indicated by colored symbols. Figure 54E shows SARS-CoV-2 neutralizing antibody titers in serum collected on day 32 from n=5 animals / group were determined using a PRNT assay. Sera were evaluated for their ability to neutralize SARS-CoV-2 USA-WA1, B.1.351 variant, or B.1.1.7 variant. For each group, bars indicate geometric mean titers (GMTs), and error bars indicate 95% confidence intervals (CIs). Individual animal titers are indicated by symbols. Statistical significance was calculated by performing one-way ANOVA with Tukey's post-hoc test on log10 transformed data.
[0090] [Figure 55A]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation. [Figure 55B]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation. [Figure 55C]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation. [Figure 55D]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation. [Figure 55E]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation. [Figure 55F]Figures 55A-55F show the protective efficacy of immunization with SARS-CoV-2 rS based on Wuhan-Hu-1 or B.1.351 against challenge with live SARS-CoV-2 B.1.351 or B.1.1.7 viruses. The study design is described in Figure 53. Immunized mice (n=10 / group) were challenged with live SARS-CoV-2 B.1.351 (left panel) or B.1.1.7 (right panel). Mice were weighed daily for 4 days after challenge, and their percentage weight loss was calculated relative to their weight on the day of challenge. Figures 55A and 55B show the mean percentage weight loss as symbols. Error bars indicate the standard error of the mean. Half of the mice were sacrificed 2 days after challenge, and lung tissue was subjected to a plaque formation assay to determine lung virus titers (Figures 55C, 55D). The remaining mice were sacrificed 4 days after challenge. Figures 55E and 55F show the levels of SARS-CoV-2 subgenomic RNA in lung tissue, expressed as the fold change in RNA compared to the mean in each placebo group 2 days after challenge. Horizontal bars indicate the group mean fold change from n = 5 mice at each time point, and error bars indicate the standard deviation.
[0091] [Figure 56A]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56B]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56C]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56D]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56E]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56F]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56G]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001. [Figure 56H]Figures 56A-56H show cell-mediated immunity induced upon immunization with BV2373 or BV2438 regimens in mice. Figure 56A shows the mouse study design. Groups of mice (n=8 / group) were immunized with various combinations of SARS-CoV-2 rS based on BV2373 or BV2438 in a prime / boost regimen on days 0 and 21. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg of rS total). All immunizations were administered with 5 μg of MATRIX-M1 adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Splenocytes were stimulated with BV2373 or BV2438 and then subjected to ELISA to determine IFN-γ-positive cells as a representative Th1 cytokine (Figure 56B) and IL-5-positive cells as a representative Th2 cytokine (Figure 56C). Data from Figures 56B and 56C were used to calculate the Th1 / Th2 balance of the response to immunization (Figure 56D). Figure 56E shows that the number of polyfunctional CD4+ T cells stained positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was quantified using intracellular cytokine staining and expressed as the number of triple-cytokine-positive cells per 106 CD4+ T cells. Figure 56F shows the quantification of T follicular helper cells. T follicular helper cells were quantified by determining the percentage of PD-1+CXCR5+ cells among total CD4+ T cells. Figure 56G shows germinal center formation. Germinal center formation was assessed by determining the percentage of GL7+CD95+ cells among CD19+ B cells using flow cytometry. Gray bars indicate the mean, and error bars indicate the standard deviation. Individual animal data are indicated by colored symbols. An example of a gating strategy is shown in Figure 56H.Differences between experimental groups were assessed by one-way ANOVA with Tukey's post-hoc test (data in Figure 56B were log transformed before analysis). A p-value <0.05 was considered statistically significant; ****=p<0.0001.
[0092] [Figure 57A] Figures 57A-57E show CD4+ and CD8+ T cell responses from immunization with BV2373 or BV2438. Groups of mice (n=8 / group) were immunized with various combinations of BV2373 or BV2438 on days 0 and 21 in a prime / boost regimen. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Isolated splenocytes were stimulated with either rS-WU1 or rS-B.1.351 and then subjected to intracellular cytokine staining to determine whether CD4+ T cells were positive for IFN-γ (Figure 57A), IL-2 (Figure 57B), TNF-α (Figure 57C), or IL-4 (Figure 57D). To test CD8+ T cell responses, cells were stimulated with a peptide pool corresponding to the entire Wuhan-Hu-1 spike protein sequence and then subjected to ICS for IFN-γ, IL-2, and TNF-α (Figure 57E). [Figure 57B]Figures 57A-57E show CD4+ and CD8+ T cell responses from immunization with BV2373 or BV2438. Groups of mice (n=8 / group) were immunized with various combinations of BV2373 or BV2438 on days 0 and 21 in a prime / boost regimen. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Isolated splenocytes were stimulated with either rS-WU1 or rS-B.1.351 and then subjected to intracellular cytokine staining to determine whether CD4+ T cells were positive for IFN-γ (Figure 57A), IL-2 (Figure 57B), TNF-α (Figure 57C), or IL-4 (Figure 57D). To test CD8+ T cell responses, cells were stimulated with a peptide pool corresponding to the entire Wuhan-Hu-1 spike protein sequence and then subjected to ICS for IFN-γ, IL-2, and TNF-α (Figure 57E). [Figure 57C]Figures 57A-57E show CD4+ and CD8+ T cell responses from immunization with BV2373 or BV2438. Groups of mice (n=8 / group) were immunized with various combinations of BV2373 or BV2438 on days 0 and 21 in a prime / boost regimen. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Isolated splenocytes were stimulated with either rS-WU1 or rS-B.1.351 and then subjected to intracellular cytokine staining to determine whether CD4+ T cells were positive for IFN-γ (Figure 57A), IL-2 (Figure 57B), TNF-α (Figure 57C), or IL-4 (Figure 57D). To test CD8+ T cell responses, cells were stimulated with a peptide pool corresponding to the entire Wuhan-Hu-1 spike protein sequence and then subjected to ICS for IFN-γ, IL-2, and TNF-α (Figure 57E). [Figure 57D]Figures 57A-57E show CD4+ and CD8+ T cell responses from immunization with BV2373 or BV2438. Groups of mice (n=8 / group) were immunized with various combinations of BV2373 or BV2438 on days 0 and 21 in a prime / boost regimen. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Isolated splenocytes were stimulated with either rS-WU1 or rS-B.1.351 and then subjected to intracellular cytokine staining to determine whether CD4+ T cells were positive for IFN-γ (Figure 57A), IL-2 (Figure 57B), TNF-α (Figure 57C), or IL-4 (Figure 57D). To test CD8+ T cell responses, cells were stimulated with a peptide pool corresponding to the entire Wuhan-Hu-1 spike protein sequence and then subjected to ICS for IFN-γ, IL-2, and TNF-α (Figure 57E). [Figure 57E]Figures 57A-57E show CD4+ and CD8+ T cell responses from immunization with BV2373 or BV2438. Groups of mice (n=8 / group) were immunized with various combinations of BV2373 or BV2438 on days 0 and 21 in a prime / boost regimen. Mice were either primed and boosted with BV2438, primed and boosted with BV2373, primed with BV2373 and boosted with BV2438, or primed and boosted with bivalent BV2373 and BV2438. The antigen dose was 1 μg of rS for each monovalent immunization or 1 μg of rS for each construct during bivalent immunization (2 μg total of rS). All antigen doses were administered with 5 μg of saponin adjuvant. The control group received formulation buffer (placebo, n=5). Spleens were harvested on day 28 for cell collection. Isolated splenocytes were stimulated with either rS-WU1 or rS-B.1.351 and then subjected to intracellular cytokine staining to determine whether CD4+ T cells were positive for IFN-γ (Figure 57A), IL-2 (Figure 57B), TNF-α (Figure 57C), or IL-4 (Figure 57D). To test CD8+ T cell responses, cells were stimulated with a peptide pool corresponding to the entire Wuhan-Hu-1 spike protein sequence and then subjected to ICS for IFN-γ, IL-2, and TNF-α (Figure 57E).
[0093] [Figure 58A]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58B]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58C]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58D]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58E]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58F]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data. [Figure 58G]Figures 58A-58G show the immunogenicity of one or two booster BV2438 doses approximately one year after immunization with BV2373 in baboons. Figure 58A shows the study design. Small cohorts of baboons (n=2-3 / group) were initially immunized with 1 μg, 5 μg, or 25 μg of BV2373 with saponin adjuvant, or 25 μg of unadjuvanted BV2373, on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). Figure 58B shows anti-CoV S IgG titers over the course of the study. Individual animal titers are shown over time, with different colored symbols and lines indicating different dose groups for the primary rS-WU1 immunization series. Sera collected before the BV2438 boost (day 303) and 7, 21, 35, and 81 days after the boost were analyzed to determine anti-rS-WU1 (Figure 58C) and rS-B.1.351 (Figure 58D) IgG titers by ELISA (horizontal lines indicate means), antibody titers capable of disrupting the interaction between rS-WU1 or rS-B.1.351 and the hACE2 receptor by ELISA (Figure 58E, horizontal lines indicate means), and antibody titers capable of neutralizing SARS-CoV-2 strains USA-WA1, B.1.351, and B.1.1.7 using a PRNT assay (Figure 58F, gray bars indicate geometric means, error bars indicate 95% confidence intervals). The presence of polyfunctional CD4+ T cells positive for three Th1 cytokines (IFN-γ, IL-2, and TNF-α) was assessed using intracellular cytokine staining after stimulation with BV2373 or BV2438 (Figure 58G). Gray bars indicate the mean, and colored symbols indicate individual animal data.
[0094] [Figure 59A]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59B]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59C]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59D]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59E]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59F]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells. [Figure 59G]Figures 59A-59G show individual cytokine responses to BV2438 boosting in baboons. Small cohorts of baboons (n=2-3 / group) were immunized with 1 μg, 5 μg, or 25 μg of BV2373 with 50 μg of saponin adjuvant, or 25 μg of unadjuvanted BV2373 on days 0 and 21 (weeks 0 and 3, respectively). Approximately one year later, all animals were boosted with one or two doses of 3 μg of BV2438 with 50 μg of saponin adjuvant on days 318 and 339 (weeks 45 and 48, respectively). PBMCs were collected before the boost (day 303; week 43), 7 days after the first rS-B.1.351 boost (day 325; week 46), and 35 days after the first rS-B.1.351 boost (day 353; week 50). PBMCs were stimulated with BV2373 or BV2438 and subjected to ELISA to measure (Figure 59A) IFN-γ-producing cells as a Th1 cytokine and (Figure 59B) IL-4-producing cells as a Th2 cytokine. CD4+ T cells were also stimulated with BV2373 or BV2438 and then subjected to ICS to measure IFN-γ (Figure 59C), IL-2 (Figure 59D), TNF-α (Figure 59E), IL-5 (Figure 59F), and IL-13 (Figure 59G)-producing cells.
[0095] [Figure 60A] Figures 60A-60B show SARS-CoV-2 variant neutralization titers from human subjects immunized with BV2373. Serum samples from clinical study participants (n=30) were subjected to a PRNT assay to determine the presence of neutralizing antibodies against USA-WA1 compared to B.1.1.7 (Figure 60A) and B.1.351 (Figure 60B). Individual subject titers are indicated by black circles, and lines link individuals' titers against USA-WA1 to their titers against each variant. [Figure 60B]Figures 60A-60B show SARS-CoV-2 variant neutralization titers from human subjects immunized with BV2373. Serum samples from clinical study participants (n=30) were subjected to a PRNT assay to determine the presence of neutralizing antibodies against USA-WA1 compared to B.1.1.7 (Figure 60A) and B.1.351 (Figure 60B). Individual subject titers are indicated by black circles, and lines link individuals' titers against USA-WA1 to their titers against each variant.
[0096] [Figure 61] Figure 61 plots the number of days since a SARS-CoV-2 variant (e.g., B.1.1.529 ("Omicron"), delta, or beta variant) accounted for 1% of sequenced SARS-CoV-2 infections against the percentage of SARS-CoV-2 infections caused by that variant in South Africa. The plot shows that the Omicron variant spreads more quickly than and outcompetes other variants.
[0097] [Figure 62] Figure 62 shows that positive tests for SARS-CoV-2 increased from 1% to 30% in Tshwane, South Africa. The Omicron variant was first discovered on November 11, 2021, suggesting that the increased positive tests were caused by the Omicron variant.
[0098] [Figure 63] Figure 63 shows mutations in the S protein of the SARS-CoV-2 Omicron variant compared to the S protein of the SARS-CoV-2 protein having the sequence of SEQ ID NO: 1.
[0099] [Figure 64]Figure 64 shows the locations of mutations in the S protein of the SARS-CoV-2 omicron variant. The omicron variant contains multiple mutations in the RBD and NTD, mutations adjacent to the furin cleavage site (H655Y; N679K; P681H), a deletion of amino acids 105-107, and R203K and G204R mutations in the nucleocapsid.
[0100] [Figure 65A-B] Figures 65A-65D show that CoV S spike polypeptides BV2373 (Figure 65A) and BV2509 (Figure 65B) bind to hACE2 with similar binding kinetics. ELISA shows that BV2373 polypeptide (Figure 65C) and BV2509 (Figure 65D) bind to hACE2 with similar affinity. [Fig. 65C-D] Figures 65A-65D show that CoV S spike polypeptides BV2373 (Figure 65A) and BV2509 (Figure 65B) bind to hACE2 with similar binding kinetics. ELISA shows that BV2373 polypeptide (Figure 65C) and BV2509 (Figure 65D) bind to hACE2 with similar affinity.
[0101] [Figure 66A] Figures 66A-66B show anti-S protein IgG titers before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 66A shows the fold increase from day 35 to day 217. Figure 66B shows the fold increase from day 189 to day 217. [Figure 66B]Figures 66A-66B show anti-S protein IgG titers before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 66A shows the fold increase from day 35 to day 217. Figure 66B shows the fold increase from day 189 to day 217.
[0102] [Figure 67A] Figures 67A-67D show functional hACE2 inhibition before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 67A shows the fold increase from day 35 to day 217. Figure 67B shows the fold increase from day 189 to day 217. Figure 67C shows the fold increase from day 35 to day 217. Figure 67D shows functional hACE2 inhibition in adolescents. Adolescents (12-18 years old) demonstrated 2.4-4 times higher functional immune responses to the variants than adults. [Figure 67B]Figures 67A-67D show functional hACE2 inhibition before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 67A shows the fold increase from day 35 to day 217. Figure 67B shows the fold increase from day 189 to day 217. Figure 67C shows the fold increase from day 35 to day 217. Figure 67D shows functional hACE2 inhibition in adolescents. Adolescents (12-18 years old) demonstrated 2.4-4 times higher functional immune responses to the variants than adults. [Figure 67C] Figures 67A-67D show functional hACE2 inhibition before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 67A shows the fold increase from day 35 to day 217. Figure 67B shows the fold increase from day 189 to day 217. Figure 67C shows the fold increase from day 35 to day 217. Figure 67D shows functional hACE2 inhibition in adolescents. Adolescents (12-18 years old) demonstrated 2.4-4 times higher functional immune responses to the variants than adults. [Figure 67D]Figures 67A-67D show functional hACE2 inhibition before and after boosting with BV2373 and saponin adjuvant against the following SARS-CoV-2 variants: (i) SARS-CoV-2 viruses having a CoV S polypeptide with a D614G mutation compared to the protein having the amino acid sequence of SEQ ID NO: 1; (ii) SARS-CoV-2 alpha, beta, delta, and omicron strains. Figure 67A shows the fold increase from day 35 to day 217. Figure 67B shows the fold increase from day 189 to day 217. Figure 67C shows the fold increase from day 35 to day 217. Figure 67D shows functional hACE2 inhibition in adolescents. Adolescents (12-18 years old) demonstrated 2.4-4 times higher functional immune responses to the variants than adults.
[0103] [Figure 68] FIG. 68 shows a booster dosing diagram for participants in the study described in Example 11.
[0104] [Figure 69A] 69A-69B show the local (FIG. 69A) and systemic (FIG. 69B) reactogenicity of patients in Group B2 of the study described in Example 11. [Figure 69B] 69A-69B show the local (FIG. 69A) and systemic (FIG. 69B) reactogenicity of patients in Group B2 of the study described in Example 11.
[0105] [Figure 70] Figure 70 shows serum IgG titers against ancestral SARS-CoV-2 strains by study day for patients described in Example 11.
[0106] [Figure 71] Figure 71 shows neutralizing antibody activity against ancestral SARS-CoV-2 strains by study date for patients described in Example 11.
[0107] [Figure 72] Figure 72 shows neutralizing antibody 99 (neut99) values for immunogenic compositions comprising BV2373 and a saponin adjuvant of Example 11 against SARS-CoV-2 strains containing the D614G mutation, B.1.617.2 (delta variant) and B.1.1.529 (omicron variant).
[0108] [Figure 73] Figure 73 shows neutralizing antibody 99 (neut99) values for immunogenic compositions comprising BV2373, BV2509, or a combination thereof with a saponin adjuvant (see Example 12) against the SARS-CoV-2 Omicron BA.1, WA1, and delta variants.
[0109] [Figure 74A] Figures 74A-74B show viral load in mouse lungs 2 days after challenge with the SARS CoV-2 Omicron BA.1 variant (Figure 74A) or the WA1 variant (Figure 74B). Each composition reduced viral load compared to placebo. Mice were immunized according to the method of Example 12. [Figure 74B] Figures 74A-74B show viral load in mouse lungs 2 days after challenge with the SARS CoV-2 Omicron BA.1 variant (Figure 74A) or the WA1 variant (Figure 74B). Each composition reduced viral load compared to placebo. Mice were immunized according to the method of Example 12.
[0110] [Fig. 75A-D] Figures 75A-75E show Tris-acetate gels of purified SARS-CoV-2 S proteins having the sequences of SEQ ID NO: 186 (Figure 75A); SEQ ID NO: 188 (Figure 75B); SEQ ID NO: 190 (Figure 75C); SEQ ID NO: 192 (Figure 75D) and SEQ ID NO: 87 (Figure 75E). [Figure 75E]Figures 75A-75E show Tris-acetate gels of purified SARS-CoV-2 S proteins having the sequences of SEQ ID NO: 186 (Figure 75A); SEQ ID NO: 188 (Figure 75B); SEQ ID NO: 190 (Figure 75C); SEQ ID NO: 192 (Figure 75D) and SEQ ID NO: 87 (Figure 75E).
[0111] [Fig. 76A-D] Figures 76A-76E show the particle size distribution of proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 76A); SEQ ID NO: 186 (Figure 76B); SEQ ID NO: 190 (Figure 76C); SEQ ID NO: 192 (Figure 76D) and SEQ ID NO: 87 (Figure 76E) (see Example 8). [Figure 76E] Figures 76A-76E show the particle size distribution of proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 76A); SEQ ID NO: 186 (Figure 76B); SEQ ID NO: 190 (Figure 76C); SEQ ID NO: 192 (Figure 76D) and SEQ ID NO: 87 (Figure 76E) (see Example 8).
[0112] [Fig. 77A-B] Figures 77A-77E show HPLC-SEC traces of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 77A); SEQ ID NO: 186 (Figure 77B); SEQ ID NO: 190 (Figure 77C); SEQ ID NO: 192 (Figure 77D) and SEQ ID NO: 87 (Figure 77E). [Fig. 77C-D] Figures 77A-77E show HPLC-SEC traces of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 77A); SEQ ID NO: 186 (Figure 77B); SEQ ID NO: 190 (Figure 77C); SEQ ID NO: 192 (Figure 77D) and SEQ ID NO: 87 (Figure 77E). [Figure 77E] Figures 77A-77E show HPLC-SEC traces of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 77A); SEQ ID NO: 186 (Figure 77B); SEQ ID NO: 190 (Figure 77C); SEQ ID NO: 192 (Figure 77D) and SEQ ID NO: 87 (Figure 77E).
[0113] [Fig. 78A-B] Figures 78A-78E show the binding kinetics of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 78A); SEQ ID NO: 186 (Figure 78B); SEQ ID NO: 190 (Figure 78C); SEQ ID NO: 192 (Figure 78D) and SEQ ID NO: 87 (Figure 78E). [Fig. 78C-D] Figures 78A-78E show the binding kinetics of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 78A); SEQ ID NO: 186 (Figure 78B); SEQ ID NO: 190 (Figure 78C); SEQ ID NO: 192 (Figure 78D) and SEQ ID NO: 87 (Figure 78E). [Figure 78E] Figures 78A-78E show the binding kinetics of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 78A); SEQ ID NO: 186 (Figure 78B); SEQ ID NO: 190 (Figure 78C); SEQ ID NO: 192 (Figure 78D) and SEQ ID NO: 87 (Figure 78E).
[0114] [Fig. 79A-B] Figures 79A-79E show the binding of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 79A); SEQ ID NO: 186 (Figure 79B); SEQ ID NO: 190 (Figure 79C); SEQ ID NO: 192 (Figure 79D) and SEQ ID NO: 87 (Figure 79E) to hACE2. [Fig. 79C-D] Figures 79A-79E show the binding of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 79A); SEQ ID NO: 186 (Figure 79B); SEQ ID NO: 190 (Figure 79C); SEQ ID NO: 192 (Figure 79D) and SEQ ID NO: 87 (Figure 79E) to hACE2. [Figure 79E] Figures 79A-79E show the binding of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 79A); SEQ ID NO: 186 (Figure 79B); SEQ ID NO: 190 (Figure 79C); SEQ ID NO: 192 (Figure 79D) and SEQ ID NO: 87 (Figure 79E) to hACE2.
[0115] [Figure 80A-B]Figures 80A-80E show the thermal stability of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 80A); SEQ ID NO: 186 (Figure 80B); SEQ ID NO: 190 (Figure 80C); SEQ ID NO: 192 (Figure 80D) and SEQ ID NO: 87 (Figure 80E). [Fig. 80C-D] Figures 80A-80E show the thermal stability of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 80A); SEQ ID NO: 186 (Figure 80B); SEQ ID NO: 190 (Figure 80C); SEQ ID NO: 192 (Figure 80D) and SEQ ID NO: 87 (Figure 80E). [Figure 80E] Figures 80A-80E show the thermal stability of SARS-CoV-2 S proteins having the amino acid sequences of SEQ ID NO: 188 (Figure 80A); SEQ ID NO: 186 (Figure 80B); SEQ ID NO: 190 (Figure 80C); SEQ ID NO: 192 (Figure 80D) and SEQ ID NO: 87 (Figure 80E).
[0116] [Figure 81] Figure 81 shows the crystal structure of the SARS-CoV-2 S protein having the amino acid sequences of SEQ ID NO:2; SEQ ID NO:188; and SEQ ID NO:92. DETAILED DESCRIPTION OF THE INVENTION
[0117] Detailed Description of the Invention definition As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a protein" can refer to one protein or a mixture of such proteins, reference to "the method" includes reference to equivalent steps and / or methods known to those skilled in the art, and so forth.
[0118] As used herein, the term "adjuvant" refers to a compound that, when used in combination with an immunogen, enhances or otherwise alters or modifies the immune response elicited against the immunogen. Modification of the immune response can include increasing or broadening the specificity of either or both the antibody and cellular immune responses.
[0119] As used herein, the terms "about" or "approximately," when preceding a numerical value, indicate a range of that value plus or minus 10%. For example, "about 100" includes 90 and 110.
[0120] As used herein, the terms "immunogen," "antigen," and "epitope" refer to substances such as proteins, including glycoproteins and peptides, that are capable of eliciting an immune response.
[0121] As used herein, an "immunogenic composition" is a composition that includes an antigen, the administration of which to a subject results in the development in the subject of a humoral and / or cellular immune response to the antigen.
[0122] As used herein, a "subunit" composition, e.g., a vaccine, comprises one or more selected antigens from a pathogen, but not all antigens. Such compositions are substantially free of intact virus or lysates of such cells or particles, and are typically prepared from immunogenic polypeptides that have been at least partially purified, often substantially purified, from the pathogen. The antigens in the subunit compositions disclosed herein are typically prepared recombinantly, often using a baculovirus system.
[0123] As used herein, "substantially" refers to the isolation of a substance (e.g., a compound, polynucleotide, or polypeptide) such that the substance constitutes the majority percentage of the sample in which it is contained. For example, in a sample, a substantially purified component constitutes 85% of the sample, preferably 85% to 90%, more preferably at least 95% to 99.5%, and most preferably at least 99%. When a component is substantially replaced, the amount remaining in the sample is less than or equal to about 0.5% to about 10%, preferably about 0.5% to about 1.0%.
[0124] The terms "treat," "treatment," and "treating," as used herein, refer to an approach for obtaining beneficial or desired results, e.g., clinical results. For purposes of this disclosure, beneficial or desired results may include inhibiting or suppressing the onset or progression of an infection or disease; ameliorating the symptoms of, or reducing the occurrence of, an infection or disease; or a combination thereof.
[0125] "Prevention," as used herein, is used interchangeably with "prophylaxis" and can mean the complete prevention of an infection or disease, or the prevention of the onset of symptoms of that infection or disease; a delay in the onset of an infection or disease or its symptoms; or a reduction in the severity of an infection or disease or its symptoms that subsequently develops.
[0126] As used herein, "effective dose" or "effective amount" refers to an amount of an immunogen sufficient to induce an immune response that reduces at least one symptom of a pathogen infection. An effective dose or amount can be determined, for example, by measuring the amount of neutralizing secretory and / or serum antibodies, for example, by plaque neutralization, complement fixation, enzyme-linked immunosorbent (ELISA), or microneutralization assays.
[0127] As used herein, the term "vaccine" refers to an immunogenic composition, e.g., an immunogen derived from a pathogen, used to induce an immune response against the pathogen that provides protective immunity (e.g., immunity that protects a subject against infection by the pathogen and / or reduces the severity of a disease or condition caused by infection by the pathogen). A protective immune response may include the formation of antibodies and / or a cell-mediated response. Depending on the context, the term "vaccine" may also refer to a suspension or solution of an immunogen that is administered to a subject to generate protective immunity.
[0128] As used herein, the term "subject" includes humans and other animals. Typically, the subject is a human. For example, the subject can be an adult, teenager, child (2-14 years old), infant (birth-2 years old), or newborn (up to 2 months old). In certain embodiments, the subject is up to 4 months old or up to 6 months old. In embodiments, the adult is about 65 years old or older, or about 60 years old or older. In embodiments, the subject is a pregnant woman or a woman who intends to become pregnant. In other embodiments, the subject is not a human; for example, a non-human primate; for example, a baboon, chimpanzee, gorilla, or macaque. In certain embodiments, the subject can be a pet, such as a dog or cat.
[0129] In some embodiments, the subject is immunocompromised. In some embodiments, the immunocompromised subject is administered a drug therapy that causes immunosuppression. Non-limiting examples of drug therapies that cause immunosuppression include corticosteroids (e.g., prednisone), alkylating agents (e.g., cyclophosphamide), antimetabolites (e.g., azathioprine or 6-mercaptopurine), transplant-related immunosuppressive drugs (e.g., cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil), mitoxantrone, chemotherapeutic agents, methotrexate, tumor necrosis factor (TNF) blockers (e.g., etanercept, adalimumab, infliximab). In some embodiments, the immunocompromised subject is infected with a virus (e.g., human immunodeficiency virus or Epstein-Barr virus). In some embodiments, the virus is a respiratory virus, such as respiratory syncytial virus, influenza, parainfluenza, adenovirus, or picornavirus. In embodiments, the immunocompromised subject has acquired immune deficiency syndrome (AIDS). In embodiments, the immunocompromised subject is a person living with human immunodeficiency virus (HIV). In embodiments, the immunocompromised subject is immunocompromised due to a treatment regimen designed to prevent inflammation or to prevent graft rejection. In embodiments, the immunocompromised subject is a subject that has received a transplant. In embodiments, the immunocompromised subject has undergone radiation therapy or splenectomy.In embodiments, the immunocompromised subject is a patient with cancer, an autoimmune disease, tuberculosis, a substance use disorder (e.g., alcohol, opioid, or cocaine use disorder), stroke or cerebrovascular disease, solid organ or blood stem cell transplant, sickle cell disease, thalassemia, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyglandular syndrome type 1 (APS-1), B-cell expansion with NF-κB and T-cell anergy, or a combination of these. anergy (BENTA) disease, caspase 8 deficiency (CEDS), chronic granulomatous disease (CGD), common variable immunodeficiency (CVID), congenital neutropenic syndrome, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) deficiency, DOCK8 deficiency, GATA2 deficiency, glycosylation disorders with immunodeficiency, hyperimmunoglobulin E syndrome (HIES), hyperimmunoglobulin M syndrome, diabetes, type 1 diabetes, type 2 diabetes, interferon gamma deficiency, interleukin-12 deficiency, interleukin-23 deficiency, leukocyte adhesion deficiency, lipopolysaccharide-responsive beige-like anchor The subject has been diagnosed with a leukemia anchor (LRBA) deficiency, a PI3 kinase disorder, a PLCG2-associated antibody deficiency and immune dysregulation (PLAID), a severe combined immunodeficiency (SCID), a STAT3 dominant-negative disorder, a STAT3 gain-of-function disorder, warts, hypogammaglobulinemia, an infection, and a myeloid cellular pool (WHIM) syndrome, Wisckott-Aldrich syndrome (WAS), X-linked agammaglobulinemia (XLA), X-linked lymphoproliferative disorder (XLP), uremia, a nutritional disorder, or an XMEN disorder. In embodiments, the immunocompromised subject is a current or former smoker. In embodiments, the immunocompromised subject has a B cell deficiency, a T cell deficiency, a macrophage deficiency, a cytokine deficiency, a phagocytic deficiency, a phagocytic dysfunction, a complement deficiency, or a combination thereof.
[0130] In embodiments, the subject is overweight or obese. In embodiments, an overweight subject is > 25 kg / m 2 and <30kg / m2 In embodiments, an obese subject has a body mass index (BMI) of ≥ 30 kg / m 2 In embodiments, the subject has a mental health condition. In embodiments, the mental health condition is depression, schizophrenia, or anxiety.
[0131] As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the U.S. federal or state government, or listed in the U.S. Pharmacopoeia, the European Pharmacopoeia, or other generally recognized pharmacopoeias, for use in mammals, more particularly humans. These compositions may be useful as vaccines and / or antigenic compositions for inducing a protective immune response in vertebrates.
[0132] As used herein, the term "about" means plus or minus 10% of the indicated numerical value.
[0133] As used herein, the term "NVX-CoV2373" refers to a vaccine composition comprising the BV2373 spike glycoprotein (SEQ ID NO: 87) and Fraction A and Fraction C iscom matrix (e.g., MATRIX-M™).
[0134] As used herein, the term "modification," when referring to a CoV S polypeptide, refers to a mutation, deletion, or addition of one or more amino acids of the CoV S polypeptide. The location of the modification within the CoV S polypeptide can be determined based on aligning the sequence of the polypeptide to SEQ ID NO: 1 (a CoV S polypeptide containing a signal peptide) or SEQ ID NO: 2 (a mature CoV S polypeptide lacking a signal peptide).
[0135] The term SARS-CoV-2 "variant," used interchangeably herein with "heterologous SARS-CoV-2 strain," refers to a SARS-CoV-2 virus comprising a CoV S polypeptide having one or more modifications compared to the SARS-CoV S polypeptide having the amino acid sequence of SEQ ID NO:2. For example, a SARS-CoV-2 variant can have at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 28, at least about 29, at least about 30, at least about 31, at least about 32, at least about 33, at least about 34, or at least about 35 modifications compared to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. at least one, and at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most eleven, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23, at most 24, at most 25, at most 26, at most 27 relative to the S polypeptide , up to 28, up to 29, up to 30, up to 31, up to 32, up to 33, up to 34, up to 35 modifications, up to 40 modifications, up to 45 modifications, up to 50 modifications, up to 55 modifications, up to 60 modifications, up to 65 modifications, up to 70 modifications, up to 75 modifications, up to 80 modifications, up to 85 modifications, up to 90 modifications, up to 95 modifications or up to 100 modifications.In embodiments, a SARS-CoV-2 variant can have between about 2 and about 35 modifications, between about 5 and about 10 modifications, between about 5 and about 20 modifications, between about 10 and about 20 modifications, between about 15 and about 25 modifications, between about 20 and about 30 modifications, between about 20 and about 40 modifications, between about 25 and about 45 modifications, between about 25 and about 100 modifications, between about 25 and about 45 modifications, or between about 35 and about 100 modifications compared to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.
[0136] In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 70% and about 99.9% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 70% and about 99.5% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 90% and about 99.9% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 90% and about 99.8% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 95% and about 99.9% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 95% and about 99.8% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain is a SARS-CoV-2 virus comprising a CoV S polypeptide having between about 95% and about 99% identity to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.In embodiments, the heterologous SARS-CoV-2 strain has a World Health Organization label of alpha, beta, gamma, delta, epsilon, eta, iota, kappa, zeta, mu, or omicron. In embodiments, the heterologous SARS-CoV-2 strain has a PANGO lineage selected from the group consisting of B.1.1.529; BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.1.1.7, B.1.351, P.1, B.1.617.2, AY, B.1.427, B.1.429, B.1.525, B.1.526, B.1.617.1, B.1.617.3, P.2, B.1.621, or B.1.621.1. The following document describes Pango lineage nomenclature and is incorporated by reference herein in its entirety: O'Toole et al. BMC Genomics, 23, 121 (2022).
[0137] In embodiments, the heterologous SARS-CoV-2 strain has an Omicron World Health Organization label. In embodiments, the heterologous SARS-CoV-2 strain with an Omicron World Health Organization label has at least 35 modifications compared to the wild-type SARS-CoV-2 S polypeptide of SEQ ID NO: 2. In embodiments, the heterologous SARS-CoV-2 strain with an Omicron World Health Organization label has 35 to 55, 35 to 65, 35 to 75, 35 to 85, 35 to 95, or 35 to 105 modifications compared to the wild-type SARS-CoV-2 S polypeptide of SEQ ID NO: 2. In embodiments, the modifications are T6I, T6R, A14S, A54V, V70A, T82I, G129D, H133Q, K134E, W139R, E143G, F144L, Q170E, I197V, L199I, V200E, V200G, G239V, G244S, G326D, G326H, R333T, L355I, S35 8F, S358L, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, V432P, G433S, L43 9R, L439Q, N447K, S464N, T465K, E471A, F473V, F473S, F477S, Q480R, G483S, Q485R, N48 8Y, Y492H, T534K, T591I, D601G, G626V, H642Y, N645S, N666K, P668H, S691L, N751K, D783Y, N843K, Q941H, N956K, L968F, D1186N, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215, and combinations thereof.
[0138] In embodiments, the variant CoV S polypeptide is (i)A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N , T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H , N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (vi) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (vii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (x) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xi)T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S 464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiv)T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S 358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S46 4N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131; (xv)T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S36 2F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F 473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; and (xviii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xix) deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131, N488Y, A557D, D601G, P668H or P668R, T703I, S969A, and D1105H; (xx) D67A, K404N, E471K, N488Y, D601G and A688V; (xxi) D67A, D202G, L229H, K404N, E471K, N488Y, D601G and A688V; (xxii) D67A, D202G, deletion of one, two, or three amino acids between amino acids 228 and 230, K404N, E471K, N488Y, D601G, and A688V; (xxiii) D67A, L229H, R233I, N488Y, K404N, E471K, D601G and A688V; (xxiv) L5F, T7N, P13S, D125Y, R177S, K404T, E471K, N488Y, D601G, H642Y, T1014I and V1163F; (xxv)W139C and L439; (xxvi) deletion of amino acid 144, deletion of amino acid 145, T6R, E143G, L439R, T465K, D601G, P668R, and D937N; (xxvii) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, L439R, T465K, D601G, P668R, and D937N; (xxviii) deletion of amino acid 144, deletion of amino acid 145, T6R, T82I, G129D, Y132H, E143G, A209V, K404N L439R, T465K, D601G, P668R, and D937N; (xxix) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, W245I, K404N, N426K, L439R, T465K, E471K, N488Y, D601G, P668R, and D937N; (xxx) deletion of amino acid 144, deletion of amino acid 145, T6R, W51H, H53W, G129D, E143G, D200V, L201R, W245I, K404N, N426K, L439R, T465K, E471K, N488Y, D601G, P668R, and D937N; (xxxi) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, K404N, L439R, T465K, E471Q, D601G, P668R, and D937N; (xxxii) Q39R, A54V, E471K; D601G, Q664H, F875L, and deletion of one, two, three, or four of amino acids 56, 57, 131, 132; (xxxiii) T82I, D240G, E471K, D601G and A688V; (xxxiv) L439R, E471Q, D601G, P668R and Q1058H; (xxxv) G62V, T63I, R233N, L439Q, F477S, D601G, T846N, and deletion of one, two, three, four, five, or six of amino acids 234 to 240; (xxxvi) T82I, Y131S, Y132N, R333K, E471K, N488Y, D601G, P668H and D937N; and (xxxvii) G129D, G326D, S360P, S362F, K404N, N427K, T465K, E471A or E471K, Q480K or Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, and N953K comprising a combination of modifications selected from the group consisting of: The amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2.
[0139] The term "efficacy" of an immunogenic or vaccine composition described herein refers to the percentage reduction in disease (e.g., COVID-19) in a group administered the immunogenic composition compared to a group not administered the immunogenic composition. In embodiments, efficacy (E) is calculated using the following equation: E(%) = (1 - RR) x 100, where RR = the relative risk of incidence between the group administered the immunogenic composition and the group not administered the immunogenic composition. In embodiments, the immunogenic compositions described herein have a IgG antibody titer of at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, between about 50% and about 99%, between about 50% and about 98%, between about 60% and about 99%, between about 60% and about 98%, between about 70% and about 98%, between about 70% and about 95%, between about 70% and about 99%, between about 80% and about 99%, between about 80% and about 98%, between about 80% and about 95%, between about 85% and about 99%, between about 85% and about 98%, between about 85% and about 95%, between about 90% and about 95%, between about 90% and 98%, or between about 90% and about 99% efficacy against SARS-CoV-2 virus or heterologous SARS-CoV-2 strains.
[0140] Vaccine compositions containing coronavirus (CoV) spike (S) proteins The present disclosure provides non-naturally occurring coronavirus (CoV) spike (S) polypeptides, nanoparticles containing CoV S polypeptides, and immunogenic and vaccine compositions containing either non-naturally occurring CoV S polypeptides or nanoparticles containing CoV S polypeptides. In embodiments, provided herein are methods of using the CoV S polypeptides, nanoparticles, immunogenic and vaccine compositions to stimulate an immune response against SARS-CoV-2 virus or heterologous SARS-CoV-2 strains. In embodiments, the heterologous SARS-CoV-2 strain has a PANGO lineage selected from the group consisting of B.1.1.529; BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.1.1.7, B.1.351, P.1, B.1.617.2, AY, B.1.427, B.1.429, B.1.525, B.1.526, B.1.617.1, B.1.617.3, P.2, B.1.621, or B.1.621.1. In embodiments, the heterologous SARS-CoV-2 strain has a World Health Organization label of alpha, beta, gamma, delta, epsilon, eta, iota, kappa, zeta, mu, or omicron.
[0141] Methods for producing nanoparticles and vaccine compositions are also provided herein. Advantageously, these methods provide nanoparticles that are substantially free of contamination with other proteins, such as proteins associated with recombinant expression of proteins in insect cells. In embodiments, expression occurs in a baculovirus / Sf9 system.
[0142] CoV S polypeptide antigen
[0143] The vaccine compositions of the present disclosure contain a non-naturally occurring CoV S polypeptide. The CoV S polypeptide can be derived from a coronavirus, including but not limited to SARS-CoV-2, for example, SARS-CoV-2, MERS CoV, and SARS CoV. In embodiments, the CoV S polypeptide is derived from a heterologous SARS-CoV-2 strain.
[0144] In contrast to the SARS-CoV S protein, the SARS-CoV-2 S protein has a four-amino acid insertion in the S1 / S2 cleavage site that creates a polybasic RRAR furin-like cleavage motif. The SARS-CoV-2 S protein is synthesized as an inactive precursor (S0) that is proteolytically cleaved at the furin cleavage site into S1 and S2 subunits that remain noncovalently linked to form a prefusion trimer. The S2 domain of the SARS-CoV-2 S protein contains a fusion peptide (FP), two heptad repeats (HR1 and HR2), a transmembrane (TM) domain, and a cytoplasmic tail (CT). The S1 domain of the SARS-CoV-2 S protein folds into four distinct domains: an N-terminal domain (NTD), a C-terminal domain containing the receptor-binding domain (RBD), and two subdomains, SD1 and SD2. The pre-fusion SARS-CoV-2 S protein trimer undergoes structural rearrangement from the pre-fusion conformation to the post-fusion conformation upon receptor binding and cleavage of the S protein.
[0145] In embodiments, the CoV S polypeptide is a glycoprotein due to post-translational glycosylation. The glycoprotein includes one or more of a signal peptide, an S1 subunit, an S2 subunit, an NTD, an RBD, two subdomains (SD1 and SD2, designated SD1 / 2 in Figures 46A-B and referred to herein as "SD1 / 2"), an intact or modified fusion peptide, an HR1 domain, an HR2 domain, a TM, and a CD. In embodiments, the amino acids for each domain are provided in Figures 2 and 46A (shown according to SEQ ID NO:1), 46B (shown according to SEQ ID NO:2), and 3 (shown corresponding to SEQ ID NO:1). In embodiments, each domain may have at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the sequence for each domain as found in SEQ ID NO:1 or SEQ ID NO:2. Each domain may have deletions, insertions, or mutations of at most about 1 amino acid, at most about 2 amino acids, at most about 3 amino acids, at most about 4 amino acids, at most about 5 amino acids, at most about 10 amino acids, at most about 20 amino acids, or at most about 30 amino acids compared to that shown in SEQ ID NO: 1 or SEQ ID NO: 2. Each domain may have deletions, insertions, or mutations of between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids compared to that shown in SEQ ID NO: 1 or SEQ ID NO: 2. Note that Figures 2 and 3 show a 13-amino acid N-terminal signal peptide that is not present in the mature peptide. CoV S polypeptides can be used to stimulate an immune response against native CoV spike (S) polypeptides.
[0146] In embodiments, a native CoV spike (S) polypeptide (SEQ ID NO: 2) is modified to produce a non-naturally occurring CoV spike (S) polypeptide (Figure 1). In embodiments, the CoV spike (S) glycoprotein comprises an S1 subunit and an S2 subunit, wherein the S1 subunit comprises the NTD, RBD, SD1 / 2, and an inactive furin cleavage site (amino acids 669-672), and the S2 subunit comprises mutations at amino acids 973 and 974; The NTD optionally comprises one or more modifications selected from the group consisting of: (a) a deletion of one or more amino acids selected from the group consisting of amino acids 11-14, 56, 57, 130, 131, 132, 144, 145, 198, 199, 228, 229, 230, 231, 234, 235, 236, 237, 238, 239, 240, and combinations thereof; (b) a mutation of one or more amino acids selected from the group consisting of amino acids 5, 6, 7, 11, 12, 13, 14, 51, 53, 54, 56, 57, 62, 63, 67, 70, 82, 125, 129, 131, 132, 133, 134, 139, 143, 144, 145, 170, 177, 197, 198, 199, 200, 201, 202, 209, 229, 233, 239, 240, 244, 245, and combinations thereof; and (c) Insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215 Includes; the RBD optionally comprises one or more amino acid mutations selected from the group consisting of amino acids 326, 333, 355, 358, 360, 362, 363, 392, 395, 404, 419, 426, 427, 431, 432, 433, 439, 440, 447, 464, 465, 471, 473, 477, 480, 481, 483, 485, 488, 492, and combinations thereof; The SD1 / 2 domain optionally includes one or more amino acid mutations selected from the group consisting of 534, 557, 591, 600, 601, 626, 642, 645, 664, 666, 668, and combinations thereof. S1 subunit; and (ii) the S2 subunit, wherein amino acids 973 and 974 are proline, and the S2 subunit optionally comprises one or more modifications selected from the group consisting of: (a) deletion of one or more amino acids from 676-685, 676-702, 702-711, 775-793, 806-815, and combinations thereof; (b) one or more amino acid mutations selected from the group consisting of 688, 691, 703, 751, 783, 843, 846, 875, 937, 941, 956, 968, 969, 1014, 1058, 1105, 1163, 1186, and combinations thereof; and (c) deletion of one or more amino acids from the TMCT S2 subunit, including Includes; The amino acids of the CoV S glycoprotein are numbered relative to the polypeptide having the sequence of SEQ ID NO:2. In embodiments, the CoV spike (S) glycoprotein comprises an S1 subunit and an S2 subunit, wherein the S1 subunit comprises the NTD, RBD, SD1 / 2, and an inactive furin cleavage site (amino acids 669-672), and the S2 subunit comprises mutations of amino acids 973 and 974 to proline; the CoV S glycoprotein comprises (i)A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N , T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H , N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (vi) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (vii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (x) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xi)T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S 464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiv)T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S 358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S46 4N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131; (xv)T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S36 2F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F 473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; and (xviii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131 The combination of modifications includes a combination of modifications selected from the group consisting of:
[0147] Figure 3 shows a CoV S polypeptide designated BV2378, which has an inactive furin cleavage site, a deleted fusion peptide (e.g., deletion of amino acids 819-828), K986P and V987 mutations, where the amino acids are numbered relative to SEQ ID NO: 1. The mature BV2378 polypeptide lacks one or more amino acids of the signal peptide, which are amino acids 1-13 of SEQ ID NO: 1.
[0148] In embodiments, the CoV S polypeptides described herein exist in a pre-fusion conformation. In embodiments, the CoV S polypeptides described herein comprise a flexible HR2 domain. Unless otherwise noted, domain flexibility is determined by transmission electron microscopy (TEM) and 2D class averaging. Reductions in electron density correspond to flexible domains.
[0149] Modifications to the CoV S polypeptide antigen-S1 subunit In embodiments, the CoV S polypeptide contains one or more modifications to the S1 subunit having the amino acid sequence of SEQ ID NO:121.
[0150] The amino acid sequence of the S1 subunit (SEQ ID NO: 121) is shown below.
[0151] QCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR
[0152] In embodiments, the CoV S polypeptides described herein comprise an S1 subunit having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the S1 subunit of SEQ ID NO: 1 or SEQ ID NO: 2. The S1 subunit may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, up to about 30 amino acids, up to about 35 amino acids, up to about 40 amino acids, up to about 45 amino acids, or up to about 50 amino acids compared to the amino acid sequence of the S1 subunit of SEQ ID NO: 1 or SEQ ID NO: 2. The S1 subunit may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the S1 subunit of SEQ ID NO:1 or SEQ ID NO:2.
[0153] In embodiments, the S1 subunit may contain any combination of the modifications shown in Table 1A.
[0154] [Table 1A-1] [Table 1A-2] [Table 1A-3] [Table 1A-4] [Table 1A-5] [Table 1A-6] [Table 1A-7] [Table 1A-8] [Table 1A-9] [Table 1A-10]
[0155] Modifications to CoV S polypeptide antigen-S1 subunit-NTD In embodiments, the CoV S polypeptide contains one or more modifications to the NTD. In embodiments, the NTD has the amino acid sequence of SEQ ID NO: 118, which corresponds to amino acids 14 to 305 of SEQ ID NO: 1 or amino acids 1 to 292 of SEQ ID NO: 2.
[0156] The amino acid sequence of the NTD (SEQ ID NO: 118) is shown below.
[0157] QCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRV YSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKS
[0158] In embodiments, the NTD has the amino acid sequence of SEQ ID NO: 45, which corresponds to amino acids 14 to 331 of SEQ ID NO: 1 or amino acids 1 to 318 of SEQ ID NO: 2. The amino acid sequence of the NTD (SEQ ID NO: 45) is shown below.
[0159] QCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPN
[0160] In embodiments, the NTD and RBD overlap by at most about 1 amino acid, at most about 5 amino acids, at most about 10 amino acids, or at most about 20 amino acids.
[0161] In embodiments, the NTDs provided herein may be extended at the C-terminus by at most 5 amino acids, at most 10 amino acids, at most 15 amino acids, at most 20 amino acids, at most 25 amino acids, or at most 30 amino acids.
[0162] In embodiments, a CoV S polypeptide described herein comprises an NTD having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the NTD of SEQ ID NO: 1 or SEQ ID NO: 2. The NTD may have deletions, insertions, or mutations of at most about 1 amino acid, at most about 2 amino acids, at most about 3 amino acids, at most about 4 amino acids, at most about 5 amino acids, at most about 10 amino acids, at most about 15 amino acids, at most about 20 amino acids, at most about 25 amino acids, or at most about 30 amino acids compared to the amino acid sequence of the NTD of SEQ ID NO: 1 or SEQ ID NO: 2. The NTD may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the NTD of SEQ ID NO:1 or SEQ ID NO:2.
[0163] In embodiments, the CoV S polypeptide contains a deletion of one or more amino acids from the N-terminal domain (NTD) (corresponding to amino acids 1-292 of SEQ ID NO: 2). In embodiments, the CoV S polypeptide contains a deletion of up to about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 292 amino acids of the NTD.
[0164] In embodiments, the CoV S polypeptide contains a deletion of one or more amino acids from the NTD (corresponding to amino acids 1-318 of SEQ ID NO:2). In embodiments, the CoV S polypeptide contains a deletion of amino acids 1-318 of the NTD of SEQ ID NO:2. In embodiments, the deletion of the NTD enhances protein expression of the CoV spike (S) polypeptide. In embodiments, the CoV S polypeptide having an NTD deletion has the amino acid sequence set forth by SEQ ID NOs:46, 48, 49, 51, 52, and 54. In embodiments, the CoV S polypeptide having an NTD deletion is encoded by an isolated nucleic acid sequence selected from the group consisting of SEQ ID NO:47, SEQ ID NO:50, and SEQ ID NO:53.
[0165] In embodiments, the NTD may contain any combination of the modifications shown in Table 1B. The modifications are shown relative to the mature S polypeptide sequence, SEQ ID NO:2, for reference.
[0166] [Table 1B-1] [Table 1B-2] [Table 1B-3] [Table 1B-4] [Table 1B-5]
[0167] Modifications to CoV S polypeptide antigen-S1 subunit-RBD In embodiments, the CoV S polypeptide contains one or more modifications to the RBD.
[0168] In embodiments, the RBD has the amino acid sequence of SEQ ID NO: 126, which corresponds to amino acids 331 to 527 of SEQ ID NO: 1 or amino acids 318 to 514 of SEQ ID NO: 2.
[0169] The amino acid sequence of the RBD (SEQ ID NO: 126) is shown below:
[0170] NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGP
[0171] In embodiments, the RBD has the amino acid sequence of SEQ ID NO: 116, which corresponds to amino acids 335 to 530 of SEQ ID NO: 1 or amino acids 322 to 517 of SEQ ID NO: 2.
[0172] The amino acid sequence of the RBD (SEQ ID NO: 116) is shown below.
[0173] LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKS
[0174] In embodiments, the RBDs provided herein may be extended at the N- or C-terminus by at most 1 amino acid, at most 5 amino acids, at most 10 amino acids, at most 15 amino acids, at most 20 amino acids, at most 25 amino acids, or at most 30 amino acids.
[0175] In embodiments, the CoV S polypeptides described herein comprise an RBD that has at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the RBD of SEQ ID NO: 1 or SEQ ID NO: 2. The RBD may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of the RBD of SEQ ID NO: 1 or SEQ ID NO: 2. The RBD may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the RBD of SEQ ID NO:1 or SEQ ID NO:2.
[0176] In embodiments, the CoV S polypeptide has at least 1, at least 2, at least 3, at least 4, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 mutations in the RBD. In embodiments, the RBD may contain any combination of the modifications shown in Table 1C.
[0177] [Table 1C-1] [Table 1C-2] [Table 1C-3] [Table 1C-4]
[0178] Modifications to CoV S polypeptide antigens - SD1 / 2 In embodiments, the CoV S polypeptide contains one or more modifications to SD1 / 2 having the amino acid sequence of SEQ ID NO: 122, which corresponds to amino acids 542 to 681 of SEQ ID NO: 1 or amino acids 529 to 668 of SEQ ID NO: 2.
[0179] The amino acid sequence of SD1 / 2 (SEQ ID NO: 122) is shown below.
[0180] NFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSP
[0181] In embodiments, the CoV S polypeptides described herein comprise an SD1 / 2 that has at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the SD1 / 2 of SEQ ID NO: 1 or SEQ ID NO: 2. The SD1 / 2 may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of SD1 / 2 of SEQ ID NO: 1 or SEQ ID NO: 2. SD1 / 2 may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to SD1 / 2 of SEQ ID NO: 1 or SEQ ID NO: 2.
[0182] In embodiments, the CoV S polypeptide has at least 1, at least 2, at least 3, at least 4, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 mutations in SD1 / 2. In embodiments, SD1 / 2 may contain any combination of the modifications shown in Table 1D.
[0183] [Table 1D-1] [Table 1D-2]
[0184] CoV S polypeptide antigen - modifications to the furin cleavage site In embodiments, the CoV S polypeptide contains a furin site (RRAR) corresponding to amino acids 682-685 of SEQ ID NO: 1 or amino acids 669-672 of SEQ ID NO: 2 that has been inactivated by one or more mutations. Inactivation of the furin cleavage site prevents furin from cleaving the CoV S polypeptide. In embodiments, the CoV S polypeptide described herein that contains an inactivated furin cleavage site is expressed as a single chain.
[0185] In some embodiments, one or more of the amino acids that make up the native furin cleavage site are mutated to any natural amino acid. In some embodiments, the amino acid is an L-amino acid. Non-limiting examples of amino acids include alanine, arginine, glycine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, serine, threonine, histidine, lysine, methionine, proline, valine, isoleucine, leucine, tyrosine, tryptophan, and phenylalanine.
[0186] In embodiments, one or more of the amino acids that make up the native furin cleavage site are mutated to glutamine. In embodiments, one, two, three, or four amino acids may be mutated to glutamine. In embodiments, one of the arginines that make up the native furin cleavage site is mutated to glutamine. In embodiments, two of the arginines that make up the native furin cleavage site are mutated to glutamine. In embodiments, three of the arginines that make up the native furin cleavage site are mutated to glutamine.
[0187] In embodiments, one or more of the amino acids that make up the native furin cleavage site are mutated to alanine. In embodiments, one, two, three, or four amino acids may be mutated to alanine. In embodiments, one of the arginines that make up the native furin cleavage site is mutated to alanine. In embodiments, two of the arginines that make up the native furin cleavage site are mutated to alanine. In embodiments, three of the arginines that make up the native furin cleavage site are mutated to alanine.
[0188] In embodiments, one or more of the amino acids that make up the native furin cleavage site are mutated to glycine. In embodiments, one, two, three, or four amino acids may be mutated to glycine. In embodiments, one of the arginines in the native furin cleavage site is mutated to glycine. In embodiments, two of the arginines that make up the native furin cleavage site are mutated to glycine. In embodiments, three of the arginines that make up the native furin cleavage site are mutated to glycine.
[0189] In embodiments, one or more of the amino acids that make up the native furin cleavage site are mutated to asparagine. For example, one, two, three, or four amino acids can be mutated to asparagine. In embodiments, one of the arginines that make up the native furin cleavage site is mutated to asparagine. In embodiments, two of the arginines that make up the native furin cleavage site are mutated to asparagine. In embodiments, three of the arginines that make up the native furin cleavage site are mutated to asparagine.
[0190] Non-limiting examples of amino acid sequences of inactivated furin sites contained within a CoV S polypeptide are found in Table 1E.
[0191] [Table 1E-1] [Table 1E-2]
[0192] In embodiments, instead of an active furin cleavage site (SEQ ID NO: 6), the CoV S polypeptide described herein contains an inactivated furin cleavage site. In embodiments, the amino acid sequence of the inactivated furin cleavage site is set forth in any one of SEQ ID NOs: 7-34 or SEQ ID NO: 97. In embodiments, the amino acid sequence of the inactivated furin cleavage site is QQAQ (SEQ ID NO: 7). In embodiments, the amino acid sequence of the inactivated furin cleavage site is GSAS (SEQ ID NO: 97). In embodiments, the amino acid sequence of the inactivated furin cleavage site is GSGA (SEQ ID NO: 111). In embodiments, the amino acid sequence of the inactivated furin cleavage site is GG, GGG (SEQ ID NO: 127), GGGG (SEQ ID NO: 128), or GGGGG (SEQ ID NO: 129).
[0193] Modifications to the CoV S polypeptide antigen - S2 subunit
[0194] In embodiments, the CoV S polypeptide contains one or more modifications to the S2 subunit having the amino acid sequence of SEQ ID NO: 120, which corresponds to amino acids 686 to 1273 of SEQ ID NO: 1 or amino acids 673 to 1260 of SEQ ID NO: 2.
[0195] The amino acid sequence of the S2 subunit (SEQ ID NO: 120) is shown below.
[0196] SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
[0197] In embodiments, the CoV S polypeptides described herein comprise an S2 subunit having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the S2 subunit of SEQ ID NO: 1 or SEQ ID NO: 2. The S2 subunit may have deletions, insertions, or mutations of at most about 1 amino acid, at most about 2 amino acids, at most about 3 amino acids, at most about 4 amino acids, at most about 5 amino acids, at most about 10 amino acids, at most about 15 amino acids, at most about 20 amino acids, at most about 25 amino acids, or at most about 30 amino acids compared to the amino acid sequence of the S2 subunit of SEQ ID NO: 1 or SEQ ID NO: 2. The S2 subunit may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the S2 subunit of SEQ ID NO:1 or SEQ ID NO:2.
[0198] In embodiments, the S2 subunit may contain any combination of the modifications shown in Table 1F.
[0199] [Table 1F-3] [Table 1F-4] [Table 1F-5]
[0200] In embodiments, the CoV S polypeptide contains a deletion corresponding to one or more deletions within amino acids 676-685 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of amino acids 676-685 of the native CoV spike (S) polypeptide (SEQ ID NO: 2) are deleted. In embodiments, the deletion of amino acids within amino acids 676-685 is contiguous, e.g., amino acids 676 and 677 are deleted, or amino acids 680 and 681 are deleted. In embodiments, the deletion of amino acids within amino acids 676-685 is non-contiguous, e.g., amino acids 676 and 680 are deleted, or amino acids 677 and 682 are deleted. In embodiments, the CoV S polypeptide containing a deletion corresponding to one or more deletions within amino acids 676-685 has an amino acid sequence selected from the group consisting of SEQ ID NO: 62 and SEQ ID NO: 63.
[0201] In embodiments, the CoV S polypeptide contains a deletion corresponding to one or more deletions within amino acids 702-711 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of amino acids 702-711 of the native SARS-CoV-2 spike (S) polypeptide (SEQ ID NO: 2) are deleted. In embodiments, the deletion of one or more of the amino acids within amino acids 702-711 is contiguous, e.g., amino acids 702 and 703 are deleted, or amino acids 708 and 709 are deleted. In embodiments, the deletion of amino acids within amino acids 702-711 is non-contiguous, e.g., amino acids 702 and 704 are deleted, or amino acids 707 and 710 are deleted. In embodiments, the CoV S polypeptide containing a deletion corresponding to one or more deletions within amino acids 702-711 has an amino acid sequence selected from the group consisting of SEQ ID NO: 64 and SEQ ID NO: 65.
[0202] In embodiments, the CoV S polypeptide contains a deletion corresponding to one or more deletions within amino acids 775-793 of a native CoV S polypeptide (SEQ ID NO: 2). In embodiments, up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 amino acids are deleted within amino acids 775-793 of a native SARS-CoV-2 spike (S) polypeptide (SEQ ID NO: 2). In embodiments, the deletion of one or more of the amino acids within amino acids 775-793 is contiguous, e.g., amino acids 776 and 777 are deleted, or amino acids 780 and 781 are deleted. In embodiments, the deletion of amino acids within amino acids 775-793 is non-contiguous, e.g., amino acids 775 and 790 are deleted, or amino acids 777 and 781 are deleted.
[0203] In embodiments, the CoV S polypeptide contains a deletion of the fusion peptide corresponding to amino acids 806-815 of SEQ ID NO:2 (SEQ ID NO:104). In embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids of the fusion peptide of the CoV spike (S) polypeptide (SEQ ID NO:2) are deleted. In embodiments, the deletion of amino acids within the fusion peptide is consecutive, e.g., amino acids 806 and 807 are deleted, or amino acids 809 and 810 are deleted. In embodiments, the deletion of amino acids within the fusion peptide is non-consecutive, e.g., amino acids 806 and 808 are deleted, or amino acids 810 and 813 are deleted. In embodiments, the CoV S polypeptide containing a deletion corresponding to one or more amino acids of the fusion peptide has an amino acid sequence selected from SEQ ID NOs:66, 77, and 105-108.
[0204] In embodiments, the CoV S polypeptide contains a mutation at Lys-973 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, Lys-973 is mutated to any naturally occurring amino acid. In embodiments, Lys-973 is mutated to proline. In embodiments, Lys-973 is mutated to glycine. In embodiments, the CoV S polypeptide containing a mutation at amino acid 973 is selected from the group consisting of SEQ ID NOs: 84-89, 105-106, and 109-110.
[0205] In embodiments, the CoV S polypeptide contains a mutation at Val-974 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, Val-974 is mutated to any naturally occurring amino acid. In embodiments, Val-974 is mutated to proline. In embodiments, Val-974 is mutated to glycine. In embodiments, the CoV S polypeptide containing a mutation at amino acid 974 is selected from the group consisting of SEQ ID NOs: 84-89, 105-106, and 109-110.
[0206] In embodiments, the CoV S polypeptide contains mutations at Lys-973 and Val-974 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, Lys-973 and Val-974 are mutated to any naturally occurring amino acid. In embodiments, Lys-973 and Val-974 are mutated to proline. In embodiments, the CoV S polypeptide containing mutations at amino acids 973 and 974 is selected from SEQ ID NOs: 84-89, 105-106, 109-110, 175, 220, and 217-228.
[0207] Modifications to the CoV S polypeptide antigen - S2 subunit - HR1 domain
[0208] In embodiments, the CoV S polypeptide contains one or more modifications to the HR1 domain having the amino acid sequence of SEQ ID NO: 119, which corresponds to amino acids 912 to 984 of SEQ ID NO: 1 or amino acids 889 to 971 of SEQ ID NO: 2.
[0209] The amino acid sequence of the HR1 domain (SEQ ID NO: 119) is shown below.
[0210] MAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRL
[0211] In embodiments, the CoV S polypeptides described herein comprise an HR1 domain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the HR1 domain of SEQ ID NO: 1 or SEQ ID NO: 2. The HR1 domain may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of the HR1 domain of SEQ ID NO: 1 or SEQ ID NO: 2. The HR1 domain may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the HR1 domain of SEQ ID NO:1 or SEQ ID NO:2.
[0212] In embodiments, the HR1 domain may contain any combination of the modifications shown in Table 1G.
[0213] [Table 1G]
[0214] Modifications to the CoV S polypeptide antigen - S2 subunit - HR2 domain In embodiments, the CoV S polypeptide contains one or more modifications to the HR2 domain having the amino acid sequence of SEQ ID NO: 125, which corresponds to amino acids 1163 to 1213 of SEQ ID NO: 1 or amino acids 1150 to 1200 of SEQ ID NO: 2.
[0215] The amino acid sequence of the HR2 domain (SEQ ID NO: 125) is shown below.
[0216] DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWP
[0217] In embodiments, the CoV S polypeptides described herein comprise an HR2 domain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the HR2 domain of SEQ ID NO: 1 or SEQ ID NO: 2. The HR2 domain may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of the HR2 domain of SEQ ID NO: 1 or SEQ ID NO: 2. The HR2 domain may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the HR2 domain of SEQ ID NO:1 or SEQ ID NO:2.
[0218] Modifications to the CoV S polypeptide antigen-TM domain
[0219] In embodiments, the CoV S polypeptide contains one or more modifications to the TM domain having the amino acid sequence of SEQ ID NO: 123, which corresponds to amino acids 1214 to 1237 of SEQ ID NO: 1 or amino acids 1201 to 1224 of SEQ ID NO: 2.
[0220] The amino acid sequence of the TM domain (SEQ ID NO: 123) is shown below.
[0221] WYIWLGFIAGLIAIVMVTIMLCCM
[0222] In embodiments, the CoV S polypeptides described herein comprise a TM domain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the TM domain of SEQ ID NO: 1 or SEQ ID NO: 2. The TM domain can have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of the TM domain of SEQ ID NO: 1 or SEQ ID NO: 2. The TM domain can have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the TM domain of SEQ ID NO:1 or SEQ ID NO:2.
[0223] In embodiments, the CoV S polypeptides described herein lack the entire TM domain. In embodiments, the CoV S polypeptides include a TM domain.
[0224] Modifications to CoV S polypeptide antigen-CT
[0225] In embodiments, the CoV S polypeptide contains one or more modifications to a CT having the amino acid sequence of SEQ ID NO: 124, which corresponds to amino acids 1238-1273 of SEQ ID NO: 1 or amino acids 1225-1260 of SEQ ID NO: 2.
[0226] The amino acid sequence of CT (SEQ ID NO: 124) is shown below:
[0227] TSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
[0228] In embodiments, the CoV S polypeptides described herein comprise a CT having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to the CT of SEQ ID NO: 1 or SEQ ID NO: 2. The CT may have deletions, insertions, or mutations of up to about 1 amino acid, up to about 2 amino acids, up to about 3 amino acids, up to about 4 amino acids, up to about 5 amino acids, up to about 10 amino acids, up to about 15 amino acids, up to about 20 amino acids, up to about 25 amino acids, or up to about 30 amino acids compared to the amino acid sequence of the CT of SEQ ID NO: 1 or SEQ ID NO: 2. The CT may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, or between about 25 and 30 amino acids deleted, inserted, or mutated compared to the CT of SEQ ID NO: 1 or SEQ ID NO: 2.
[0229] In embodiments, the CoV S polypeptides described herein lack a CT. In embodiments, the CoV S polypeptides comprise a CT.
[0230] In embodiments, the CoV S polypeptide comprises a TM and a CT. In embodiments, the CoV spike (S) polypeptide contains a deletion of one or more amino acids from the transmembrane and cytoplasmic tail (TMCT) (corresponding to amino acids 1201-1260). The amino acid sequence of the TMCT is set forth in SEQ ID NO: 39. In embodiments, CoV S polypeptides having deletions of one or more residues of the TMCT have enhanced protein expression. In embodiments, the CoV spike (S) polypeptides having one or more deletions from the TMCT have an amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 41, 42, 52, 54, 59, 61, 88, and 89. In embodiments, the CoV S polypeptides having one or more deletions from the TM-CD are encoded by an isolated nucleic acid sequence selected from the group consisting of SEQ ID NOs: 39, 43, 53, and 60.
[0231] CoV S polypeptide antigens - non-limiting combinations of mutations
[0232] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56 and 57 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0233] In embodiments, the CoV S polypeptide contains a deletion of amino acids 131 and 132 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0234] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56 and 131 of the native CoV spike (S) polypeptide (SEQ ID NO: 2). In embodiments, the CoV S polypeptide contains a deletion of amino acids 57 and 131 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0235] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56, 57 and 131 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0236] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56 and 132 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0237] In embodiments, the CoV S polypeptide contains a deletion of amino acids 57 and 132 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0238] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56, 57 and 132 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0239] In embodiments, the CoV S polypeptide contains a deletion of amino acids 56, 57, 131 and 132 of the native CoV spike (S) polypeptide (SEQ ID NO: 2).
[0240] In embodiments, the CoV S polypeptide contains a mutation that stabilizes the pre-fusion conformation of the CoV S polypeptide. In embodiments, the CoV S polypeptide contains a proline or glycine substitution that stabilizes the pre-fusion conformation. This strategy has been utilized to develop a stabilized pre-fusion MERS-CoV S protein, as described in the following documents: Proc Natl Acad Sci USA. 2017 Aug 29;114(35):E7348-E7357; Sci Rep. 2018 Oct 24;8(1):15701; U.S. Patent Application Publication No. 2020 / 0061185; and PCT Application No. PCT / US2017 / 058370, each of which is incorporated by reference in its entirety.
[0241] In embodiments, the CoV S polypeptide contains mutations at Lys-973 and Val-974 and an inactivated furin cleavage site. In embodiments, the CoV S polypeptide contains mutations at Lys-973 and Val-974 to proline and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:7) or GSAS (SEQ ID NO:96). Exemplary CoV S polypeptides containing mutations at Lys-973 and Val-974 and an inactivated furin cleavage site are shown in Figure 8. In embodiments, the CoV S polypeptide containing mutations at Lys-973 and Val-974 to proline and an inactivated furin cleavage site has the amino acid sequence of SEQ ID NO:86 or 87 and the nucleic acid sequence of SEQ ID NO:96.
[0242] In embodiments, the CoV S polypeptide contains mutations at Lys-973 and Val-974, an inactivated furin cleavage site, and a deletion of one or more amino acids from the fusion peptide. In embodiments, the CoV S polypeptide contains mutations at Lys-973 and Val-974 to proline, an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:7) or GSAS (SEQ ID NO:96), and a deletion of one or more amino acids from the fusion peptide. In embodiments, the CoV S polypeptide containing mutations at Lys-973 and Val-974 to proline, an inactivated furin cleavage site, and a deletion of one or more amino acids from the fusion peptide has the amino acid sequence of SEQ ID NO:105 or 106. In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a Leu-5 to phenylalanine mutation, a Thr-7 to asparagine mutation, a Pro-13 to serine mutation, an Asp-125 to tyrosine mutation, an Arg-177 to serine mutation, a Lys-404 to threonine mutation, a Glu-471 to lysine mutation, an Asn-488 to tyrosine mutation, a His-642 to tyrosine mutation, a Thr-1014 to isoleucine mutation, and Lys-973 and Val-974 to proline mutations, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96).
[0243] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a mutation of Trp-139 to cysteine, a mutation of Leu-439 to arginine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96). In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 1), a mutation of Trp-152 to cysteine, a mutation of Leu-452 to arginine, a mutation of Ser-13 to isoleucine, mutations of Lys-986 and Val-987 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96).
[0244] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a mutation of Lys-404 to threonine or asparagine, a mutation of Glu-471 to lysine, a mutation of Asn-488 to tyrosine, a mutation of Leu-5 to phenylalanine, a mutation of Asp-67 to alanine, a mutation of Asp-202 to glycine, a deletion of one or more of amino acids 229-231, a mutation of Arg-233 to isoleucine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96).
[0245] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a mutation of Asn-488 to tyrosine, a mutation of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96). In embodiments, the CoV S polypeptide having a mutation of Asn-488 to tyrosine, a mutation of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96) comprises the amino acid sequence of SEQ ID NO: 112.
[0246] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a mutation of Asn-488 to tyrosine, a mutation of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96). In embodiments, the CoV S polypeptide having a mutation of Asn-488 to tyrosine, a mutation of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96) comprises the amino acid sequence of SEQ ID NO: 113.
[0247] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a deletion of amino acids 56, 57, and 131, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7), GSAS (SEQ ID NO: 96), or GG. In embodiments, the CoV S polypeptide having a deletion of amino acids 56, 57, and 131, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96), comprises the amino acid sequence of SEQ ID NO: 114. In embodiments, the CoV S polypeptide having a deletion of amino acids 56, 57, and 131, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96) or GG comprises the amino acid sequence of SEQ ID NO: 136.In embodiments, a CoV S polypeptide having a deletion of amino acids 56, 57, and 131, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of GG comprises the amino acid sequence of SEQ ID NO: 137 or SEQ ID NO: 138. In some embodiments, a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 114 or SEQ ID NO: 136 is encoded by a nucleic acid having the nucleic acid sequence of SEQ ID NO: 135. In some embodiments, a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 137 or SEQ ID NO: 138 is encoded by a nucleic acid having the sequence of SEQ ID NO: 139.
[0248] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), a deletion of amino acids 56, 57, and 132, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96). In embodiments, the CoV S polypeptide having a deletion of amino acids 56, 57, and 132, a mutation of Asn-488 to tyrosine, a mutation of Ala-557 to aspartic acid, a mutation of Asp-601 to glycine, a mutation of Pro-668 to histidine, a mutation of Thr-703 to isoleucine, a mutation of Ser-969 to alanine, a mutation of Asp-1105 to histidine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96), comprises the amino acid sequence of SEQ ID NO: 114.
[0249] In embodiments, the CoV S polypeptide contains, relative to the native CoV spike (S) polypeptide (SEQ ID NO: 2), an Asn-488 to tyrosine mutation, an Asp-67 to alanine mutation, a Leu-229 to histidine mutation, an Asp-202 to glycine mutation, a Lys-404 to asparagine mutation, a Glu-471 to lysine mutation, an Ala-688 to valine mutation, an Asp-601 to glycine mutation, Lys-973 and Val-974 to proline mutations, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96). In embodiments, the CoV S polypeptide having an Asn-488 mutation to tyrosine, an Asp-67 mutation to alanine, a Leu-229 mutation to histidine, an Asp-202 mutation to glycine, a Lys-404 mutation to asparagine, a Glu-471 mutation to lysine, an Ala-688 mutation to valine, an Asp-601 mutation to glycine, mutations of Lys-973 and Val-974 to proline, and an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO: 7) or GSAS (SEQ ID NO: 96) comprises the amino acid sequence of SEQ ID NO: 115.
[0250] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 131, N488Y, A557D, D601G, P668H, T703I, S969A, and D1105H, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the inactivated furin cleavage site has an amino acid sequence of QQAQ (SEQ ID NO: 7). In embodiments, the inactivated furin cleavage site has an amino acid sequence of GG.
[0251] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, D67A, D202G, L229H, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the inactivated furin cleavage site has the amino acid sequence of QQAQ (SEQ ID NO: 7). In embodiments, the inactivated furin cleavage site has the amino acid sequence of GG.
[0252] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, a deletion of amino acids 229-231, D67A, D202G, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.
[0253] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:7), a deletion of amino acids 229-231, L5F, D67A, D202G, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2. In embodiments, a CoV S polypeptide having one or more modifications selected from K973P, V974P, an inactivated furin cleavage site having an amino acid sequence of QQAQ (SEQ ID NO:7), a deletion of amino acids 229-231, L5F, D67A, D202G, K404N, E471K, N488Y, D601G, and A688V, wherein the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO:2, comprises the amino acid sequence of SEQ ID NO: 144. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 144 is encoded by a nucleic acid having the sequence of SEQ ID NO:145.
[0254] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site having an amino acid sequence of GG, a deletion of amino acids 229-231, L5F, D67A, D202G, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide having one or more modifications selected from K973P, V974P, an inactivated furin cleavage site having an amino acid sequence of GG, a deletion of amino acids 229-231, L5F, D67A, D202G, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, comprises the amino acid sequence of SEQ ID NO: 144. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO:144 is encoded by a nucleic acid having the sequence of SEQ ID NO:145.
[0255] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, L5F, T7N, P13S, D125Y, R177S, K404T, E471K, N488Y, D601G, H642Y, T1014I and V1163F, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2. In embodiments, a CoV S polypeptide containing one or more alterations selected from K973P, V974P, an inactivated furin cleavage site, L5F, T7N, P13S, D125Y, R177S, K404T, E471K, N488Y, D601G, H642Y, T1014I and V1163F, wherein the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, has the amino acid sequence of SEQ ID NO: 151. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 151 is encoded by a nucleic acid having the sequence of SEQ ID NO: 150.
[0256] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, a deletion of amino acids 229-231, L5F, D67A, D202G, L229H, K404N, E471K, N488Y, D601G, and A688V, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.
[0257] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, K404N, E471K, N488Y, L5F, D67A, D202G, L229H, D601G, A688V, and a deletion of amino acids 229-231, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the inactivated furin cleavage site has the amino acid sequence of QQAQ (SEQ ID NO: 7). In embodiments, the inactivated furin cleavage site has the amino acid sequence of GG.
[0258] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, K404N, E471K, and N488K, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, K404N, E471K, and N488Y. In embodiments, the CoV S polypeptide is the RBD of a CoV S polypeptide with one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, K404N, E471K, and N488K, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide is the RBD of a CoV S polypeptide having one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, K404N, E471K, and N488Y, and the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.
[0259] In embodiments, the CoV S polypeptide contains one or more modifications selected from an inactivated furin cleavage site having an amino acid sequence of K973P, V974P, GG, D601G, E404N, E471K, and N488Y. In embodiments, the CoV S polypeptide contains one or more modifications selected from an inactivated furin cleavage site having an amino acid sequence of K973P, V974P, GG, and a D601G mutation, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide containing a modification selected from an inactivated furin cleavage site having an amino acid sequence of K973P, V974P, GG, and a D601G mutation has the amino acid sequence of SEQ ID NO: 133.
[0260] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7) or GG, K404N, E471K, N488K, D67A, D202G, L229H, D601G, and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7) or GG, K404N, E471K, N488K, D67A, D202G, L229H, D601G, and A688V, has the amino acid sequence of SEQ ID NO: 132 or SEQ ID NO: 141. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 132 is encoded by a nucleic acid having the nucleic acid sequence of SEQ ID NO: 131. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 132 is encoded by a nucleic acid having the nucleic acid sequence of SEQ ID NO: 142.
[0261] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, W139C and L439R, and the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide comprising the K973P, V974P, an inactivated furin cleavage site, W139C and L439R modifications is expressed with a signal peptide having the amino acid sequence of SEQ ID NO: 117 or SEQ ID NO: 5. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, D601G, W139C and L439R, and the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide comprises the K973P, V974P, an inactivated furin cleavage site, D601G, W139C and L439R modifications and is expressed with a signal peptide having the amino acid sequence of SEQ ID NO:117 or SEQ ID NO:5.
[0262] In embodiments, the CoV S polypeptide comprises one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, D601G, L5F, D67A, D202G, a deletion of amino acids 229-231, R233I, K404N, E471K, N488Y, and A688V, wherein the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO:2.
[0263] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), W139C, S481P, D601G and L439R, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), W139C, D601G and L439R, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), W139C, S481P, and D601G, where the amino acids are numbered relative to a CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide containing one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), W139C, S481P, D601G, and L439R has the amino acid sequence of SEQ ID NO: 153. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 153 comprises a signal peptide having the amino acid sequence of SEQ ID NO: 117. In embodiments, the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 153 comprises a signal peptide having the amino acid sequence of SEQ ID NO: 5.
[0264] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), T82I, D240G, E471K, D601G and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), T82I, D240G, E471K, D601G and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, has the amino acid sequence of SEQ ID NO: 156. In embodiments, a CoV S polypeptide containing one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), an inactivated furin cleavage site, T82I, D240G, E471K, D601G and A688V, wherein the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, comprises a signal peptide having the amino acid sequence of SEQ ID NO: 154 or SEQ ID NO: 5.
[0265] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), T82I, D240G, S464N, D601G and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), T82I, D240G, S464N, D601G and A688V, where the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, has the amino acid sequence of SEQ ID NO: 158. In embodiments, the CoV S polypeptide containing one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), T82I, D240G, S464N, D601G and A688V, wherein the amino acids are numbered relative to the CoV S polypeptide having the amino acid sequence of SEQ ID NO: 2, comprises a signal peptide of SEQ ID NO: 154.
[0266] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 131, an N488Y mutation, an A557D mutation, a D601G mutation, a P668H mutation, a T703I mutation, an S969A mutation, and a D1105H mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 2. In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 132, an N488Y mutation, an A557D mutation, a D601G mutation, a P668H mutation, a T703I mutation, an S969A mutation, and a D1105H mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 2.
[0267] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), a D67A mutation, a L229H mutation, a R233I mutation, an A688V mutation, a N488Y mutation, a K404N mutation, an E471K mutation, and a D601G mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 2.
[0268] In embodiments, the CoV S polypeptide contains one or more modifications selected from K973P, V974P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), an inactivated furin cleavage site, an L5F mutation, a T7N mutation, a P13S mutation, a D125Y mutation, an R177S mutation, a K404T mutation, an E471K mutation, an N488Y mutation, a D601G mutation, an H642Y mutation, a T1014I mutation, and a T1163F mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 2.
[0269] In embodiments, the CoV S polypeptide contains one or more modifications selected from K986P, V987P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), an S13I mutation, a W152C mutation, and an L452R mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 1. In embodiments, the CoV S polypeptide contains one or more modifications selected from K986P, V987P, an inactivated furin cleavage site, optionally QQAQ (SEQ ID NO: 7), an S13I mutation, a W152C mutation, and an L452R mutation, and the CoV S polypeptide is numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 1, and lacks an N-terminal signal peptide.
[0270] In embodiments, the CoV S polypeptide is selected from the group consisting of K986P, V987P, A67V, T95I, G142D, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, H679K, P681H , N764K, D796Y, N856K, Q954H, N969K, L981F, a deletion of amino acids 69, 70, 143, 144, 145, and 211, and an insertion of amino acids EPE between amino acids 214 and 215, and optionally the inactivated furin cleavage site is QQAQ (SEQ ID NO: 7), and the CoV S polypeptide is numbered relative to a wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 1. In embodiments, the CoV S polypeptide having one or more of the above-described modifications lacks an N-terminal signal peptide. In embodiments, the CoV S polypeptide has the amino acid sequence of SEQ ID NO: 159.
[0271] In embodiments, the CoV S polypeptide contains one or more modifications selected from K986P, V987P, A67V, T95I, G142D, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, H679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F, and optionally the inactivated furin cleavage site is QQAQ (SEQ ID NO: 7), and the CoV S polypeptides are numbered relative to the wild-type SARS-CoV-2 S polypeptide having the amino acid sequence of SEQ ID NO: 1. In embodiments, CoV S polypeptides having one or more of the above-described modifications lack an N-terminal signal peptide. In embodiments, the CoV S polypeptide has the amino acid sequence of SEQ ID NO: 160.
[0272] In embodiments, the CoV S polypeptide is any one of SEQ ID NOs: 159 or 167. In embodiments, the amino acid sequence of the CoV S polypeptide has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to any one of SEQ ID NOs: 159 or 167. In embodiments, the CoV S polypeptide is any one of SEQ ID NOs: 160 or 170. In embodiments, the amino acid sequence of the CoV S polypeptide has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity to any one of SEQ ID NOs: 160 or 170. In embodiments, the CoV S polypeptide is encoded by the nucleic acid of any one of SEQ ID NOs: 161, 162, 163, 164, 165, 166, 168, 169, 171, and 172. In embodiments, the CoV S polypeptide of any one of SEQ ID NOs: 160, 170, 159, or 167 lacks an N-terminal signal peptide. For example, the CoV S polypeptide comprises the polypeptide sequence of SEQ ID NO: 160, 170, 159, or 167 C-terminal to MFVFLVLLPLVSS (SEQ ID NO: 5).
[0273] In embodiments, the CoV S polypeptide contains the set of modifications set forth in the table below, where the modifications are numbered relative to SEQ ID NO: 1. In embodiments, the CoV S polypeptide contains the set of modifications set forth in the table below; an inactivated furin cleavage site (optionally, the furin cleavage site is QQAQ (SEQ ID NO: 7)), and the K986P and V987P modifications, where the modifications are numbered relative to SEQ ID NO: 1. [Table 1H-1] [Table 1H-2]
[0274] In embodiments, the CoV spike (S) polypeptide comprises a polypeptide linker. In embodiments, the polypeptide linker contains glycine and serine. In embodiments, the linker has about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% glycines.
[0275] In embodiments, the polypeptide linker is (SGGG) n (SEQ ID NO:91), where n is an integer between 1 and 50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50). In embodiments, the polypeptide linker has an amino acid sequence corresponding to SEQ ID NO:90.
[0276] In embodiments, the polypeptide linker is (GGGGS) n (SEQ ID NO: 93), where n is an integer between 1 and 50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50).
[0277] In embodiments, the polypeptide linker is (GGGS) n (SEQ ID NO: 92), where n is an integer between 1 and 50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50).
[0278] In aspects, the polypeptide linker is a poly-(Gly)n linker, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 16, 17, 18, 19, or 20. In other embodiments, the linker is selected from the group consisting of a dipeptide, a tripeptide, and a quadripeptide. In embodiments, the linker is a dipeptide selected from the group consisting of alanine-serine (AS), leucine-glutamic acid (LE), and serine-arginine (SR).
[0279] In embodiments, the polypeptide linker comprises between 1 and 100 contiguous amino acids of a naturally occurring CoV S polypeptide or a CoV S polypeptide disclosed herein. In embodiments, the polypeptide linker has an amino acid sequence corresponding to SEQ ID NO:94.
[0280] In embodiments, the CoV spike (S) polypeptide comprises a foldon. In embodiments, TMCT is replaced with a foldon. In embodiments, the foldon causes trimerization of the CoV spike (S) polypeptide. In embodiments, the foldon is an amino acid sequence known in the art. In embodiments, the foldon has the amino acid sequence of SEQ ID NO: 68. In embodiments, the foldon is a T4 fibritin trimerization motif. In embodiments, the T4 fibritin trimerization domain has the amino acid sequence of SEQ ID NO: 103. In embodiments, the foldon is separated in amino acid sequence from the CoV spike (S) polypeptide by a polypeptide linker. Non-limiting examples of polypeptide linkers are found throughout this disclosure.
[0281] In embodiments, the present disclosure provides CoV S polypeptides comprising fragments of coronavirus S proteins, as well as nanoparticles and vaccines comprising same. In embodiments, the fragment of a coronavirus S protein is between 10 and 1500 amino acids in length (e.g., about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 1050, about 1100, about 1150, about 1200, about 1250, about 1300, about 1350, about 1400, about 1450, or about 1500 amino acids in length). In embodiments, the fragment of a coronavirus S protein is selected from the group consisting of a receptor binding domain (RBD), subdomain 1, subdomain 2, upper helix, fusion peptide, connecting region, heptad repeat 1, central helix, heptad repeat 2, NTD, and TMCT.
[0282] In embodiments, the CoV S polypeptide comprises an RBD and subdomain 1. In embodiments, the CoV S polypeptide comprising an RBD and subdomain 1 is amino acids 319 to 591 of SEQ ID NO:1.
[0283] In embodiments, the CoV S polypeptide contains a fragment of a coronavirus S protein, and the fragment of the coronavirus S protein is an RBD. Non-limiting examples of RBDs include the RBD of SARS-CoV-2 (amino acid sequence = SEQ ID NO: 69), the RBD of SARS (amino acid sequence = SEQ ID NO: 70), and the RBD of MERS (amino acid sequence = SEQ ID NO: 71).
[0284] In embodiments, the CoV S polypeptide contains two or more RBDs connected by a polypeptide linker, in embodiments, the polypeptide linker has the amino acid sequence of SEQ ID NO:90 or SEQ ID NO:94.
[0285] In embodiments, the CoV S polypeptide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 RBDs.
[0286] In some embodiments, the CoV S polypeptide contains two or more SARS-CoV-2 RBDs connected by a polypeptide linker. In embodiments, the antigen containing two or more SARS-CoV-2 RBDs has an amino acid sequence corresponding to one of SEQ ID NOs: 72-75.
[0287] In embodiments, the CoV S polypeptide contains a SARS-CoV-2 RBD and a SARS RBD. In embodiments, the CoV S polypeptide contains a SARS-CoV-2 RBD and a SARS RBD, each RBD separated by a polypeptide linker. In embodiments, the CoV S polypeptide containing a SARS-CoV-2 RBD and a SARS RBD has an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-79.
[0288] In embodiments, the CoV S polypeptide comprises a SARS-CoV-2 RBD and a MERS RBD. In embodiments, the CoV S polypeptide comprises a SARS-CoV-2 RBD and a MERS RBD, wherein each RBD is separated by a polypeptide linker.
[0289] In embodiments, the CoV S polypeptide comprises a SARS RBD and a MERS RBD. In embodiments, the CoV S polypeptide comprises a SARS RBD and a MERS RBD, wherein each RBD is separated by a polypeptide linker.
[0290] In embodiments, the CoV S polypeptide contains a SARS-CoV-2 RBD, a SARS RBD, and a MERS RBD. In embodiments, the CoV S polypeptide contains a SARS-CoV-2 RBD, a SARS RBD, and a MERS RBD, each RBD separated by a polypeptide linker. In embodiments, the CoV S polypeptide comprising a SARS-CoV-2 RBD, a SARS RBD, and a MERS RBD has an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-83.
[0291] In embodiments, the CoV S polypeptides described herein are expressed with an N-terminal signal peptide. In embodiments, the N-terminal signal peptide has the amino acid sequence of SEQ ID NO: 5 (MFVFLVLLPLVSS). In embodiments, the N-terminal signal peptide has the amino acid sequence of SEQ ID NO: 117 (MFVFLVLLPLVSI). In embodiments, the N-terminal signal peptide has the amino acid sequence of SEQ ID NO: 154 (MFVFFVLLPLVSS). In embodiments, the N-terminal signal peptide has the amino acid sequence of SEQ ID NO: 193 (MFGFLVLLPLVSS). In embodiments, the signal peptide can be replaced with any signal peptide that allows expression of the CoV S protein. In embodiments, one or more of the amino acids of the CoV S protein signal peptide can be deleted or mutated. An initial methionine residue is maintained to initiate expression. In embodiments, the CoV S polypeptide is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:95, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:96, SEQ ID NO:60, SEQ ID NO:131, SEQ ID NO:135, SEQ ID NO:142, SEQ ID NO:145, SEQ ID NO:148, SEQ ID NO:150, SEQ ID NO:196, SEQ ID NO:197; SEQ ID NO:198; SEQ ID NO:199; SEQ ID NO:201; SEQ ID NO:202; SEQ ID NO:204; SEQ ID NO:206; SEQ ID NO:208; SEQ ID NO:210; SEQ ID NO:212; SEQ ID NO:214; and SEQ ID NO:216. In embodiments, the N-terminal signal peptide of the CoV S polypeptide contains a mutation at Ser-13 compared to the native CoV spike (S) signal polypeptide (SEQ ID NO:5). In embodiments, Ser-13 is mutated to any naturally occurring amino acid. In embodiments, Ser-13 is mutated to alanine, methionine, isoleucine, leucine, threonine, or valine. In embodiments, Ser-13 is mutated to isoleucine.
[0292] Following expression of the CoV S protein in a host cell, the N-terminal signal peptide is cleaved to provide the mature CoV protein sequence (SEQ ID NOS: 2, 4, 38, 41, 44, 48, 51, 54, 58, 61, 63, 65, 67, 73, 75, 78, 79, 82, 83, 85, 87, 89, 106, 110, 132, 133, 114, 138, 141, 144, 147, 151, 153, 156, 158, 174, 175, 176, 181-184, 186, 188, 190, 195, 217-228, 233-236, and 243). In embodiments, the signal peptide is cleaved by a host cell protease. In aspects, the full-length protein can be isolated from the host cell and the signal peptide can be subsequently cleaved.
[0293] During expression and purification, CoV spike (S) polynucleotides having amino acid sequences corresponding to SEQ ID NOs: 1, 3, 36, 40, 42, 46, 49, 52, 56, 59, 62, 64, 66, 72, 74, 76, 77, 80, 81, 84, 86, 87, 105, 107, 88, 109, 130, 134, 136, 137, 140, 143, 146, 149, 152, 155, 157, 159, 160, 173, 177-180, 185, 189, 191, 194, 200, 203, 205, 207, 209, 211, 213, 215, 229-232, and 242 were prepared. After cleavage of the signal peptide from the peptide, a mature polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 38, 41, 44, 48, 51, 54, 58, 61, 63, 65, 67, 73, 75, 78, 79, 82, 83, 85, 106, 108, 89 and 110, 112-115, 132, 133, 114, 138, 141, 144, 147, 151, 153, 156, 158, 174, 175, 176, 181-184, 186, 188, 190, 195, 217-228, 233-236 and 243 is obtained and used to produce a CoV S nanoparticle vaccine or CoV S nanoparticles.
[0294] Advantageously, the disclosed CoV S polypeptides can have enhanced protein expression and stability compared to native CoV spike (S) protein.
[0295] In embodiments, the CoV S polypeptides described herein contain additional modifications from the native coronavirus S protein (SEQ ID NO: 2). In embodiments, the coronavirus S proteins described herein exhibit at least 80%, or at least 90%, or at least 95%, or at least 97%, or at least 99% identity to the native coronavirus S protein. One skilled in the art would use known techniques to calculate the percent identity of a recombinant coronavirus S protein to a native protein or to any of the CoV S polypeptides described herein. For example, percentage identity can be calculated using the online tools CLUSTALW2 or Basic Local Alignment Search Tool (BLAST). The following default parameters can be used for CLUSTALW2 Pairwise alignment: protein weight matrix = Gonnet; gap open = 10; gap extension = 0.1.
[0296] In embodiments, the CoV S polypeptides described herein are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a CoV S polypeptide having the amino acid sequence of any one of SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NOs:181-184, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:190, SEQ ID NO:195; SEQ ID NOs:217-228, SEQ ID NOs:233-236, and SEQ ID NO:243. The CoV S polypeptide may have deletions, insertions, or mutations of at most about 1 amino acid, at most about 2 amino acids, at most about 3 amino acids, at most about 4 amino acids, at most about 5 amino acids, at most about 10 amino acids, at most about 15 amino acids, at most about 20 amino acids, at most about 25 amino acids, at most about 30 amino acids, at most about 35 amino acids, at most about 40 amino acids, at most about 45 amino acids, or at most about 50 amino acids, compared to the amino acid sequence of a CoV S polypeptide having any one of the amino acid sequences of SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NOs:181-184, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:190, SEQ ID NO:195; SEQ ID NOs:217-228, SEQ ID NOs:233-236, and SEQ ID NO:243.The CoV S polypeptide is a CoV having any one of the amino acid sequences of SEQ ID NO: 87, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NOs: 181 to 184, SEQ ID NO: 186, SEQ ID NO: 188, SEQ ID NO: 190, SEQ ID NO: 195; SEQ ID NOs: 217 to 228, SEQ ID NOs: 233 to 236, and SEQ ID NO: 243. The polypeptide may have between about 1 and about 5 amino acids, between about 3 and about 10 amino acids, between about 5 and 10 amino acids, between about 8 and 12 amino acids, between about 10 and 15 amino acids, between about 12 and 17 amino acids, between about 15 and 20 amino acids, between about 18 and 23 amino acids, between about 20 and 25 amino acids, between about 22 and about 27 amino acids, between about 25 and 30 amino acids, between about 30 and 35 amino acids, between about 35 and 40 amino acids, between about 40 and 45 amino acids, or between about 45 and 50 amino acids deleted, inserted, or mutated compared to the S polypeptide. In embodiments, the CoV S polypeptide described herein comprises about one, about two, about three, about four, about five, about six, about seven, about eight, about nine, about ten, about eleven, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, or about 25 substitutions compared to a coronavirus S protein having the amino acid sequence of any one of SEQ ID NO:87, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NOs:181-184, SEQ ID NO:186, SEQ ID NO:188, SEQ ID NO:190, SEQ ID NO:195; SEQ ID NOs:217-228, SEQ ID NOs:233-236, and SEQ ID NO:243.
[0297] In embodiments, the coronavirus S polypeptide is extended at the N-terminus, C-terminus, or both the N-terminus and C-terminus. In aspects, the extension is a tag useful for function, e.g., purification or detection. In aspects, the tag contains an epitope. For example, the tag can be a polyglutamic acid tag, a FLAG tag, an HA tag, a polyHis tag (having approximately 5-10 histidines) (SEQ ID NO: 101), a hexahistidine tag (SEQ ID NO: 100), an 8x-His tag (having 8 histidines) (SEQ ID NO: 102), a Myc tag, a glutathione-S-transferase tag, a green fluorescent protein tag, a maltose-binding protein tag, a thioredoxin tag, or an Fc tag. In other aspects, the extension can be an N-terminal signal peptide fused to the protein to enhance expression. Such signal peptides are often cleaved during expression in cells, but some nanoparticles may contain antigens with an intact signal peptide. Thus, when the nanoparticle contains an antigen, the antigen may contain an extension and thus may be a fusion protein when incorporated into the nanoparticle. For purposes of calculating sequence identity, the extension is not included. In embodiments, the tag is a protease cleavage site. Non-limiting examples of protease cleavage sites include HRV3C protease cleavage site, chymotrypsin, trypsin, elastase, endopeptidase, caspase-1, caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, enterokinase, factor Xa, granzyme B, TEV protease, and thrombin. In embodiments, the protease cleavage site is an HRV3C protease cleavage site. In embodiments, the protease cleavage site comprises the amino acid sequence of SEQ ID NO:98.
[0298] In embodiments, the CoV S glycoprotein comprises a fusion protein. In embodiments, the CoV S glycoprotein comprises an N-terminal fusion protein. In embodiments, the CoV S glycoprotein comprises a C-terminal fusion protein. In embodiments, the fusion protein includes a tag useful for protein expression, purification, or detection. In embodiments, the tag is a polyHis-tag (having about 5-10 histidines), Myc-tag, glutathione-S-transferase-tag, green fluorescent protein-tag, maltose binding protein-tag, thioredoxin-tag, Strep-tag, Twin-Strep-tag, or Fc-tag. In embodiments, the tag is an Fc-tag. In embodiments, the Fc-tag is monomeric, dimeric, or trimeric. In embodiments, the tag is a hexahistidine tag containing six histidines (SEQ ID NO: 100), e.g., a polyHis-tag. In embodiments, the tag is a Twin-Strep-tag having the amino acid sequence of SEQ ID NO: 99.
[0299] In embodiments, the CoV S polypeptide is a fusion protein that includes another coronavirus protein. In embodiments, the other coronavirus protein is from the same coronavirus. In embodiments, the other coronavirus protein is from a different coronavirus.
[0300] In embodiments, the CoV S protein can be truncated. For example, the N-terminus can be truncated by about 10, 30, 50, 75, 100, or 200 amino acids. The C-terminus can be truncated instead of or in addition to the N-terminus. For example, the C-terminus can be truncated by about 10, 30, 50, 75, 100, or 200 amino acids. For purposes of calculating identity to a protein having a truncation, identity is measured across the remainder of the protein.
[0301] Nanoparticles containing CoV spike (S) polypeptide In embodiments, mature CoV S polypeptide antigens are used to produce vaccines comprising coronavirus S nanoparticles. In embodiments, nanoparticles of the present disclosure comprise a CoV S polypeptide described herein. In embodiments, nanoparticles of the present disclosure comprise a CoV S polypeptide associated with a surfactant core. The presence of the surfactant facilitates nanoparticle formation by forming a core that organizes and presents the antigen. In embodiments, nanoparticles may contain CoV S polypeptides assembled into multi-oligomeric glycoprotein-surfactant (e.g., PS80) nanoparticles, with the PS80 surfactant having an outwardly protruding head region and a hydrophobic region, forming a central core surrounded by glycoproteins. In embodiments, CoV S polypeptides inherently contain or are adapted to contain a transmembrane domain to facilitate protein association into the surfactant core. In embodiments, the CoV S polypeptide contains a head domain. Figure 10 shows an exemplary structure of a CoV S polypeptide of the present disclosure. Primarily, the transmembrane domain of the CoV S polypeptide trimer associates with the surfactant; however, other portions of the polypeptide may also interact. Advantageously, the nanoparticles have improved resistance to environmental stress due to the organization of multiple copies of the protein around the surfactant, providing enhanced stability and / or improved presentation to the immune system.
[0302] In embodiments, the surfactant core is a non-ionic surfactant core. In embodiments, the CoV S polypeptide is associated with the non-ionic surfactant core. In embodiments, the surfactant is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65), and polysorbate-80 (PS80).
[0303] In an embodiment, the surfactant is PS80.
[0304] In embodiments, CoV S polypeptides form trimers. In embodiments, CoV S polypeptide nanoparticles are composed of multiple polypeptide trimers surrounding a nonionic surfactant core. In embodiments, the nanoparticles contain at least about one trimer or more. In embodiments, the nanoparticles contain at least about 5 trimers to about 30 trimers of the spike protein. In embodiments, each nanoparticle may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 15, 20, 25, or 30 trimers, including all values and ranges therebetween. The compositions disclosed herein may contain nanoparticles with different numbers of trimers. For example, a composition may contain nanoparticles where the number of trimers ranges from 2 to 9; in embodiments, nanoparticles in a composition may contain 2 to 6 trimers. In embodiments, a composition contains a heterogeneous population of nanoparticles having 2 to 6 trimers per nanoparticle or 2 to 9 trimers per nanoparticle. In embodiments, a composition may contain a substantially homogeneous population of nanoparticles. For example, the population may contain about 95% nanoparticles with five trimers.
[0305] The nanoparticles disclosed herein range in particle size. In embodiments, the nanoparticles disclosed herein range in particle size from Z-ave size to about 20 nm to about 60 nm, about 20 nm to about 50 nm, about 20 nm to about 45 nm, about 20 nm to about 35 nm, about 20 nm to about 30 nm, about 25 nm to about 35 nm, about 25 nm to about 45 nm, about 30 nm to about 120 nm, about 30 nm to about 80 nm, about 30 nm to about 60 nm, about 30 nm to about 65 nm, or about 30 nm to about 50 nm. Particle size (Z-ave) is measured by dynamic light scattering (DLS) using a Zetasizer NanoZS (Malvern, UK) unless otherwise specified.
[0306] In embodiments, nanoparticles comprising a CoV S polypeptide disclosed herein have a reduced particle size compared to nanoparticles comprising a wild-type CoV S polypeptide, in embodiments, the CoV S polypeptide is at least about 40% smaller in particle size, e.g., at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, or at least about 85% smaller in particle size.
[0307] Nanoparticles comprising the CoV S polypeptides disclosed herein are more uniform in size, shape, and mass than nanoparticles comprising wild-type CoV S polypeptides. The polydispersity index (PDI), a measure of heterogeneity, is measured by dynamic light scattering using a Malvern Setasizer, unless otherwise specified. In embodiments, the particles measured herein have a PDI of about 0.1 to about 0.45, e.g., about 0.1, about 0.2, about 0.25, about 0.29, about 0.3, about 0.35, about 0.40, or about 0.45. In embodiments, the nanoparticles measured herein have a PDI that is at least about 25% smaller than the PDI of nanoparticles comprising the wild-type CoV S polypeptide of SEQ ID NO:2, e.g., at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, or at least about 60% smaller.
[0308] CoV S polypeptides and nanoparticles comprising the same have improved thermal stability compared to wild-type CoV S polypeptides or nanoparticles thereof. The thermal stability of CoV S polypeptides is measured using differential scanning calorimetry (DSC) unless otherwise specified. The transition enthalpy (ΔHcal) is the energy required to unfold a CoV S polypeptide. In embodiments, the CoV S polypeptide has an increased ΔHcal compared to a wild-type CoV S polypeptide. In embodiments, the ΔHcal of the CoV S polypeptide is about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold greater than the ΔHcal of the wild-type CoV S polypeptide.
[0309] Several nanoparticle types can be included in the vaccine compositions disclosed herein. In some embodiments, the nanoparticle type is in the form of anisotropic rods, which can be dimeric or monomeric. In other embodiments, the nanoparticle type is a spherical oligomer. In still other embodiments, the nanoparticles can be described as intermediate nanoparticles with sedimentation properties intermediate between the first two types. The formation of nanoparticle types can be regulated by controlling the surfactant and protein concentrations during the production process. The nanoparticle type can be determined by measuring the sedimentation coefficient.
[0310] Production of nanoparticles containing CoV S polypeptide antigens
[0311] The nanoparticles of the present disclosure are non-naturally occurring products, and their components do not occur together in nature. Generally, the methods disclosed herein use a surfactant exchange approach, in which a first surfactant is used to isolate proteins, and then the first surfactant is exchanged with a second surfactant to form nanoparticles.
[0312] Antigens contained in nanoparticles are typically produced by recombinant expression in host cells. Standard recombinant techniques can be used. In embodiments, CoV S polypeptides are expressed in insect host cells using a baculovirus system. In embodiments, the baculovirus is a cathepsin-L knockout baculovirus, a chitinase knockout baculovirus. Optionally, the baculovirus is double knockout for both cathepsin-L and chitinase. High-level expression can be obtained in insect cell expression systems. Non-limiting examples of insect cells are Spodoptera frugiperda (Sf) cells, e.g., Sf9, Sf21, Trichoplusia ni cells, e.g., High Five cells, and Drosophila S2 cells. In embodiments, the CoV S polypeptides described herein are produced in any suitable host cell. In embodiments, the host cell is an insect cell. In embodiments, the insect cell is an Sf9 cell.
[0313] Typical transfection and cell growth methods can be used to culture cells.Vector, for example, vector containing polynucleotide encoding fusion protein, can be transfected into host cells according to methods well known in the art.For example, introducing nucleic acid into eukaryotic cells can be achieved by calcium phosphate co-precipitation, electroporation, microinjection, lipofection and transfection using polyamine transfection reagent.In one embodiment, the vector is a recombinant baculovirus.
[0314] Methods for growing host cells include, but are not limited to, batch, fed-batch, continuous, and perfusion cell culture techniques. Cell culture refers to the growth and expansion of cells in a bioreactor (fermentation chamber) where the cells are expanded and express proteins (e.g., recombinant proteins) for purification and isolation. Typically, cell culture is carried out in a bioreactor under sterile, controlled temperature and atmospheric conditions. A bioreactor is a chamber used to cultivate cells in which environmental conditions, such as temperature, air pressure, agitation, and / or pH, can be monitored. In one embodiment, the bioreactor is a stainless steel chamber. In another embodiment, the bioreactor is a pre-sterilized plastic bag (e.g., Cellbag®, Wave Biotech, Bridgewater, NJ). In another embodiment, the pre-sterilized plastic bag is a bag of approximately 50 L to 3500 L.
[0315] Extraction and purification of nanoparticles containing CoV spike (S) protein antigen
[0316] After host cell growth, proteins can be recovered from the host cells using detergents and purification protocols. After the host cells have grown for 48 to 96 hours, the cells are isolated from the culture medium, and a detergent-containing solution is added to solubilize the cell membranes, releasing the proteins into a detergent extract. Triton® X-100 and TERGITOL® nonylphenol ethoxylate, also known as NP-9, are preferred detergents for extraction. The detergent can be added to a final concentration of about 0.1% to about 1.0%. For example, the concentration can be about 0.1%, about 0.2%, about 0.3%, about 0.5%, about 0.7%, about 0.8%, or about 1.0%. The range can be about 0.1% to about 0.3%. In some embodiments, the concentration is about 0.5%.
[0317] In other embodiments, a different first detergent can be used to isolate proteins from host cells. For example, the first detergent can be bis(polyethylene glycol bis[imidazoylcarbonyl]), nonoxynol-9, bis(polyethylene glycol bis[imidazoylcarbonyl]), BRIJ® Polyethylene Glycol Dodecyl Ether 35, BRIJ® Polyethylene Glycol (3) Cetyl Ether 56, BRIJ® Alcohol Ethoxylate 72, BRIJ® Polyoxyl 2 Stearyl Ether 76, BRIJ® Polyethylene Glycol Monoolelyl Ether 92V, BRIJ® Polyoxyethylene (10) Oleyl Ether 97, BRIJ® Polyethylene Glycol Hexadecyl Ether 58P, CREMOPHOR® EL Macrogolglycerol Ricinoleate, or CREMOPHOR® EL Macrogolglycerol Ricinoleate. ricinoleate), Decaethylene Glycol Monododecyl Ether, N-Decanoyl-N-Methylglucamine, n-Decyl Alpha-D Glucopyranoside, Decyl Beta-D-Maltopyranoside, n-Dodecanoyl-N-Methylglucamide, n-Dodecyl Alpha-D-Maltoside, n-Dodecyl Beta-D-Maltoside, n-Dodecyl Beta-D-Maltoside, Heptaethylene Glycol Monodecyl Ether, Heptaethylene Glycol Monododecyl Ether, Heptaethylene Glycol Monotetradecyl Ether, n-Hexadecyl Beta-D-Maltoside, Hexaethylene Glycol Monododecyl Ether, Hexaethylene Glycol Monohexadecyl Ether, Hexaethylene Glycol Monooctadecyl Ether, Hexaethylene Glycol Monotetradecyl Ether, Igepal CA-630, Igepal CA-630, methyl-6-O-(N-heptylcarbamoyl)-alpha-D-glucopyranoside, nonaethylene glycol monododecyl ether, N-nonanoyl-N-methylglucamine, N-nonanoyl N-methylglucamine, octaethylene glycol monodecyl ether, octaethylene glycol monododecyl ether, octaethylene glycol monohexadecyl ether,Octaethylene glycol monooctadecyl ether, octaethylene glycol monotetradecyl ether, octyl beta-D glucopyranoside, pentaethylene glycol monodecyl ether, pentaethylene glycol monododecyl ether, pentaethylene glycol monohexadecyl ether, pentaethylene glycol monohexyl ether, pentaethylene glycol monooctadecyl ether, pentaethylene glycol monooctyl ether, polyethylene glycol diglycidyl ether, polyethylene glycol ether W-1, polyoxyethylene 10 tridecyl ether, polyoxyethylene 100 stearate, polyoxyethylene 20 isohexadecyl ether, polyoxyethylene 20 oleyl ether, polyoxyethylene 40 stearate, polyoxyethylene 50 stearate, polyoxyethylene 8 stearate, polyoxyethylene bis(imidazolylcarbonyl), polyoxyethylene 25 propylene glycol stearate, saponin from Quillaja bark, SPAN® 20 sorbitan laurate, SPAN® 40 sol Sorbitan Monopalmitate, SPAN® 60 Sorbitan Stearate, SPAN® 65 Sorbitan Tristearate, SPAN® 80 Sorbitan Monooleate, SPAN® 85 Sorbitan Trioleate, TERGITOL® Secondary Alcohol Ethoxylate Type 15-S-12, TERGITOL® Secondary Alcohol Ethoxylate Type 15-S-30, TERGITOL® Secondary Alcohol Ethoxylate Type 15-S-5, TERGITOL® Secondary Alcohol Ethoxylate Type 15-S-7, TERGITOL® Secondary Alcohol Ethoxylate Type 15-S-9, TERGITOL® Nonylphenol Ethoxylate Type NP-10, TERGITOL® Nonylphenol Ethoxylate Type NP-4, TERGITOL® Nonylphenol Ethoxylate Type NP-40, TERGITOL® Nonylphenol Ethoxylate Type NP-7, TERGITOL® Nonylphenol Ethoxylate Type NP-9,The copolymer may be TERGITOL® Branched Chain Secondary Alcohol Ethoxylate Type TMN-10, TERGITOL® Branched Chain Secondary Alcohol Ethoxylate Type TMN-6, TRITON™ X-100 Polyethylene Glycol Tert-Octyl Phenyl Ether, or a combination thereof.
[0318] The nanoparticles can then be isolated from the cell debris using centrifugation. In embodiments, for example, gradient centrifugation using cesium chloride, sucrose, and iodixanol can be used. Other techniques, such as standard purification techniques including, for example, ion exchange, affinity, and gel filtration chromatography, can be used as an alternative or in addition.
[0319] For example, the first column can be an ion exchange chromatography resin, such as FRACTOGEL® EMD methacrylate-based polymeric bead TMAE (EMD Millipore), the second column can be a Lens culinaris lectin affinity resin, and the third column can be a cation exchange column, such as FRACTOGEL® EMD methacrylate-based polymeric bead SO3 (EMD Millipore) resin. In other embodiments, the cation exchange column can be an MMC column or a Nuvia C Prime column (Bio-Rad Laboratories, Inc.). Preferably, the methods disclosed herein do not use detergent extraction columns; e.g., hydrophobic interaction columns. Such columns are often used to remove detergents during purification, but can negatively affect the methods disclosed herein.
[0320] Surfactant exchange of nanoparticles containing CoV S polypeptide antigens
[0321] To form nanoparticles, the first surfactant used to extract proteins from host cells is essentially replaced with a second surfactant to achieve a nanoparticle structure. NP-9 is the preferred extraction surfactant. Typically, the nanoparticles contain no detectable NP-9 as measured by HPLC. The second surfactant is typically selected from the group consisting of PS20, PS40, PS60, PS65, and PS80. Preferably, the second surfactant is PS80.
[0322] In certain embodiments, detergent exchange is performed using affinity chromatography, which binds glycoproteins via their carbohydrate moieties. For example, affinity chromatography can use a legume lectin column. Legume lectins are proteins originally identified in plants and found to specifically and reversibly interact with carbohydrate residues. See, for example, Sharon and Lis, "Legume lectins—a large family of homologous proteins," FASEB J. 1990 Nov;4(14):3198-208; Liener, "The Lectins: Properties, Functions, and Applications in Biology and Medicine," Elsevier, 2012. Suitable lectins include concanavalin A (con A), pea lectin, sainfoin lectin, and lentil lectin. Due to its binding properties, lentil lectin is a preferred column for detergent exchange. Lectin columns are commercially available; for example, Capto Lentil Lectin is available from GE Healthcare. In certain aspects, the lentil lectin column may use recombinant lectin. At the molecular level, it is believed that carbohydrate moieties bind to the lentil lectin, freeing amino acids of the protein to coalesce around the surfactant, resulting in the formation of a surfactant core, providing nanoparticles with multiple copies of the antigen, e.g., glycoprotein oligomers that may be dimers, trimers, or tetramers, anchored to the surfactant. In embodiments, the CoV S polypeptide forms a trimer. In embodiments, the CoV S polypeptide trimer is anchored to the surfactant. In embodiments, each CoV S polypeptide nanoparticle contains at least one trimer associated with a non-ionic core.
[0323] When detergents are incubated with proteins to form nanoparticles during detergent exchange, they can be present at up to about 0.1% (w / v) during early purification steps; this amount is reduced to obtain final nanoparticles with optimal stability. For example, nonionic detergents (e.g., PS80) can be present at concentrations of about 0.005% (v / v) to about 0.1% (v / v), such as about 0.005% (v / v), about 0.006% (v / v), about 0.007% (v / v), about 0.008% (v / v), about 0.009% (v / v), about 0.01% (v / v), about 0.015% (v / v), about 0.02% (v / v), about 0.025% (v / v), about 0.03% (v / v), and about 0.04% (v / v). The PS80 may be about 0.035% (v / v), about 0.04% (v / v), about 0.045% (v / v), about 0.05% (v / v), about 0.055% (v / v), about 0.06% (v / v), about 0.065% (v / v), about 0.07% (v / v), about 0.075% (v / v), about 0.08% (v / v), about 0.085% (v / v), about 0.09% (v / v), about 0.095% (v / v), or about 0.1% (v / v). In embodiments, the nanoparticles contain about 0.03% to about 0.05% PS80. In embodiments, the nanoparticles contain about 0.01% (v / v) PS80.
[0324] In embodiments, the purified CoV S polypeptide is dialyzed. In embodiments, the dialysis is performed after purification. In embodiments, the CoV S polypeptide is dialyzed in a solution comprising sodium phosphate, NaCl, and PS80. In embodiments, the sodium phosphate-containing dialysis solution contains between about 5 mM and about 100 mM sodium phosphate, for example, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, or about 100 mM sodium phosphate. In embodiments, the pH of the solution containing sodium phosphate is about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5. In embodiments, the dialysis solution containing sodium chloride has a pH of about 50 mM to about 500 mM NaCl, for example, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, about 240 mM, about 250 mM, about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, about 400 mM, about 410 mM, about 420 mM, about 430 mM, about 440 mM, about 450 mM, about 460 mM, about 470 mM, about 480 mM, about 490 mM, about 500 mM, about 510 mM, about 520 mM, about 530 mM, about 540 mM, about 550 mM, about 560 mM, about 570 mM, about 580 mM, about 590 mM, about 600 mM, about 610 mM, about 62 , about 260 mM, about 270 mM, about 280 mM, about 290 mM, about 300 mM, about 310 mM, about 320 mM, about 330 mM, about 340 mM, about 350 mM, about 360 mM, about 370 mM, about 380 mM, about 390 mM, about 400 mM, about 410 mM, about 420 mM, about 430 mM, about 440 mM, about 450 mM, about 460 mM, about 470 mM, about 480 mM, about 490 mM, or about 500 mM NaCl.In embodiments, the dialysis solution containing PS80 is about 0.005% (v / v), about 0.006% (v / v), about 0.007% (v / v), about 0.008% (v / v), about 0.009% (v / v), about 0.01% (v / v), about 0.015% (v / v), about 0.02% (v / v), about 0.025% (v / v), about 0.03% (v / v), about 0.035% (v / v), about 0.04% (v / v), about 0.05% (v / v), about 0.06% (v / v), about 0.07% (v / v), about 0.08% (v / v), about 0.09% (v / v), about 0.10% (v / v), about 0.11% (v / v), about 0.12% (v / v), about 0.13% (v / v), about 0.14% (v / v), about 0.15% (v / v), about 0.16% (v / v), about 0.17% (v / v), about 0.18% (v / v), about 0.19% (v / v), about 0.20% (v / v), about 0.21% (v / v), about 0.22% (v / v), about 0.23% (v / v), about 0.24% (v / v), about 0.25% (v / v), about 0.26% (v / v), about 0.27% (v / v), about 0.28% (v / v), about 0.29% (v / v), about 0.30% (v / v), about 0.31% (v / v), about 0.32% (v / v), about 0.33% (v / (v / v), about 0.045% (v / v), about 0.05% (v / v), about 0.055% (v / v), about 0.06% (v / v), about 0.065% (v / v), about 0.07% (v / v), about 0.075% (v / v), about 0.08% (v / v), about 0.085% (v / v), about 0.09% (v / v), about 0.095% (v / v), or about 0.1% (v / v) of PS80. In embodiments, the dialysis solution comprises about 25 mM sodium phosphate (pH 7.2), about 300 mM NaCl, and about 0.01% (v / v) of PS80.
[0325] Detergent exchange can be performed with proteins purified as discussed above, purified, frozen for storage, and then thawed for detergent exchange.
[0326] The stability of the compositions disclosed herein can be measured in a variety of ways. In one approach, peptide maps can be prepared to determine the integrity of antigenic proteins after various treatments designed to stress nanoparticles by mimicking harsh storage conditions. Thus, a measure of stability is the relative abundance of antigenic peptides in stressed samples compared to control samples. For example, the stability of nanoparticles containing CoV S polypeptides can be assessed by exposing them to various pHs, proteases, salts, oxidizing agents including, but not limited to, hydrogen peroxide, various temperatures, freeze / thaw cycles, and agitation. Figures 12A-B show that BV2373 (SEQ ID NO: 87) and BV2365 (SEQ ID NO: 4) retain binding to hACE2 under various stress conditions. The location of glycoproteins anchored to the surfactant core is believed to provide enhanced stability by reducing undesirable interactions. For example, improved protection against protease-based degradation can be achieved through a shielding effect, whereby anchoring glycoproteins to the core at the molar ratios disclosed herein creates steric hindrance that blocks protease access. Stability can also be measured by monitoring intact protein. Figures 33 and 34 compare nanoparticles containing CoV polypeptides with the amino acid sequences of SEQ ID NOs: 109 and 87, respectively. Figure 34 shows that the CoV polypeptide with the amino acid sequence of SEQ ID NO: 87 exhibits particularly good stability during purification. The polypeptide in Figure 34 contains a furin cleavage site with the amino acid sequence of QQAQ (SEQ ID NO: 7).
[0327] Vaccine compositions containing CoV S polypeptide antigens The present disclosure provides, for example, vaccine compositions comprising CoV S polypeptides in nanoparticles. In aspects, the vaccine compositions may contain nanoparticles bearing antigens from more than one viral strain from the same virus species. In another embodiment, the present disclosure provides pharmaceutical packs or kits comprising one or more containers filled with one or more of the components of the vaccine composition.
[0328] The compositions disclosed herein can be used either prophylactically or therapeutically, but are typically prophylactic. Thus, the present disclosure includes methods for treating or preventing infectious diseases. These methods include administering a therapeutic or prophylactic amount of the immunogenic composition of the present disclosure to a subject. Preferably, the pharmaceutical composition is a vaccine composition that provides a protective effect. In other aspects, the protective effect may include the alleviation of symptoms associated with infection in a percentage of an exposed population. For example, the composition may prevent or reduce one or more viral disease symptoms selected from the following, compared to untreated subjects: fever, fatigue, muscle pain, headache, sore throat, vomiting, diarrhea, rash, symptoms of impaired kidney and liver function, internal bleeding, and external bleeding.
[0329] The nanoparticles can be formulated for administration as a vaccine in the presence of various excipients, buffers, etc. For example, the vaccine composition can contain sodium phosphate, sodium chloride, and / or histidine. Sodium phosphate can be present at about 10 mM to about 50 mM, about 15 mM to about 25 mM, or about 25 mM; in certain cases, about 22 mM sodium phosphate is present. Histidine can be present at about 0.1% (w / v), about 0.5% (w / v), about 0.7% (w / v), about 1% (w / v), about 1.5% (w / v), about 2% (w / v), or about 2.5% (w / v). Sodium chloride, if present, can be about 150 mM. In certain compositions, sodium chloride can be present at higher concentrations, e.g., about 200 mM to about 500 mM. In embodiments, sodium chloride is present at a high concentration, including but not limited to, about 200 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM, or about 500 mM.
[0330] In embodiments, the nanoparticles described herein have improved stability at certain pH levels. In embodiments, the nanoparticles are stable at slightly acidic pH levels. For example, the nanoparticles are stable at slightly acidic pH levels, e.g., pH 5.8 to pH 7.0. In embodiments, the nanoparticles and compositions containing the nanoparticles may be stable at pH levels ranging from about pH 5.8 to about pH 7.0, including about pH 5.9 to about pH 6.8, about pH 6.0 to about pH 6.5, about pH 6.1 to about pH 6.4, about pH 6.1 to about pH 6.3, or about pH 6.2. In embodiments, the nanoparticles and compositions described herein are stable at neutral pH levels, including about pH 7.0 to about pH 7.4. In embodiments, the nanoparticles and compositions described herein are stable at slightly alkaline pH levels, e.g., about pH 7.0 to about pH 8.5, about pH 7.0 to about pH 8.0, or about pH 7.0 to about pH 7.5, including all values and ranges therebetween.
[0331] Adjuvants In certain embodiments, the compositions disclosed herein can be combined with one or more adjuvants to enhance immune response.In other embodiments, the compositions are prepared without adjuvants and can therefore be used for administration as adjuvant-free compositions.Advantageously, the adjuvant-free compositions disclosed herein can provide a protective immune response when administered as a single dose.Alum-free compositions that induce robust immune response are particularly useful in adults aged about 60 years and older.
[0332] Aluminum-based adjuvants
[0333] In embodiments, the adjuvant can be alum (e.g., AlPO4 or Al(OH)3). Typically, the nanoparticles are substantially bound to alum. For example, the nanoparticles may be at least 80% bound, at least 85% bound, at least 90% bound, or at least 95% bound to alum. Often, the nanoparticles in the composition are 92% to 97% bound to alum. The amount of alum present per dose is typically in the range of about 400 μg to about 1250 μg. For example, alum can be present in an amount per dose of about 300 μg to about 900 μg, about 400 μg to about 800 μg, about 500 μg to about 700 μg, about 400 μg to about 600 μg, or about 400 μg to about 500 μg. Typically, alum is present at about 400 μg per 120 μg dose of protein nanoparticles.
[0334] Saponin adjuvants Adjuvants containing saponins can also be combined with the immunogens disclosed herein. Saponins are glycosides derived from the bark of the Quillaja saponaria Molina tree. Typically, saponins are prepared using a multi-step purification process that produces multiple fractions. As used herein, the term "saponin fraction from Quillaja saponaria Molina" is used collectively to describe semi-purified or defined saponin fractions of Quillaja saponaria or substantially pure fractions thereof.
[0335] Saponin fraction Several approaches for producing saponin fractions are suitable. Fractions A, B, and C are described in U.S. Patent No. 6,352,697 and can be prepared as follows: The lipophilic fraction from Quil A, a crude aqueous Quillaja saponaria Molina extract, is separated by chromatography and eluted with 70% acetonitrile in water to recover the lipophilic fraction. This lipophilic fraction is then separated by semi-preparative HPLC by elution with a gradient of 25% to 60% acetonitrile in acidic water. The fraction referred to herein as "Fraction A" or "QH-A" is or corresponds to the fraction eluted at approximately 39% acetonitrile. The fraction referred to herein as "Fraction B" or "QH-B" is or corresponds to the fraction eluted at approximately 47% acetonitrile. The fraction referred to herein as "Fraction C" or "QH-C" is or corresponds to the fraction eluted at approximately 49% acetonitrile. Further information regarding fraction purification can be found in U.S. Patent No. 5,057,540. When prepared as described herein, Quillaja saponaria Molina fractions A, B, and C each represent a group or family of closely chemically related molecules with definable properties. The chromatographic conditions under which they are obtained are such that batch-to-batch reproducibility with respect to elution profile and biological activity is highly consistent.
[0336] Other saponin fractions have been described: fractions B3, B4, and B4b are described in EP 0436620; fractions QA1 to QA22 are described in EP 03632279 B2, Q-VAC (Nor-Feed, AS Denmark), Quillaja saponaria Molina Spikoside (Isconova AB, Ultunaallen 2B, 756 51 Uppsala, Sweden). Fractions QA-1, QA-2, QA-3, QA-4, QA-5, QA-6, QA-7, QA-8, QA-9, QA-10, QA-11, QA-12, QA-13, QA-14, QA-15, QA-16, QA-1...
Claims
1. 1. A coronavirus (CoV) spike (S) glycoprotein, (i) an S1 subunit having an inactivated furin cleavage site, the S1 subunit comprising an N-terminal domain (NTD), a receptor binding domain (RBD), subdomains 1 and 2 (SD1 / 2), and the inactivated furin cleavage site having the amino acid sequence of QQAQ (SEQ ID NO:7); The NTD optionally comprises one or more modifications selected from the group consisting of: (a) a deletion of one or more amino acids selected from the group consisting of amino acids 11-14, 56, 57, 130, 131, 132, 144, 145, 198, 199, 228, 229, 230, 231, 234, 235, 236, 237, 238, 239, 240, and combinations thereof; and (b) a mutation of one or more amino acids selected from the group consisting of amino acids 5, 6, 7, 11, 12, 13, 14, 51, 53, 54, 56, 57, 62, 63, 67, 70, 82, 125, 129, 131, 132, 133, 134, 139, 143, 144, 145, 170, 177, 197, 198, 199, 200, 201, 202, 209, 229, 233, 239, 240, 244, 245, and combinations thereof; and (c) insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215 Including; the RBD optionally comprises one or more amino acid mutations selected from the group consisting of amino acids 326, 333, 355, 358, 360, 362, 363, 392, 395, 404, 419, 426, 427, 431, 432, 433, 439, 440, 447, 464, 465, 471, 473, 477, 480, 481, 483, 485, 488, 492, and combinations thereof; and The SD1 / 2 domain optionally comprises one or more amino acid mutations selected from the group consisting of 534, 557, 591, 600, 601, 626, 642, 645, 664, 666, 668, and combinations thereof. S1 subunit; and (ii) the S2 subunit, wherein amino acids 973 and 974 are proline; The S2 subunit optionally has one or more modifications selected from the group consisting of: (a) a deletion of one or more amino acids from 676-685, 676-702, 702-711, 775-793, 806-815, and combinations thereof; and (b) one or more amino acid mutations selected from the group consisting of 688, 691, 703, 751, 783, 843, 846, 875, 937, 941, 956, 968, 969, 1014, 1058, 1105, 1163, 1186, and combinations thereof; and (c) deletion of one or more amino acids from TMCT an S2 subunit comprising: and (i) any one of the modifications in (a)-(c) and (ii) (a)-(c). Including; A coronavirus (CoV) spike (S) glycoprotein, wherein the amino acids of said CoV S glycoprotein are numbered relative to a polypeptide having the sequence of SEQ ID NO:
2.
2. (i) one or more mutations of amino acids selected from the group consisting of 6, 14, 54, 70, 82, 129, 133, 134, 139, 143, 144, 170, 197, 199, 200, 239, 244, 326, 333, 355, 358, 360, 362, 363, 392, 395, 404, 427, 431, 432, 433, 439, 447, 464, 465, 471, 473, 477, 480, 483, 485, 488, 492, 534, 591, 601, 626, 642, 645, 666, 668, 691, 751, 783, 843, 941, 956, 968, and 1186; (ii) a deletion of one or more amino acids selected from the group consisting of 11, 12, 13, 56, 57, 130, 131, 132, 144, 145, and 198; and (iii) insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215 comprising one or more modifications selected from: The CoV S glycoprotein of claim 1 , wherein the amino acids of the CoV S glycoprotein are numbered relative to a polypeptide having the sequence of SEQ ID NO:
2.
3. T6I, T6R, A14S, A54V, V70A, T82I, G129D, H133Q, K134E, W139R, E143G, F144L, Q17 0E, I197V, L199I, V200E, V200G, G239V, G244S, G326D, G326H, R333T, L355I, S358F , S358L, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, V432P, G433S, L439R, L439Q, N447K, S464N, T465K, E471A, F473V, F473S, F477S, Q480R, G483S, Q4 85R, N488Y, Y492H, T534K, T591I, D601G, G626V, H642Y, N645S, N666K, P668H, S691L, N751K, D783Y, N843K, Q941H, N956K, L968F, D1186N, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, deletion of amino acid 130, deletion of amino acid 131, deletion of amino acid 132, deletion of amino acid 144, deletion of amino acid 145, deletion of amino acid 198, and insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215. or a modification selected from; The CoV S glycoprotein of claim 1 or 2, wherein the amino acids of the CoV S glycoprotein are numbered relative to a polypeptide having the sequence of SEQ ID NO:
2.
4. (i) A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N , T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H , N751K, D783Y, N843K, Q941H, N956K, L968F, a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 130, a deletion of amino acid 131, a deletion of amino acid 132, a deletion of amino acid 198, and an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, a deletion of amino acid 144, a deletion of amino acid 145, a deletion of amino acid 198, and an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (vi) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (vii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (x) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xi) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S 464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiv) T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S 358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S46 4N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131; (xv) T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S36 2F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F 473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; and (xviii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131. The combination of modifications includes those selected from the group consisting of: The CoV S glycoprotein of claim 1 , wherein the amino acids of the CoV S glycoprotein are numbered relative to a polypeptide having the sequence of SEQ ID NO:
2.
5. 5. The CoV S glycoprotein of any one of claims 1 to 4, which is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
6. 6. The CoV S glycoprotein of any one of claims 1 to 5, wherein the NTD of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the NTD of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
7. 7. The CoV S glycoprotein of any one of claims 1 to 6, wherein the RBD of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the RBD of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
8. 8. The CoV S glycoprotein of any one of claims 1 to 7, wherein the S1 subunit of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the S1 subunit of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
9. 9. The CoV S glycoprotein of any one of claims 1 to 8, wherein the S2 subunit of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the S2 subunit of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, and 233-236 and 243.
10. 10. The CoV S glycoprotein of any one of claims 1 to 9, wherein the SD1 / 2 of the CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SD1 / 2 of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
11. 11. The CoV S glycoprotein of any one of claims 1 to 10, wherein each of the NTD, RBD, S1 subunit, S2 subunit and SD1 / 2 is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the respective NTD, RBD, S1 subunit, S2 subunit and SD1 / 2 of any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228, 233-236, and 243.
12. 12. The CoV S glycoprotein of claim 1 , comprising a protein tag.
13. The CoV S glycoprotein of claim 12 , wherein the protein tag is at the N-terminus of the glycoprotein.
14. The CoV S glycoprotein of claim 12 , wherein the protein tag is at the C-terminus of the glycoprotein.
15. 15. The CoV S glycoprotein of any one of claims 12 to 14, wherein the protein tag is selected from a polyglutamic acid tag, a FLAG-tag, an HA-tag, a polyHis-tag (having about 5-10 histidines) (SEQ ID NO: 101), a hexahistidine tag (SEQ ID NO: 100), an 8x-His-tag (having 8 histidines) (SEQ ID NO: 102), a Myc-tag, a glutathione-S-transferase-tag, a green fluorescent protein-tag, a maltose binding protein-tag, a thioredoxin-tag, an Fc-tag, or a combination thereof.
16. 16. The CoV S glycoprotein of claim 1 , comprising an N-terminal signal peptide.
17. The CoV S glycoprotein of claim 16, wherein the N-terminal signal peptide is selected from any one of SEQ ID NOs: 5, 117, 154 and 193.
18. A nucleic acid comprising the CoV S glycoprotein of any one of claims 1 to 17.
19. 20. The nucleic acid of claim 18, which is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of the nucleic acids of SEQ ID NOs: 196, 197, 198, 199, 201, 202, 204, 206, 208, 210, 212, 214, or 216.
20. A vector comprising the nucleic acid of claim 18 or 19.
21. 18. A nanoparticle comprising the CoV S glycoprotein of any one of claims 1 to 17 and a non-ionic surfactant core.
22. 22. The nanoparticles of claim 21, wherein the nanoparticles have a melting temperature of at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, at least 65°C, or from about 55°C to about 65°C after about one month of storage at 4°C, as determined by differential scanning calorimetry.
23. 23. The nanoparticles of claim 21 or 22, wherein the melting temperature of the nanoparticles is at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, at least 65°C, or from about 55°C to about 65°C after about one month of storage at 25°C, as determined by differential scanning calorimetry.
24. 24. The nanoparticles of any one of claims 21 to 23, wherein the melting temperature of the nanoparticles is at least 55°C, at least 56°C, at least 57°C, at least 58°C, at least 59°C, at least 60°C, at least 61°C, at least 62°C, at least 63°C, at least 64°C, at least 65°C, or from about 55°C to about 65°C after about one month of storage at 37°C, as determined by differential scanning calorimetry.
25. 25. The nanoparticle of any one of claims 21 to 24, having a Zavg diameter of about 30 nm to about 65 nm or about 30 nm to about 50 nm after about 1 month of storage at 4°C as determined by dynamic light scattering.
26. 26. The nanoparticle of any one of claims 21 to 25, having a Zavg diameter of about 30 nm to about 65 nm or about 30 nm to about 50 nm after about 1 month of storage at 25°C as determined by dynamic light scattering.
27. 27. The nanoparticle of any one of claims 21 to 26, having a Zavg diameter of about 30 nm to about 120 nm, about 30 nm to about 80 nm, or about 30 nm to about 60 nm after about one month of storage at 37°C as determined by dynamic light scattering.
28. 28. The nanoparticle of any one of claims 21 to 27, having a polydispersity index of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 4°C, as determined by dynamic light scattering.
29. 29. The nanoparticles of any one of claims 21 to 28, having a polydispersity index of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 25°C, as determined by dynamic light scattering.
30. 30. The nanoparticle of any one of claims 21 to 29, having a polydispersity index of about 0.1 nm to about 0.4 nm, about 0.15 nm to about 0.35 nm, or about 0.2 nm to about 0.45 nm after about one month of storage at 37°C, as determined by dynamic light scattering.
31. 31. The nanoparticle of any one of claims 21 to 30, wherein the non-ionic surfactant is selected from the group consisting of polysorbate-20 (PS20), polysorbate-40 (PS40), polysorbate-60 (PS60), polysorbate-65 (PS65) and polysorbate-80 (PS80).
32. The nanoparticle of claim 31 , wherein the non-ionic surfactant is PS80.
33. A cell expressing a CoV S glycoprotein according to any one of claims 1 to 17.
34. 34. The cell of claim 33 which is an insect cell.
35. 33. An immunogenic composition comprising at least one CoV S glycoprotein according to any one of claims 1 to 17 or a nanoparticle according to any one of claims 21 to 32 and a pharma- ceutically acceptable buffer.
36. 36. The immunogenic composition of claim 35, comprising 2, 3, 4, 5, 6, 7, 8, 9 or 10 different CoV S glycoproteins.
37. At least one CoV S glycoprotein comprises (i) A54V, T82I, G129D, L199I, G326D, S358L, S360P, S362F, K404N, N427K, G433S, S464N , T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H , N751K, D783Y, N843K, Q941H, N956K, L968F, a deletion of amino acid 56, a deletion of amino acid 57, a deletion of amino acid 130, a deletion of amino acid 131, a deletion of amino acid 132, a deletion of amino acid 198, and an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (ii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (iii) T6R, A14S, T82I, G129D, E143G, L199I, G326D, S358L, S360P, K404N, N427K, G433S, S464N, T465K, E471A, Q480R, G483S, Q485R, N488Y, Y492H, T534K, D601G, H642Y, N666K, P668H, N751K, D783Y, N843K, Q941H, N956K, L968F, a deletion of amino acid 144, a deletion of amino acid 145, a deletion of amino acid 198, and an insertion of a tripeptide having the amino acid sequence of EPE between amino acids 214 and 215; (iv) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, K404N, N427K, L439Q, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, S691L, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (v) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, S464N, T465K, E471A, Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (vi) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, D601G, H642Y, N645S, N666K, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (vii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, G626V, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (viii) V3G, T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (ix) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (x) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, N447K, S464N, T465K, E471A, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xi) T6I, A14S, G129D, K134E, W139R, F144L, I197V, V200G, G244S, G326H, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, G433S, L439R, N447K, S 464N, T465K, E471A, F473S, Q485R, N488Y, Y492H, T591I, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, D1186N, deletion of amino acid 11, deletion of amino acid 12, and deletion of amino acid 13; (xii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N645S, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xiv) T6I, A14S, V70A, G129D, H133Q, Q170E, V200E, G239V, G326H, R333T, L355I, S 358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S46 4N, T465K, E471A, F473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, and deletion of amino acid 131; (xv) T6I, A14S, G129D, H133Q, Q170E, V200E, G326H, R333T, L355I, S358F, S360P, S36 2F, T363A, D392N, R395S, K404N, N427K, V432P, G433S, N447K, S464N, T465K, E471A, F 473S, F477S, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131; (xvi) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; (xvii) T6I, A14S, G129D, V200G, G326D, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, K431T, L439R, N447K, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, and deletion of amino acid 57; and (xviii) T6I, A14S, G129D, V200G, G326D, R333T, S358F, S360P, S362F, T363A, D392N, R395S, K404N, N427K, L439R, S464N, T465K, E471A, F473V, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, N956K, deletion of amino acid 11, deletion of amino acid 12, deletion of amino acid 13, deletion of amino acid 56, deletion of amino acid 57, and deletion of amino acid 131.
37. The immunogenic composition of claim 35 or 36, comprising a combination of modifications selected from the group consisting of:
38. 38. The immunogenic composition of any one of claims 35-37, wherein at least one CoV S glycoprotein is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 174, 175, 186, 188, 190, 195, 217-228 and 233-236.
39. At least one CoV S glycoprotein comprises (xix) a deletion of amino acid 56, a deletion of amino acid 57, and a deletion of amino acid 131, N488Y, A557D, D601G, P668H or P668R, T703I, S969A, and D1105H; (xx) D67A, K404N, E471K, N488Y, D601G and A688V; (xxi) D67A, D202G, L229H, K404N, E471K, N488Y, D601G, and A688V; (xxii) D67A, D202G, a deletion of one, two or three amino acids between amino acids 228-230, K404N, E471K, N488Y, D601G and A688V; (xxiii) D67A, L229H, R233I, N488Y, K404N, E471K, D601G, and A688V; (xxiv) L5F, T7N, P13S, D125Y, R177S, K404T, E471K, N488Y, D601G, H642Y, T1014I, and V1163F; (xxv) W139C and L439; (xxvi) deletion of amino acid 144, deletion of amino acid 145, T6R, E143G, L439R, T465K, D601G, P668R, and D937N; (xxvii) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, L439R, T465K, D601G, P668R, and D937N; (xxviii) deletion of amino acid 144, deletion of amino acid 145, T6R, T82I, G129D, Y132H, E143G, A209V, K404N L439R, T465K, D601G, P668R, and D937N; (xxix) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, W245I, K404N, N426K, L439R, T465K, E471K, N488Y, D601G, P668R, and D937N; (xxx) deletion of amino acid 144, deletion of amino acid 145, T6R, W51H, H53W, G129D, E143G, D200V, L201R, W245I, K404N, N426K, L439R, T465K, E471K, N488Y, D601G, P668R, and D937N; (xxxi) deletion of amino acid 144, deletion of amino acid 145, T6R, G129D, E143G, K404N, L439R, T465K, E471Q, D601G, P668R, and D937N; (xxxii) Q39R, A54V, E471K; D601G, Q664H, F875L, and a deletion of one, two, three or four of amino acids 56, 57, 131, 132; (xxxiii) T82I, D240G, E471K, D601G and A688V; (xxxiv) L439R, E471Q, D601G, P668R and Q1058H; (xxxv) G62V, T63I, R233N, L439Q, F477S, D601G, T846N, and a deletion of one, two, three, four, five, or six of amino acids 234-240; (xxxvi) T82I, Y131S, Y132N, R333K, E471K, N488Y, D601G, P668H, and D937N; and (xxxvii) G129D, G326D, S360P, S362F, K404N, N427K, T465K, E471A or E471K, Q480K or Q480R, Q485R, N488Y, Y492H, D601G, H642Y, N666K, P668H, N751K, D783Y, Q941H, and N953K.
39. The immunogenic composition of any one of claims 35 to 38, comprising a combination of modifications selected from the group consisting of:
40. 40. The immunogenic composition of any one of claims 35 to 39, comprising a CoV S glycoprotein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the CoV S glycoprotein of SEQ ID NO:
87.
41. 41. The immunogenic composition of any one of claims 35 to 40, comprising a CoV S glycoprotein having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the CoV S glycoproteins of SEQ ID NOs: 85-89, 105, 106 and 112-115.
42. 42. The immunogenic composition of any one of claims 35 to 41, comprising an mRNA encoding the SARS-Cov-2 spike glycoprotein, a plasmid DNA encoding the SARS-Cov-2 spike glycoprotein, a viral vector encoding the SARS-Cov-2 spike glycoprotein, or an inactivated SARS-CoV-2 virus.
43. 43. The immunogenic composition of any one of claims 35 to 42, comprising at least one, at least two, at least three or at least four hemagglutinin (HA) glycoproteins, each HA glycoprotein being from a different influenza strain.
44. 44. The immunogenic composition of any one of claims 35 to 43, comprising a respiratory syncytial virus (RSV) fusion (F) glycoprotein.
45. 45. The immunogenic composition of any one of claims 35-44, comprising: (i) a first CoV S glycoprotein having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of SEQ ID NO: 87; and (ii) a second CoV S glycoprotein having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to a polypeptide of SEQ ID NO:
175.
46. 46. The immunogenic composition of any one of claims 35 to 45, comprising about 1 μg to about 50 μg; about 3 μg to about 25 μg, about 5 μg to about 25 μg, or about 5 μg to about 100 μg of CoV S glycoprotein.
47. 46. The immunogenic composition of any one of claims 35 to 45, comprising about 1 μg to about 50 μg; about 3 μg to about 25 μg, about 5 μg to about 25 μg, or about 5 μg to about 100 μg of each CoV S glycoprotein.
48. 47. The immunogenic composition of any one of claims 35 to 46, comprising about 5 μg of CoV S glycoprotein.
49. 46. The immunogenic composition of any one of claims 35 to 45, comprising about 5 μg of each CoV S glycoprotein.
50. 50. The immunogenic composition of any one of claims 35 to 49, comprising an adjuvant.
51. the adjuvant comprises at least two types of iscom particles, The first iscom particle comprises fraction A of Quillaja Saponaria Molina and does not comprise fraction C of Quillaja Saponaria Molina; and The second iscom particle contains fraction C of Quillaja Saponaria Molina and does not contain fraction A of Quillaja Saponaria Molina. The immunogenic composition of claim 50.
52. 52. The immunogenic composition of claim 51, wherein Fraction A of Quillaja Saponaria Molina and Fraction C of Quillaja Saponaria Molina constitute about 85% by weight and about 15% by weight, respectively, of the combined weight of Fraction A of Quillaja Saponaria Molina and Fraction C of Quillaja Saponaria Molina in the adjuvant.
53. 52. The immunogenic composition of claim 51, wherein Fraction A of Quillaja Saponaria Molina and Fraction C of Quillaja Saponaria Molina constitute about 92% by weight and about 8% by weight, respectively, of the combined weight of Fraction A of Quillaja Saponaria Molina and Fraction C of Quillaja Saponaria Molina in the adjuvant.
54. 52. The immunogenic composition of claim 51, wherein the combined weight of Fraction A of Quillaja Saponaria Molina and Fraction C of Quillaja Saponaria Molina in the adjuvant is at least about 85% by weight, and Fraction C of Quillaja Saponaria Molina accounts for the remainder.
55. The immunogenic composition of claim 51, wherein the weight of the Fraction A of Quillaja Saponaria Molina and the Fraction C of Quillaja Saponaria Molina in the adjuvant is 50 to 96% by weight, and the Fraction C of Quillaja Saponaria Molina is the remainder.
56. 56. The immunogenic composition of any one of claims 50 to 55, comprising about 25 μg to about 100 μg of adjuvant.
57. 56. The immunogenic composition of any one of claims 50 to 55, comprising about 50 μg of adjuvant.
58. 58. A pre-filled syringe comprising the immunogenic composition of any one of claims 35 to 57.
59. 60. A method of stimulating an immune response against SARS-CoV-2 or a heterologous SARS-CoV-2 strain, comprising administering to a subject an immunogenic composition of any one of claims 35 to 57.
60. 60. The method of claim 59 comprising administering 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 doses of the immunogenic composition.
61. 61. The method of claim 59 or 60, comprising administering a first dose of the immunogenic composition and a second dose of the immunogenic composition about 3 weeks after the first dose.
62. 62. The method of any one of claims 59 to 61, comprising administering a first dose of the immunogenic composition and a second dose of the immunogenic composition about 21 days after the first dose.
63. 63. The method of any one of claims 59 to 62, comprising administering at least three doses of the immunogenic composition, wherein a third dose of the immunogenic composition is administered at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, or at least 24 months after the first or second dose.
64. 64. The method of any one of claims 59 to 63, comprising administering a second immunogenic composition that is different from the first immunogenic composition.
65. 65. The method of claim 64, wherein the second immunogenic composition comprises an mRNA encoding the SARS-Cov-2 spike glycoprotein, a plasmid DNA encoding the SARS-Cov-2 spike glycoprotein, a viral vector encoding the SARS-Cov-2 spike glycoprotein, or an inactivated SARS-CoV-2 virus.
66. 65. The method of claim 64, wherein the second immunogenic composition comprises at least one, at least two, at least three, or at least four hemagglutinin (HA) glycoproteins, each HA glycoprotein being from a different influenza strain.
67. 65. The method of claim 64, wherein the second immunogenic composition comprises a different CoV S glycoprotein than the first immunogenic composition.
68. 68. The method of any one of claims 59 to 67, wherein the immunogenic composition is administered intramuscularly.
69. 69. The method of any one of claims 59 to 68, comprising administering the immunogenic composition in a pre-filled syringe.
70. at least about 2 months, at least about 2.5 months, at least about 3 months, at least about 3.5 months, at least about 4 months, at least about 4.5 months, at least about 5 months, at least about 5.5 months, at least about 6 months, at least about 6.5 months, at least about 7 months, at least about 7.5 months, at least about 8 months, at least about 8.5 months, at least about 9 months, at least about 9.5 months, at least about 10 months, at least about 10.5 months, at least about 11 months, at least about 11.5 months, at least about 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months about 50% to about 99%, about 50% to about 95%, about 50% to about 90%, about 50% to about 85%, about 50% to about 80%, about 60% to about 99%, about 65% to about 95%, about 65% to about 90%, about 65% to about 85%, about 69% to about 81%, about 60% to about 95% 70. The method of any one of claims 59 to 69, wherein the method prevents COVID-19 with an efficacy of about 60% to about 90%, about 60% to about 85%, about 60% to about 80%, about 40% to about 99%, about 40% to about 95%, about 40% to about 90%, about 40% to about 85%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to about 65%, about 40% to about 55%, or about 40% to about 50%.
71. up to about 2 months, up to about 2.5 months, up to about 3 months, up to about 3.5 months, up to about 4 months, up to about 4.5 months, up to about 5 months, up to about 5.5 months, up to about 6 months, up to about 6.5 months, up to about 7 months, up to about 7.5 months, up to about 8 months, up to about 8.5 months, up to about 9 months, up to about 9.5 months, up to about 10 months, up to about 10.5 months, up to about 11 months, up to about 11.5 months, up to about 12 months, up to 13 months, up to 14 months, up to 15 months, up to 16 months, up to 17 months, up to 18 months, up to 19 months, up to 20 months, up to 21 months, up to for 22 months, up to 23 months or up to 24 months, about 50% to about 99%, about 50% to about 95%, about 50% to about 90%, about 50% to about 85%, about 50% to about 80%, about 60% to about 99%, about 65% to about 95%, about 65% to about 90%, about 65% to about 85%, about 69% to about 81%, about 60% to about 95%, about 60% to about 90%, about 60% to about 70. The method of any one of claims 59 to 69, wherein the method prevents COVID-19 with an efficacy of 85%, about 60% to about 80%, about 40% to about 99%, about 40% to about 95%, about 40% to about 90%, about 40% to about 85%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to about 65%, about 40% to about 55%, or about 40% to about 50%.
72. 72. The method of any one of claims 59 to 71, wherein the heterologous SARS-CoV-2 strain has a PANGO lineage selected from the group consisting of B.1.1.529; BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, B.1.1.7, B.1.351, P.1, B.1.617.2, AY, B.1.427, B.1.429, B.1.525, B.1.526, B.1.617.1, B.1.617.3, P.2, B.1.621, or B.1.621.
1.
73. 73. The method of any one of claims 59 to 72, wherein the heterologous SARS-CoV-2 strain has a World Health Organization label of alpha, beta, gamma, delta, epsilon, iota, kappa, zeta, mu, or omicron.
74. 44. A method of stimulating an immune response in a subject against SARS-CoV-2, a heterologous SARS-CoV-2 strain, influenza virus, or a combination thereof, comprising administering the immunogenic composition of claim 43.
75. 45. A method of stimulating an immune response in a subject against SARS-CoV-2, a heterologous SARS-CoV-2 strain, influenza virus, respiratory syncytial virus (RSV), or a combination thereof, comprising administering the immunogenic composition of claim 43 or 44.
Citation Information
Patent Citations
Coronavirus vaccine formulations
WO2021154812A1
